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ABSTRACT
Background: Non-cystic fibrosis bronchiectasis is a chronic debilitating disease. A
perpetual cycle of excessive neutrophilic inflammation and chronic bacterial infection is
thought to occur within the permanently damaged and dilated airways.
Aim: The aims of this thesis were to explore whether the vicious cycle of infection and
inflammation in bronchiectasis can be disrupted, improving the clinical features of the
disease and to identify potentially useful clinical markers for monitoring treatment
response.
Methods: Patients with a radiological diagnosis of bronchiectasis and a clinical history
of a daily productive cough, recurrent infective exacerbations and evidence of
chronically infected sputum were recruited. The first study was a randomised crossover
trial of regular chest physiotherapy in 20 patients assessing whether augmentation of the
impaired mucociliary system can improve health related quality of life (HRQL) and the
clinical features of bronchiectasis. The second study was a prospective cohort study of
32 infective exacerbations of bronchiectasis managed with two weeks' intravenous
antibiotic therapy and assessed the impact of reducing bacterial infection in the airways
during acute exacerbations on HRQL, sputum bacteriology, purulence and volume as
well as lung function and systemic markers of inflammation. The third study was a
randomised crossover trial of regular, long term nebulised gentamicin over 12 months in
57 patients exploring the impact on airways infection and inflammation, lung function,
exercise capacity, HRQL and exacerbation frequency. The fourth study sought to
identify potentially useful markers of response to chronic treatment strategies for stable
disease by analysing markers common to the preceding two interventional studies to
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assess their robustness and relevance, including sputum bacteriology and purulence,
lung function, exercise capacity, systemic inflammatory markers and exacerbation
frequency.
Results: Augmenting the impaired mucociliary system with regular chest physiotherapy
improved HRQL and exercise capacity as well as increasing 24 hour sputum volume.
Treatment of acute infective exacerbations improved patients' HRQL and exercise
capacity as well as reducing 24 hour sputum volume, improving sputum purulence and
decreasing systemic inflammation. Long term regular nebulised gentamicin
significantly reduced sputum bacterial density and airways inflammation. Exercise
capacity and HRQL improved with treatment and patients suffered fewer exacerbations.
Parameters that may be useful in predicting a successful response to long term treatment
strategies for clinically stable disease include an improvement of >50m in the
incremental shuttle walk test and eradication of pathogens from the sputum.
Conclusion: Augmentation of the impaired mucociliary system, effective treatment of
acute infective insults and reducing chronic bacterial infection improves the clinical
features of bronchiectasis and suppresses the vicious cycle of infection and
inflammation. Potentially useful markers of a successful treatment response in the
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Bronchiectasis {Greek: bronkhia- "windpipe" and ektasis- "a stretching out"): a
chronic respiratory condition characterised by abnormal, permanently damaged and
dilated bronchi with clinical manifestations of persistent or recurrent bronchial sepsis.
Rene Laennec first described bronchiectasis in a brief chapter entitled "On dilatation of
the bronchi" in his treatise Auscultation Mediate in 1819 (Laennec, 1834). He
commented on the clinical history and physical signs of four fatal cases and reported the
morbid anatomy of the unifying condition: abnormal, permanent dilatation of the
bronchi. Clark, Hadley and Chaplin in 1894 published the first living case series of 45
patients with the condition (Clark, 1894). They described symptoms of cough and
sputum in their cases, briefly terming the chronic condition "fibroid disease of the
lung". However, it was not until over a century after Laennec's original description that
Sicard and Forestier in 1922 introduced the technique of injecting lipiodol into the
trachea with concurrent radiological imaging that the anatomy of bronchiectasis could
be studied with precision in living individuals (Sicard, 1922). This technique led to
descriptions of different degrees of bronchial dilatation. In 1932 Moll described the
varying appearances of the dilated bronchi as "(1) uniform, tubular or cylindrical; (2)
fusiform or glove-finger; (3) globular or sacculated; (4) moniliform or bead-like."
(Moll, 1932). The clinical relevance of describing the appearance of the dilated airways
was made apparent by Perry and King in their case series published in 1940, which
evaluated the prognosis of the condition observing that patients diagnosed with
"saccular or cystic" dilatation as opposed to "cylindrical" dilatation had a poorer
prognosis in terms of both morbidity and mortality (Perry K.M.A, 1940). The
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description and classification of the different degrees of bronchial dilatation is observer
dependent and various interchangeable terms have been used over the years. However,
in 1950 Reid reported on the findings of pathological and radiographic examination of
45 cases of bronchiectasis. Cylindrical (a uniform, minimal dilatation), varicose
(irregular and greater dilatation) and cystic or saccular (progressive dilatation) types of
bronchiectasis were described from the appearance of the bronchograms (Reid, 1950).
These latter descriptions remain in use today for reporting the appearance of the bronchi
on high resolution computed tomography of the chest, the now gold standard technique
for diagnosing the condition.
1.2 Prevalence
Population studies in bronchiectasis are limited perhaps given the diagnostic
methodology required for an established diagnosis: morbid anatomy in the early 19th
century, invasive bronchograms and chest radiographs in the first half of the 20th
century to the current gold standard of computed tomography (CT) chest scans
necessitating high dose radiation exposure. Some of the earliest UK prevalence reports
were in the 1950s, with between 1.3 to 1.5 cases per 1000 reported in England and
Wales in 1953 and 1956 from follow-up of abnormal chest radiographs during the
tuberculosis eradication campaign (Wynn-Williams, 1953, MinistryofHealth, 1947 &
1957). Throughout the following decades, indices of incidence and prevalence of
bronchiectasis have used studies reporting hospital admission rates or thoracic surgical
resection rates for bronchiectasis.
It is widely believed that there has been an overall decline in incidence of bronchiectasis
with more effective treatment of childhood respiratory conditions, successful
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vaccination programmes (particularly for measles and whooping cough) and effective
treatment strategies for control and management of pulmonary tuberculosis. However,
there is still little data available regarding the actual prevalence of bronchiectasis in the
21st century, again with no formal population studies to date. In 2005 a retrospective
cohort study of US health claims by Weycker et al suggested a prevalence of
bronchiectasis affecting 4.2 per 100 000 population aged 18-34years and 271.8 per
100,000 population aged over 75 years of age (Weycker D, 2005). Twiss et al in New
Zealand found an incidence of 3.7/100 000 in the paediatric population (Twiss et al.,
2005b). More recently, 1,409 participants aged between 23 to 86 years old in a Korean
health screening programme underwent a CT chest scan with 9.1% demonstrating
evidence of bronchiectasis (Kwak et al., 2010). In primary care in the UK, a survey of
respiratory disorders in a middle class suburban general practice serving 5840 patients
identified 28 patients with bronchiectasis (0.47% of the practice's population) equating
to approximately 12 cases per an average General Practitioner list of 2500 patients
(Masters, 2010).
Bronchiectasis is recognised in the literature as an important problem in developing
countries with Marostica emphasising the increased frequency of particular causative
factors such as pneumonias, tuberculosis, postviral obliterative bronchiolitis in Latin
America as factors that could be responsible for an increased frequency of
bronchiectasis (Marostica and Fischer, 2006). Babayigit et al in their review of
characteristics and aetiologic factors of bronchiectasis in a paediatric population in
Turkey suggested that prevalence may reflect the socioeconomic conditions of the
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particular population- where access to vaccinations is difficult and pulmonary infections
are more frequent and severe (Babayigit et al., 2009).
Although it has not been a primary consideration, clinical studies of bronchiectasis to
date have demonstrated an overall increased prevalence amongst females: 62.7% in
Pasteur's study of causative factors (Pasteur et al., 2000); 69% in Nicotra's study of the
characterisation of bronchiectasis in an ageing cohort (Nicotra et al., 1995); 53% in
Ellis's study of prognosis and 55.8% in Keistinen's work (Ellis et al., 1981, Keistinen et
al., 1997). Weycker and Shoemark found an increased prevalence amongst females of
63-68% (Weycker D, 2005, Shoemark et al., 2007). This observed difference in gender
distribution was explored by Morrissey and Harper in 2004 (Morrissey and Harper,
2004) who proposed that both sociological and biological factors may be responsible.
Sociologically, females may be more likely to seek medical attention for their
symptoms and traditional societal roles may expose females to more aetiological risk
factors, for example inhalation of smoke from open fire cooking in poorly ventilated
areas or exposure to repeated viral infections while caring for young children. Such
links are currently tenuous and would perhaps apply only to select geographic areas of
the world. Biological factors may include the influence of the luteal phase of the
menstrual cycle increasing airways reactivity which has been investigated to a limited
extent in asthma as well as the different pulmonary anatomy in women compared with
men: women have smaller lungs and with less muscle mass and strength, there is less
pronounced expansion (and collapse) of the thorax than in men. Diseases that are
frequently associated with or complicated by bronchiectasis may primarily be more
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common in women, such as rheumatoid arthritis and Sjogren's syndrome (Symmons,
2002, Mavragani and Moutsopoulos, 2010).
1.3 Burden
Morbidity in bronchiectasis can be measured in several ways, but perhaps of greatest
socioeconomic importance is the morbidity associated with recurrent chest infections,
necessitating days off work and utilisation of health care resources including hospital
admissions. A retrospective study of 410 patients with bronchiectasis attending a
respiratory outpatient clinic in Northern Ireland in 2003 randomly selected 100 patients
and found that they had had a total of 321 clinic attendances over a 6 month period,
with 39 patients requiring four or more reviews during this period. 48 of these patients
had received four or more courses of antibiotics in the preceding 12 months and hospital
admission for bronchiectasis had been necessary in 30 in the past year (Kelly et al.,
2003). UK hospital admission data for 2007-8 found bronchiectasis to be the primary
diagnosis in 1 in 1800 hospitalisations. A New Zealand study of factors predicting
readmission and mortality in acute exacerbations of bronchiectasis found that the 152
patients included in their analysis had required a total of 307 hospital admissions over a
12 month period (Roberts et al., 2011). In a separate New Zealand study the Maori
population were noted to have a high rate of hospitalisations for bronchiectasis of 30-
50/100 000 (O'Neill M, 1995). US data for 1993-2006 found the average annual
prevalence of hospitalisations due to bronchiectasis to be 16.5 per 100 000 population
(Seitz et al., 2010). The latter study found an annual percentage increase in
hospitalisations between 1993-2006 of 2.4% for men and 3.0% for women. The median
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cost for inpatient care was US$7,827(13-543,914). To date, no studies have explored
the rate of primary care consultations for bronchiectasis patients.
More recently, studies have explored trends in mortality in bronchiectasis, although data
are still limited. Bronchiectasis related deaths in England and Wales have shown a rise
in absolute numbers of deaths per year from 797 in 2001 to 908 in 2007, a statistical
increase in mortality of 3% per annum (Roberts and Hubbard, 2010). An analysis of
factors related to mortality in bronchiectasis in 98 outpatients followed over a 4 year
period found cumulative survival rates of 97% at one year, 89% at two years, 76% at
three years and 58% at four years (Onen et al., 2007).
1.4 Clinical features
"copious foetid sputum...marked constitutional symptoms...a social outcast... " Warner
1932 (Warner, 1932).
As a clinical entity, the presentation of bronchiectasis is well described. Respiratory
symptoms predominate with the defining feature of a persistent, productive cough
present in 90.2-96% of patients (Nicotra et al., 1995, King et al., 2006a). Daily sputum
is reported in approximately 75% of patients with mean±standard deviation daily
volumes of 38±34mls of sputum found in a study of 103 patients with newly diagnosed
bronchiectasis (King et al., 2006a). In clinical practice, sputum volume is variable
depending on the extent of bronchiectasis and clinical stability of the patient. Sputum is
often discoloured with a yellow or green purulence reflecting airways inflammation. An
early study that included 14 patients with bronchiectasis and 7 patients with chronic
bronchitis found that purulent sputum correlated strongly with increased concentrations
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of neutrophil elastase (r=0.871) and myeloperoxidase (r=0.882) (Stockley et al., 2001).
Haemoptysis is a variably reported feature with studies reporting frequencies of 26%-
51.2% at diagnosis. Dyspnoea is also predominant with 60% of 103 newly diagnosed
patients having a mean±standard deviation MRC dyspnoea score of 2.1±1.2units. Non-
ischaemic chest pain, typically described as pleuritic or musculoskeletal may be
described, with reported rates of between 19% and 46.3% (Nicotra et ah, 1995, King et
ah, 2006a). One study found that 94.4% of chest pains reported in bronchiectasis were
in an area associated with a bronchiectatic lobe (Munro et ah, 1989). A major cause of
morbidity is recurrent chest infections, with reports of 2.4±1.6 exacerbations per year in
King's study of 103 patients with bronchiectasis (King et ah, 2006a). Patients frequently
suffer systemically with fatigue which, together with the chronic respiratory symptoms,
adversely affects patients' health related quality of life (Wilson et ah, 1997a). An earlier
study also explored the impact of symptoms on patients' spouses and reported that 46%
found their partner's cough to be distasteful and 29% reported that the symptoms
interfered with their sexual life (Ellis et ah, 1981).
Clinical signs in bronchiectasis may typically include crackles (69.9%-73%) and
wheeze (21-34%). Clubbing is a recognised but infrequent clinical finding reported in 2-
3% (King et ah, 2006a). Frequently, physical examination may be entirely normal.
22
1.5 Diagnosis
For almost a century after bronchiectasis was first described, the diagnosis of the
disease was predominantly made on a clinical basis. Chest radiographs were insensitive
and had poor specificity with potential diagnostic features including the presence of
linear markings, bronchial wall thickening, patchy or confluent pulmonary shadowing,
pleural thickening, lung collapse or volume loss or circular markings (Gudbjerg, 1955).
The introduction of lipiodol (an iodine containing vegetable oil) into radiological
practise by Sicard in the early 1920s and its later establishment in bronchopulmonary
radiology by Sergent and Cottentot offered a more objective and reliable means of
diagnosis with the injection of contrast into the bronchial tree (initially via intratracheal
injection and later via bronchoscopy to produce a bronchogram) immediately prior to x-
ray imaging of the chest (Sicard, 1922, Sergent E, 1923). The earliest signs of bronchial
dilatation could be detected by bronchogram and were described in the literature as
"small irregular fusiform shadows in connexion with medium sized bronchi" (Armand-
Delille and Moncrieff, 1924). By 1935, it was recommended that
"in every case of suspected bronchiectasis, radiology of the chest after lipiodol
injection into the bronchial tree shouldform part ofthe routine investigation... " (Lloyd,
1935).
Later studies confirmed that plain chest radiographs were insensitive for diagnosing
bronchiectasis in comparison with bronchograms (Currie et al., 1987a). The procedure
was not without morbidity however, with potential risks including allergic reactions to
the contrast or anaesthetic and temporary impairment of ventilation and diffusion. With
the advent of more advanced radiological imaging techniques, the role of CT in the
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diagnosis of bronchiectasis was investigated and later formally established such that it
remains the 'gold standard' today to confirm clinically suspected bronchiectasis.
The role of CT in establishing the presence of bronchiectasis was initially proposed by
in 1982 when 6 patients already diagnosed with bronchiectasis on the basis of chest
radiograph (2 patients) and bronchogram (4 patients) underwent a CT scan confirming
the chest radiograph and bronchogram findings (Naidich et al., 1982). CT signs of
bronchiectasis were reported to include air-fluid levels, distended bronchi, linear arrays
or clusters of cysts, dilated bronchi in the periphery of the lung and bronchial wall
thickening (Naidich et al., 1982). The accuracy and reliability of CT in bronchiectasis
was explored over the following decade, with the early studies comparing the accuracy
of CT with the traditional bronchogram. An initial study found CT to be useful for
cystic bronchiectasis but in cylindrical and varicose bronchiectasis CT scan did not
detect disease in 5 cases diagnosed on bronchogram (Muller et al., 1984). A later study
of cylindrical and mild varicose bronchiectasis diagnosed by bronchogram in 15
patients found that CT scans in these patients had a sensitivity of 79% and a specificity
of 99%, indicating that CT is reliable but too insensitive (Phillips et al., 1986). Reasons
for poorer sensitivity were explored and issues such as motion artefacts simulating the
appearance of bronchiectasis (transmitted cardiac pulsations could mimic cystic
bronchiectasis) and pathologic variations of disease such as mucoid impaction altering
classical appearances of dilated bronchi were thought to contribute (Tarver et al., 1988).
The development of thin section CT imaging markedly improved the sensitivity of the
investigation with the rate improving to 84% in a study of 27 patients undergoing CT
scans with 3mm high resolution images (Munro et al., 1990). A separate study of high-
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resolution CT scans (HRCT) compared with bronchography found HRCT to be positive
in 87 out of 89 segmental bronchi with bronchiectasis at bronchography and negative in
169 out of 170 segmental bronchi without bronchiectasis at bronchography giving a
false negative rate of 2% and false positive rate of 1% (Young et al., 1991). HRCT
assessment of the bronchi in bronchiectasis was also proven to have minimal inter- and
intra-observer variation with good reproducibility of bronchial wall circumference
(Desai et ah, 1994). Such studies prompted the recommendation in 1993 that optimal
evaluation necessitated selecting the thinnest possible slices of at least 1 -2mm thickness
for diagnosing bronchiectasis(McGuinness et ah, 1993). HRCT imaging is now the gold
standard investigation for diagnosing bronchiectasis with the defining feature being the
presence of bronchial dilatation with the internal diameter of the bronchial lumen
measuring greater than that of the adjacent artery, with the degree of dilatation typically
categorised as tubular, varicose or cystic (Figure 1).
25




Cylindrical, varicose and cystic bronchial dilatation in comparison with the adjacent
bronchial artery.
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Other radiological features that may be present in addition to those originally described
by Naidich include emphysema, interlobular septal thickening (Sibtain et al., 2005) and
a mosaic attenuation pattern due to small airways disease (Hansell et al., 1994). The role
of HRCT scans beyond initial diagnosis in bronchiectasis has been explored in studies
over the past few decades, including its discriminative value for aetiology and utility in
assessing extent and progression of disease. Although there is no specific scoring
system validated for use in bronchiectasis, modifications of a score for cystic fibrosis
has been used in research studies. The Bhalla score includes the number of lobes
affected and segments involved; degree of bronchial dilatation; severity of bronchial
wall thickening; extent of mucus plugging; presence or absence of sacculations;
presence and number of bullae; presence of emphysema and number of lobes affected;
collapse or consolidation; mosaic perfusion; air trapping (Bhalla et al., 1991). Using a
modification of the Bhalla score a study of 46 patients with bronchiectasis found that
more severe disease on HRCT scan correlated with a poorer health related quality of life
(Eshed et al., 2007). A separate study compared HRCT findings with pulmonary
function tests in 94 patients (62 of whom had cystic disease and 32 cylindrical), finding
that with cystic dilatation patients had a significantly lower FEVi, FVC, diffusion
capacity of carbon monoxide and blood oxygenation than those with cylindrical
dilatation (Alzeer, 2008). There have been few studies assessing whether serial CT
imaging can be used to assess disease progression. The relationship between changes in
serial CT scans and markers of pulmonary function in bronchiectasis in 48 patients with
bronchiectasis over a median follow-up period of 28(6-74) months found that changes
in the severity of bronchiectasis were seen more frequently on CT scan including areas
of decreased attenuation, bronchial wall thickening and mucus plugging than in changes
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in pulmonary function particularly the FEVi (Sheehan et al., 2002). Mucus plugging
was the only radiological feature identified that correlated significantly with change in
the FEVi (Sheehan et al., 2002). This study suggests that radiological disease
progression may be evident within short time periods, but to date there are no long-term
studies assessing regular radiological follow-up of disease.
The utility of CT scan in identifying the cause of bronchiectasis has been explored in a
number of studies and at present it is thought to be of limited value particularly on an
individual patient basis (Reiff et al., 1995) with poor inter-observer agreement on
radiological findings in terms of likely cause (Lee et al., 1995, Cartier et al., 1999).
In addition to the radiological assessment of bronchiectasis, clinical and microbiological
parameters are reviewed to help further define disease severity (Table 1).
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Table 1. Assessment of disease severity.
Characteristic Disease Severity
Mild Moderate Severe






< 3 per annum > 3per annum
Exacerbation
Severity




















Tubular dilatation Varicose dilatation Cystic dilatation
Clinical, microbiological and radiological indices used in disease severity assessment.
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1.6 Aetiology
Bronchiectasis is a pathological description of irreversibly damaged and dilated
airways. It may be present as an independent entity or it may be an association of
another disease process. Identifying the underlying aetiology of the bronchiectasis is
important for formulating an appropriate management strategy.
In a study of 165 adult patients with a clinical and radiological diagnosis of
bronchiectasis, an identifiable cause was found in 122 affecting management in 61 cases
whose underlying aetiologies required specific therapeutic strategies. The underlying
causes identified which affected management included primary ciliary dyskinesia,
allergic bronchopulmonary aspergillosis, immune deficiency such as common variable
immunodeficiency (CVID), ulcerative colitis, panbronchiolitis, mycobacterium
infection (tuberculous or non-tuberculous infection), rheumatoid arthritis, aspiration and
cystic fibrosis (Shoemark et al., 2007). An earlier study of 150 adult patients identified
a causative factor for bronchiectasis in 47% of cases which had prognostic and
therapeutic implications in 15% (Pasteur et ah, 2000). Li et al examined a paediatric
population group and found that identifying a cause for bronchiectasis led to a specific
change in management in 56% (Li et ah, 2005).
The presence of bronchiectasis as an association of another disease may have
implications for the prognosis of the underlying disease. In rheumatoid arthritis,
bronchiectasis is a well recognised feature that may be diagnosed either before or after
the development of joint symptoms (Allain et ah, 1997). In a study of 23 patients with
rheumatoid arthritis and bronchiectasis, 18 were diagnosed with bronchiectasis at a
mean of 24.7 years after onset of arthritic symptoms (Shadick et ah, 1994). These
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patients all had seropositive, severe nodular rheumatoid disease in comparison with
patients who had bronchiectasis prior to the onset of arthritic disease which was
typically seronegative, non-severe rheumatoid disease (Shadick et al., 1994). In a
separate study of 32 patients over a 5.5 year follow-up period, the presence of both
rheumatoid arthritis and bronchiectasis meant patients were five times more likely to die
than matched controls with rheumatoid disease alone (Swinson et al., 1997). The
presence of bronchiectasis in chronic obstructive pulmonary disease (COPD) is known
to adversely influence clinical course of the disease. A study of 54 patients with COPD
who underwent HRCT chest imaging found bronchiectasis to be present in 50%, with
lower lobe bronchiectasis in 33.3% (Patel et al., 2004). COPD patients with
bronchiectasis had greater levels of airways inflammation as measured by interleukin-8
and interleukin-6 in their sputum than those without bronchiectasis [for interleukin-8
(pg/ml) median(interquartile range) 3,939(3,173-5,528) versus 3,897(1,772-4,733),
P=0.001 respectively and for interleukin-6 (pg/ml) median(interquartile range)
113.2(20.1-218.9) versus 50.2(13.6-213), P=0.01 respectively). The presence of lower
lobe bronchiectasis was associated with a longer time to symptom recovery after an
acute exacerbation (median of 12 days versus 10 days) (Patel et al., 2004). In interstitial
lung disease, the presence of traction bronchiectasis on HRCT in patients with usual
interstitial pneumonia adversely influenced prognosis, with increased mortality rates
(hazard ratio 1.3, confidence interval 1.18-14.2) (Sumikawa et al., 2008).
A systematic investigation for causative factors or associated diseases is therefore
important. Studies to date have published variable rates of identifiable aetiologies, with
no cause found in up to 50% of patients (Kelly et al., 2003, Shoemark et al., 2007,
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Pasteur et al., 2000). The rate of aetiological diagnosis varies perhaps due to differences
in criteria for investigations as well as the population being studied- a higher proportion
of post infective bronchiectasis as an identifiable cause may be seen in lower
socioeconomic countries where undertreated infection or rate of tuberculous infection
for example is greater. However, there are clearly defined causes or risk factors for
bronchiectasis either as a single disease entity or as part of a syndrome that require
exploration.
Aetiologies for bronchiectasis include: post-infective; aspiration/inhalation injuries to
the airways; immunological- including both impaired immune defences and exaggerated
immune responses; congenital syndromes; genetic diseases; systemic diseases and
pulmonary diseases.
Table 2 gives the typical incidence of these causes and associations of bronchiectasis
with their supporting diagnostic features.
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Table 2. Aetiologies and incidences of bronchiectasis.


















3-6% • History or clinical signs of connective tissue
disease ± vasculitis
• Positive findings on autoimmune screen







• History of asthma
• Peripheral eosinophilia
• fTotal serum Immunoglobulin (Ig) E
• tSpecific IgE and IgG to Aspergillus
fumigatus
• +ve skin test reactivity to Aspergillus
fumigatus
• Fleeting infiltrates on chest radiograph or
CT chest or proximal bronchiectasis on CT
chest scan
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• Variable deficiencies possible [IgG
(including IgG subclasses), IgA, IgM]
• In IgG subclass 2 deficiency, history of
recurrent infections with Gram+ve
encapsulated organisms
• Low baseline specific antibody levels and
poor antibody response against Tetanus
toxoid and the polysaccharide capsules of
Streptococcus pneumoniae and
Haemophilus influenzae type B
Cystic Fibrosis 1-4%
• Symptoms of malabsorption, male infertility
• Upper lobe bronchiectasis on CT chest scan
• Persistent culture ofStaphylococcus aureus
in sputum
• Positive cytogenetics for cystic fibrosis
transmembrane regulator receptor mutations





• History of chronic upper respiratory tract
problems, otitis media, male infertility
• Positive saccharin taste test (saccharin not
tasted after 60 minutes)






1-3% • History or clinical signs
• Positive pathological features on
colonoscopy
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• History of aspiration
• Localised (single lobe) bronchiectasis
• Positive findings at bronchoscopy
Idiopathic 26-53% • Above causes excluded
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Post-infectious
An infective insult to the airways is thought to be sufficient to cause bronchiectasis.
Exposure to infective pathogens causing airway wall inflammation and structural
damage may follow bacterial pneumonia, infection with Bordetella pertussis, infection
with Mycobacterial disease (both tuberculous and non-tuberculous) and viral infections
(such as measles, adenovirus, rhinovirus and respiratory syncytial virus). Symptoms
may occur soon after the original infection or there may be a significant delay between
the original infective insult and presentation with chronic respiratory symptoms. The
closer the occurrence between insult and presentation, the greater likelihood that the
infection is responsible for the bronchiectasis. Post-tuberculous bronchiectasis is
typically in a segmental or lobar distribution. Non-tuberculous mycobacterial infection
may be implicated before or after the diagnosis of bronchiectasis, the most frequent
isolate being Mycobacterium avium complex (Marras and Daley, 2002, Field and
Cowie, 2006, Waller et al., 2006, Winthrop et ah, 2010, Wickremasinghe et ah, 2005).
There is a greater frequency of non-tuberculous mycobacterial infection and
bronchiectasis in females and a classic syndrome of isolated middle lobe or lingular
bronchiectasis due to non-tuberculous mycobacterial infection in females often
described "the Lady Windermere syndrome". The term "Lady Windermere syndrome"
was proposed by Reich and Johnson following their case reports of pulmonary
Mycobacterium avium infection and isolated middle lobe or lingular bronchiectasis in
females (Reich and Johnson, 1992). They proposed that cough suppression, likely to be
more common in females for societal purposes, led to inadequate clearance of
dependant lobes prolonging the exposure of the airways in such lobes to infection and
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consequent development of bronchiectasis. Oscar Wilde's play "Lady Windermere's
fan" described such a female character inhibited by society to cough effectively.
Inhalational Injuries and aspiration
Aspiration of a foreign body causes a mechanical obstruction in the affected airways
with accumulation of distal secretions. The prolonged exposure of such secretions to the
airways' walls leads to chronic inflammation, structural wall damage and
bronchiectasis. Intrinsic airway tumours (both benign and malignant) may theoretically
through the same mechanism lead to the development of bronchiectasis, although this is
exceptionally rare in series studied to date.
Gastro-oesophageal reflux disease is acknowledged as a potential risk factor for
bronchiectasis and the association of Helicobacter pylori (H.pylori) infection in disease
pathogenesis has been explored. An early study of 100 patients with bronchiectasis
found 76% to be seropositive for IgG to H.pylori compared with a 54.3% prevalence in
94 healthy controls (Tsang et al., 1998b). In the patients with bronchiectasis, H.pylori
seroprevalence was significantly higher in those who expectorated more than 5mls of
sputum per 24hour period. A smaller study of 46 patients found a seroprevalence of
46% but on immunohistochemical staining of bronchial mucosa there was no evidence
of presence of H.pylori (Angrill et al., 2006). A later study of 26 patients found no
evidence of H.pylori in bronchial washings using a DNA polymerase chain reaction
technique and also found no significant difference in serum IgG levels for H.pylori
compared with healthy controls (Gulhan et al., 2007). The role of H.pylori in
pathogenesis of bronchiectasis remains unclear but the earlier studies suggest that there
may be an association. The prevalence of gastro-oesophageal reflux disease in patients
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with bronchiectasis is unknown although there has been one study of patients with non-
tuberculous mycobacterial infection that observed a 26% prevalence in patients with
nodular bronchiectasis and non-tuberculous mycobacterial infection (Koh et al., 2007).
Immunological
Impairment of the host defences may lead to recurrent bacterial infections and airway
damage. Host defences may be impaired directly in the airways as with ciliary defects
that inhibit the normal function of the mucociliary clearance mechanism or the presence
of systemic immune deficiency may predispose to recurrent infection and airway wall
damage.
Primary ciliary dyskinesia is usually an autosomal recessive disorder causing
ultrastructural defects in the cilia affecting normal motility and is characterised by upper
and lower respiratory tract infections (Noone et ah, 2004). Kartagener's Syndrome
describes the classic triad of situs inversus, bronchiectasis and chronic sinusitis due to a
congenital reduction or absence of ciliary function (Kartagener, 1933).
Primary antibody deficiency syndromes have been associated with bronchiectasis for
over half a century (Busse et ah, 2007). Common variable immune deficiency (CVID)
is associated with bronchiectasis in 16% - 68% of cases and 7% - 20% of X-linked
agammaglobulinemia (XLA) cases are associated with bronchiectasis (Thickett et ah,
2002, Martinez Garcia et ah, 2001, Aghamohammadi et ah, 2010). Less commonly,
bronchiectasis may complicate patients with immunoglobulin A (IgA) deficiency,
although this tends to happen when other associated autoimmune defects occur
(Aghamohammadi et ah, 2009). Studies have also explored the role of immunoglobulin
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G (IgG) and IgG subclass deficiencies in bronchiectasis. An early study of 65 patients
aged 10-74 years with bronchiectasis of unknown aetiology found that 48% had IgG
deficiency (61.3% were deficient in IgG subclass 2) all of whom had an impaired
antibody response to Haemophilus influenzae Type B (De Gracia et al., 1996). A
separate study also observed an impaired antibody response to Haemophilus influenzae
Type B and Streptococcus pneumoniae, in patients with IgG subclass 2 deficiency
(Vendrell et al., 2005). Other studies however, have suggested that such isolated
antibody subclass deficiency is an uncommon cause or association in adults aged over
40 years presenting with bronchiectasis with incidences ranging from 6.6% - 23.2%
(Hill et al., 1998, Stead et al., 2002, King et al., 2006b). Considering an underlying
immunodeficiency disorder is essential, particularly in those with opportunistic
infections or indeed persistent severe infections as disease progression may be
prevented with effective immunoglobulin replacement. The current UK national
guidelines consensus expert opinion advocates functional testing to peptide and
polysaccharide antigens as well as measurement of serum IgG, IgA and IgM in routine
practice (Pasteur et al., 2010).
Secondary immune deficiency syndromes have recently become increasingly recognised
as risk factors for bronchiectasis. Human Immunodeficiency Virus (HIV) and Acquired
Immunodeficiency Disease (AIDS) are frequently associated with both recurrent lower
respiratory tract infections and with more severe infection with opportunistic organisms
and viruses such as non-tuberculous mycobacteria and Pneumocystis jiroveci
pneumonitis which in a study of paediatric HIV patients have been reported as
significant risk factors for the development of bronchiectasis (Berman et al., 2007).
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Exaggerated immune responses exposing the airways to excessive inflammation and
damage can also lead to bronchiectasis. Allergic bronchopulmonary aspergillosis
(ABPA) is a complex clinical condition that arises from an allergic immune response to
Aspergillus fumigatus. It is defined by clinical, laboratory and radiologic features
including active asthma, elevated levels of total serum IgE, serum eosinophilia and
fleeting pulmonary parenchymal opacities on the chest radiograph (Patterson and Strek,
2010). More advanced disease is complicated by bronchiectasis which is classically
central with peripheral sparing on HRCT scan (McGuinness and Naidich, 2002).
Institution of glucocorticoid therapy may help to control the immunologic response and
may limit the progressive damage (Patterson and Strek, 2010).
Congenital Syndromes
Congenital abnormalities causing bronchiectasis are rare but important to diagnose
given that most are associated with other complications. Specific congenital causes
include Mounier-Kuhn syndrome and the Williams-Campbell syndrome.
Mounier-Kuhn syndrome (tracheobronchomegaly) was first described in 1932 and is a
rare congenital abnormality characterised by marked thinning of the smooth muscle
layer in the trachea and main bronchi as well as atrophy or complete absence of the
elastic fibres (Mounier-Kuhn, 1932). The airways are therefore flaccid and markedly
dilated on inspiration with complete collapse on expiration, leading to increased dead
space and diminished clearance of secretions.
Williams-Campbell syndrome (bronchomalacia) was described in 1960 and refers to the
complete absence of bronchial wall cartilage (Williams and Campbell, 1960). This
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produces a mechanical abnormality with marked dilatation of the proximal airways on
inspiration and complete collapse with expiration again leading to ineffective clearance
of secretions and the development of bronchiectasis.
Pulmonary sequestration is a congenital abnormality that may lead to the development
of bronchiectasis (Savic et al., 1979). There are two forms: extralobar (where the
primitive tissue is enclosed within its own pleural sac and venous drainage is via the
systemic venous system) and intralobar (where the primitive tissue is invested by the
normal visceral lung pleura and venous drainage is via the pulmonary veins). In both
forms there is no communication with the normal tracheobronchial tree and are instead
aerated via the pores of Kohn. These patients are vulnerable to multiple respiratory
infections and are therefore exposed to the risk of developing bronchiectasis.
Genetic Diseases
Perhaps the most well defined, researched and specifically managed cause of
bronchiectasis is cystic fibrosis (Fanconi G, 1936, Anderson, 1938). It is an autosomal
recessive condition with a genetic mutation (the most common genotype being
homozygous deltaF508) causing a reduction in the activity of the chloride channel the
cystic fibrosis transmembrane conductor receptor (CFTR) (Riordan et al., 1989). The
defect impairs electrolyte transport, causing viscous secretions to accumulate in the
bronchial lumen, leading to disruption of the normal mucociliary clearance system.
Recurrent respiratory tract infections occur, cystic bronchiectasis develops and
progressive respiratory failure ensues. Extrapulmonary manifestations of the disease
may include pancreatic insufficiency or failure, gastrointestinal disease, male infertility
and raised sweat chloride levels. The condition is now screened for in all newborns in
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the UK but may still present in later life and should be considered as a diagnosis. This
form of bronchiectasis is studied and managed as an entirely distinct clinical entity.
More recently, Fajac et al proposed that a genetic defect causing dysfunction of the
epithelial sodium channel protein ENaC could be responsible for development of non-
cystic fibrosis bronchiectasis (Fajac et al., 2008).They analysed the genes ENaCp and
ENaCy in 55 patients with idiopathic bronchiectasis of whom 38 had functional
evidence of a defective sodium channel and found eight patients had an ENaC mutation.
Further studies are needed to explore this potential genetic cause of bronchiectasis.
Systemic Diseases
Bronchiectasis is a recognised association of several systemic diseases, in particular
connective tissue diseases and inflammatory bowel disease.
The association of rheumatoid arthritis and bronchiectasis was reported by Walker in
1967 who found the incidence of bronchiectasis to be 3.1% (Walker, 1967). In a later
study of 68 patients with rheumatoid arthritis who underwent HRCT chest scans, the
most frequent abnormality observed was bronchiectasis (30%) and 8% of these patients
had no respiratory symptoms (Cortet et al., 1995). The association is well recognised
however, the mechanism of development of bronchiectasis in patients with rheumatoid
arthritis is unknown.
Primary Sjogren's syndrome is a chronic inflammatory autoimmune disorder
characterised by a triad of keratoconjunctivitis sicca, xerostomia and in more than 50%
a connective tissue disorder. A recent study of 507 patients with Primary Sjogren's
syndrome who underwent F1RCT chest scans found bronchiectasis present in 50
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patients, 41 of whom had no other identifiable cause for the bronchiectasis (Soto-
Cardenas et al., 2010). Although this study sought to further characterise the patients
with bronchiectasis and immunologically found a lower frequency of anti-Ro/SSA
antibodies and a higher frequency of anti-smooth muscle antibodies compared to those
patients without bronchiectasis, the pathogenesis of bronchiectasis development in the
syndrome is unknown.
Ankylosing spondylitis is a multisystem disorder with both articular and extra-articular
features. Pulmonary complications include apical fibrobullous disease that is susceptible
to supra-added infection. Infection in structurally abnormal lung can predispose to
bronchiectasis. A study of 52 patients with ankylosing spondylitis and no respiratory
symptoms who underwent HRCT scans found bronchiectasis present in 8% (Sampaio-
Barros et al., 2007).
Associations between other connective tissue disorders such as systemic lupus
erythematosus (SLE) and relapsing polychondritis with bronchiectasis are documented
and should be considered as an aetiological risk factor or cause (Fenlon et al., 1996,
Tillie-Leblond et al., 1998).
Inflammatory bowel diseases are associated with bronchiectasis. The association was
first recognised by Kraft in 1976 and is more commonly reported with ulcerative colitis
than Crohn's disease (Kraft et al., 1976). Although the immunopathological basis for
the development of bronchiectasis is unknown, it is thought that the relationship may be
due to the common origin of bowel and lung from the primitive gut (Higenbottam et al.,
1980). Studies to date have shown that patients with inflammatory bowel disease and
bronchiectasis have airways that are typically inflamed and patients expectorate
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purulent sputum but bacterial colonisation is infrequent (Moles et al., 1988, Bonniere et
al., 1986). Studies have suggested that inhaled or systemic corticosteroids may be
beneficial in therapeutic management (Camus et al., 1993, Mahadeva et al., 2000).
Yellow nail syndrome was first described in 1964 and is characterised by the triad of
dystrophic yellow coloured nails, lymphoedema and chronic respiratory manifestations
(Samman and White, 1964). A study of 41 consecutive cases of patients with yellow
nail syndrome found bronchiectasis in 44% (Maldonado et al., 2008). The pathogenesis
for the development of bronchiectasis in yellow nail syndrome has not been established.
Pulmonary Diseases
Bronchiectasis is frequently found in association with other pulmonary conditions,
particularly COPD, ILD and possibly a-1 antitrypsin deficiency. Bronchiectasis is
typically recognised as a complication in COPD and ILD, however in alpha-one
antitrypsin deficiency there is debate as to whether bronchiectasis is a complication of
the condition or caused by the disease, a-1 antitrypsin is an antiprotease responsible for
control of protease activity from lysed phagocytes. The condition classically causes
panacinar and basal emphysema and is also associated with cirrhosis of the liver. The
association of the deficiency as a causative factor for bronchiectasis is contentious as
two large case series found no radiological evidence of bronchiectasis on the chest
radiographs of patients with a-1 antitrypsin deficiency (Hutchison et al., 1983, Brantly
et al., 1988). However, other radiological studies have contested this finding, observing
bronchiectasis in 43% (King et al., 1996) and 95% (Parr et al., 2007) of a-1 antitrypsin
deficient patients and a post-mortem study found evidence of bronchiectasis in 15% of
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42 cases examined (Tomashefski et al., 2004). It should be considered as a diagnosis
when patients have basal emphysema.
Traction bronchiectasis is a radiological feature of idiopathic interstitial pneumonias,
particularly usual interstitial pneumonia and non-specific interstitial pneumonia(Lynch
et al., 2005). In a recent study of 146 patients with fibrotic interstitial idiopathic
pneumonias, increasingly severe traction bronchiectasis was found to be a factor
indicative of increased mortality irrespective of the high resolution CT chest
radiological pattern and extent of disease (Edey et al., 2011).
Radiological studies of patients with COPD have found variable rates of bronchiectasis.
Two studies of patients diagnosed with COPD in primary care found radiological
evidence of bronchiectasis in 29% and 50% respectively although the studies did not
explore whether these patients had any alternative cause for the bronchiectasis (O'Brien
et al., 2000, Patel et al., 2004). The latter study found that in those patients with COPD
and bronchiectasis there were higher sputum concentrations of interleukin-8 and time to
recovery from an exacerbation of COPD was longer than in those without
bronchiectasis (Patel et al., 2004). More recently, a study of 92 patients with COPD (51
with severe COPD and 41 with moderate COPD) found that 53 patients had
bronchiectasis (Martinez-Garcia et al., 2011). The study identified the presence of
severe airflow obstruction, isolation of a potentially pathogenic organism in the sputum
and at least one hospitalisation with an exacerbation of COPD in the 12 months
preceding entry to the study to be independent variables associated with the presence of
bronchiectasis. The association ofCOPD and bronchiectasis requires further study.
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Idiopathic
In up to 50% of patients no clear aetiology for the bronchiectasis is found. Such patients
are described as having idiopathic bronchiectasis. It is however, a diagnosis only after
major aetiologies and in particularly aetiologies that demand specific therapeutic
strategies are investigated for and excluded.
Irrespective of the aetiology for bronchiectasis developing, the end result is irreversibly
damaged and dilated airways. The usual pulmonary defence system is disrupted which
has significant consequences for airway integrity with subsequent bacterial invasion and
inflammation causing the perpetual symptoms and significant respiratory morbidity.
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1.7 Airway host defence and damage
The airway mucociliary clearance system is a key component of primary host defence in
the lungs, responsible for maintaining airway sterility and health. The system comprises
of a mucus gel layer that lines the airway lumen trapping pathogens, inhaled toxins and
cellular debris as it is swept by beating cilia from the distal airways to the proximal
airways for expectoration and clearance (Figure 2).
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Figure 2. The normal mucociliary clearance system.
Airway lumen
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Secretory cells Ciliated epithelium
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In health, the respiratory tract is lined by equal numbers of ciliated columnar epithelial
cells and secretory cells. The epithelial cells each have 200 cilia, approximately 7pm
length that rest in a thin layer of periciliary fluid. The cilia beat in a 2 stage process, an
effective beat where their tips engage with the airway mucus sweeping it through the
airways and a recovery beat in the opposite direction where their tips disengage and
recover (Purkinje, 1835, Lucas, 1934). The secretory cells release mucins, antimicrobial
molecules (such as defensins and lysozymes), immunomodulatory molecules
(cytokines) and protective molecules which become integrated within the extracellular
mucus gel that lines the airway lumen. The airway mucus is composed predominantly
of water (97%) and mucins (3%) and accumulates as it is transported through the larger
airways, trachea and pharynx for expectoration (Figure 3).
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Figure 3. Mucus transport through the airways.
Mucus finally ascends the trachea
reaching the vocal cords that are lined by
squamous epithelium and promote cough
and mucus clearance.
1
A thick mucus gel layer accumulates in the
larger proximal airways
l.
Bronchioles are now lined with ciliated epithelium
and secretory cells that produce a thin mucus
layer for the airway lumen.
Alveoli produce surfactant to maintain bronchial
patency. Macrophages remove pathogens.
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The integrity and efficiency of this system is crucial for airway sterility: a deficient
mucus layer leaves the airways vulnerable to injury; disorders of ciliary structure or
function impair clearance of the mucus and excessive mucus accumulation causes the
airways to be persistently exposed to toxic insults and pathogens. In bronchiectasis, the
airways are permanently damaged and the normal mucociliary mechanism is believed to
be impaired (Figure 4).
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Tracheobronchial clearance studies provided the initial evidence for impaired
mucociliary clearance in bronchiectasis. In 1972, Lourenco et al studied the distribution
and clearance of inhaled aerosols in 14 patients with bronchiectasis (Lourenco et al.,
1972). 8 patients were noted to have a central deposition of particles compared with the
diffuse distribution of inhaled particles in healthy subjects. It was also observed that
fewer particles were deposited in the saccular bronchiectatic areas than in the areas
without bronchiectasis when reviewed with the patients' original diagnostic
bronchography. These patients reported more severe symptoms and had more marked
airways obstruction on lung function testing. All patients in the study were noted to
have abnormalities in clearance of the inhaled aerosols, with a particularly slow rate
immediately following inhalation. These findings were confirmed when similar
observations were made in a study of 12 patients with bronchiectasis and 10 healthy
controls (Currie et al., 1987b). In patients with bronchiectasis, the particles from an
inhaled radio-aerosol were deposited in the more proximal airways which the authors
postulated was due to deficiencies in airway patency. Tracheobronchial clearance of the
particles in the 6 hours following inhalation was significantly slower in the
bronchiectasis group despite a significantly greater cough frequency in these patients
[36 coughs versus 0 coughs in the healthy subjects]. The relationship between impaired
mucus clearance and clinical features was demonstrated in a study of 21 patients with
bronchiectasis (Svartengren et al., 1986). At 2 hours following inhalation of labelled
Teflon particles, patients with bronchiectasis retained 65±27% compared with 36±22%
in healthy subjects and with more impaired clearance, there was found to be a greater
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presence of generalised airway symptoms, more continuous symptoms and a longer
history of the disease. A later study of mucociliary clearance in 20 patients with
bronchiectasis demonstrated a diminished or uneven distribution of inhaled
radiolabeled aerosol particles in bronchiectatic regions of the lung and in 19 (95%) of
the patients transport of the aerosol from the bronchiectatic regions was abnormal
(Isawa et al., 1990). The pattern of abnormal clearance from these areas of
bronchiectasis included total stasis (12 patients), regurgitation backwards within the
airway (14 patients), straying (9 patients) or a spiral movement (one patient). Abnormal
clearance was further accentuated by cough, with increased regurgitation and straying of
particles within the bronchiectatic regions observed.
Abnormal ciliary structure
Normal ciliary structure is integral to the function of the mucociliary clearance system.
Each cilium is composed of an axoneme which consists of a circular formation of 9
pairs of microtubules surrounding 2 single, central microtubules. Each pair of
microtubules is connected by nexin links and spokes radiate inwards from each pair to
the central microtubules to maintain the integrity of the axoneme. Each pair of
microtubules has small inner and outer dynein arms which contain adenine
triphosphatase (ATP) which is hydrolysed to ultimately facilitate the movement of the
microtubule pairs. Key features of normal ciliary structure are the "9+2" formation of
the axoneme and the parallel orientation of each cilia's 2 central microtubules which is
essential for coordinated ciliary movement. Studies of ciliary abnormalities in
bronchiectasis are limited, mainly involving patients with primary ciliary dyskinesia
(proven genetic deficiencies causing recognised ultrastructural abnormalities of the
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cilia) rather than those with idiopathic or other aetiologies for their bronchiectasis.
Secondary ciliary dyskinesias include ciliary abnormalities responsible for
dysfunctional movement that are present independent of any specific genetic ciliary
defects. Ciliary anomalies that have been recognised in bronchiectasis include
abnormalities of the orientation of the central microtubules, loss of the 9+2 formation,
deficiencies or absence of the dynein arms and abnormalities of the nexin links in the
pairs of microtubules (Sturgess et al., 1979, Cowan et ah, 2001). An early study
observed either partial or complete loss of the dynein arms within the ultrastructure of
the cilia in 20 Polynesian patients with bronchiectasis (Waite et ah, 1981). A later study
including 15 patients with idiopathic bronchiectasis and proven normal ciliary
ultrastructure and beat frequency observed that the beat direction was disorientated,
correlating with impaired mucociliary clearance (Rayner et ah, 1995). In a study of 133
patients with bronchiectasis, patients with more severe disease (defined as FEVi and
FVC both <60% predicted and >4 lobes affected) had a significantly lower angle of
orientation of the central microtubules than those with non-severe disease. The central
orientation angle of the microtubules correlated with reduced ciliary beat frequency and
the percentage of cilia with ultrastructural defects. However, the angle of the
microtubules was not found to have any relationship in terms of aetiology of the
bronchiectasis or colonisation with Pseudomonas aeruginosa, questioning the clinical
relevance of this aspect of ciliary function (Tsang et ah, 2005c). A prospective
systematic evaluation of ciliary defects and clinical parameters in 152 patients with
idiopathic bronchiectasis compared with 127 healthy controls found a greater
percentage of central and peripheral microtubule defects [odds ratio 14.4(95%
confidence interval 5.6-36.8), typically additional peripheral microtubules (disrupting
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the 9+2 formation) in the bronchiectasis group. The percentage of cilia with central
microtubular defects correlated with increased 24hour sputum volume and reduced
FEVi, suggesting that structural abnormalities of the cilia may have an important
clinical impact (Tsang et al., 2005b).
Abnormal ciliaryfunction
In order to ensure effective mucus transport, the cilia must beat at a normal rate, in a
consistent direction and in a coordinated fashion (Eliezer et al., 1970). Studies have
used ciliated nasal epithelium as a non-invasive means of assessing ciliary function in
the respiratory tract. Ciliary beat frequency is significantly slower in bronchiectasis with
an early study of 10 patients with bronchiectasis observing the mean±SD ciliary beat
frequency to be 12.8±1.3beats/second compared with 14.2±0.7beats/second in healthy
ciliated nasal epithelium (P<0.02) (Rutland and Cole, 1981). This finding has been
confirmed in a more recent study of 152 patients with idiopathic bronchiectasis which
found ciliary beat frequency to be significantly slower than healthy controls (Tsang et
al., 2005b). In vitro studies have sought to explore potential causes for reduced ciliary
beat frequency and have observed that cilia from sites of purulent secretions beat more
slowly (13.6Hz in bronchiectasis compared with 14.3Hz in cilia not exposed to purulent
secretions) (Wilson et al., 1986). Potential reasons for a reduced ciliary beat frequency
in areas of purulent secretions have been investigated and may be broadly classified as
either host factors or pathogen factors. Host factors include exposure to excessive
release of inflammatory mediators from persistent neutrophilic inflammation in the
airways and pathogen factors include exposure to potentially toxic bacterial products
from persistent colonisation within the damaged airway lumen. Early in vitro work
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observed that the proteolytic enzyme elastase released by neutrophils is capable of
inhibiting normal ciliary activity and damaging respiratory epithelium (Tegner et al.,
1979). The purulent sputum in bronchiectasis contains excessive quantities of elastase
due to the persistent neutrophilic airways inflammation. Such purulent sputum from
patients with bronchiectasis has been shown to slow ciliary beat frequency on normal
ciliated nasal epithelium in healthy controls from 13.4beats/second to 6.78beats/second
over a 6 hour exposure period. The addition to the sputum of an elastase inhibitor (al-
antitrypsin) resulted in no significant change in ciliary beat frequency over the same
time period, suggesting that elastase activity is an independent factor affecting ciliary
function (Smallman et al., 1984). The effect of elastase on ciliary function and ciliated
epithelium has been shown in vitro to increase with increasing concentrations of
elastase in the sputum with progressive disruption of the epithelium and slowing of
ciliary beat frequency at higher levels (Amitani et al., 1991). The effect of other
inflammatory molecules on ciliary function in bronchiectasis is unknown and needs
further study. The effect of bacterial products on ciliary function has been investigated
in vitro. Exposure of ciliated nasal epithelium to the supernatants of Pseudomonas
aeruginosa and Haemophilus influenzae over a 4 hour period was associated with
significant slowing of ciliary beat frequency and a disorganised beating pattern. A dose
related effect was also observed and it may be that the release of a factor or factors by
these organisms complements the effect of human neutrophil elastase on ciliary
inhibition (Wilson et al., 1985). The hypothesis that both host factors and bacterial
factors may together affect ciliary function was further supported in a study of 20
patients with bronchiectasis, of whom 13 had a slower ciliary beat frequency. In these
13 patients, two distinct patterns of epithelial damage and ciliary function were
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observed: the first pattern involved a gradual disruption of the epithelium and was
inhibited by the addition of the elastase inhibitor a1-antitrypsin; the second pattern
involved the immediate disruption of the epithelium, ciliary dyskinesia and ciliary stasis
and was inhibited by extraction of chloroform, a recognised bacterial product (Sykes et
ah, 1987). A separate study found that elastase released by Pseudomonas aeruginosa
caused epithelial disruption and when combined with human neutrophil elastase a
marked cytotoxic effect including epithelial cell and basement membrane detachment as
well as mitochondrial damage was seen (Amitani et ah, 1991). The effect of other
products of Pseudomonas aeruginosa have been studied including pyocyanin which
slows ciliary beat frequency and alkaline protease which has not been found to have an
effect (Amitani et ah, 1991).
Abnormal mucus composition
The efficiency of the mucociliary transport system depends on the quantity and
rheological characteristics of the airway mucus. Airway mucus has several important
properties that contribute to its function: viscoelasticity (provided predominantly by the
mucin glycoproteins); spinability; contact angle and surface tension. An in vitro study
using a mucus depleted bovine trachea found that sputum from patients with
bronchiectasis was transported 15% slower than the mean transportability rate of
sputum from healthy human controls (Wills et al., 1995). Later studies in
bronchiectasis focused on altering the osmolality of the mucus to influence the degree
of hydration and thus its physical properties. In a study of 15 sputum samples, the
mean(SEM) osmolality of the sputum was 240(9)mosM/kg. Addition of sodium
chloride improved the transportability index of the sputum from 26±3 to 58±5. Other
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means of increasing the osmolality of the mucus were explored (including glucose,
mannitol and urea) and were found to also enhance transportability (Wills et al., 1997).
A later study manipulated the osmolality of 10 separate sputum samples with the
addition of sodium chloride and observed that increasing the osmolality improved
transportability by 41%. The investigators postulated that hyperosmolality of the airway
surface liquid induces the release of mediators such as prostaglandin E2, histamine and
leukotriene C4 which are known to stimulate ciliary beat frequency hence improving
ciliary beat frequency and mucus transportability (Shibuya et al., 2003). The influence
of inhaled mannitol on sputum rheology and ciliary transportability has been explored
particularly with the intention for therapeutic intervention. It has been demonstrated to
reduce interfacial tension and spinability as well as increasing the wettability and
hydration of airway mucus (Daviskas et al., 2005).
A deficient mucociliary transport system leaves the airways vulnerable to persistent
exposure to potential pathogens. In bronchiectasis, the airways are frequently
chronically infected with organisms.
Airways colonisation
Chronic infection of the airways in bronchiectasis has been recognised since the disease
was first described although more detailed knowledge of the microbiology of the
airways was limited until the early 20thcentury. Initial sputum studies were small such
as Boggs in 1905 and Voigt in 1911 whose studies each involved sputum from only 5
cases of bronchiectasis, but it was observed that all were infected with Haemophilus
influenzae (Boggs, 1905, Allison PR, 1943). Further studies remained limited and relied
more on information from aspirated lung abscesses or sinuses until the advent of the
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bronchoscope when it became possible to examine bronchial secretions that were
minimally contaminated by oropharyngeal flora. In 1950, Benstead published his paper
entitled "The Flora of One Hundred Bronchial Secretions" which included secretions
from 30 patients with bronchiectasis. A variety of pathogens were isolated from these
patients' secretions including Haemophilus influenzae (n=12), Streptococcus
pneumoniae, (n=10), ahaemolytic Streptococci (n=9), yhaemolytic Streptococci (n=7),
Neiserria catarrhalis (n=6), phaemolytic Streptococci (n=3), Staphylococcus albis
(n=l), Staphylococcus aureus (n=l) and coliforms (n=l). It was also observed that there
was no growth from the secretions of 8 patients with proven bronchiectasis (Benstead,
1950). A later study investigated the infecting pathogens in 108 patients with cylindrical
bronchiectasis, using bronchial washings to isolate potential pathogens. Different
bacterial species and types were identified in the washings, including Streptococcus
mitis, Streptococcus salivarius, Haemophilus influenzae, Staphylococcus aureus,
Pseudomonas aeruginosa and Mycoplasma, although again, in a small number the
washings were reported as sterile (Rytel et al., 1964). A later study in Hong Kong
proposed that geographical variation may influence the infecting pathogens isolated in
bronchiectasis (Pang et al., 1989). In their study of 23 patients, bacteria isolated
included Pseudomonas aeruginosa, Klebsiella ozaenae and Pseudomonas fluroescens
which at that time had been reported far less frequently (if indeed at all) in the
predominantly European studies. Their conclusion has not been supported by later,
larger studies. Microbiological studies over the past decade have however confirmed
the early findings that the majority of patients with bronchiectasis are chronically
infected or colonised with a variety of pathogens in their sputum even when clinically
stable. A cohort study of 150 patients with bronchiectasis observed for a 12month
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period found 66% to be chronically colonised (Pasteur et al., 2000) and similar rates
were noted in a separate study of 77 patients of whom 64% were infected with
pathogens in their sputum (Angrill et al., 2002). The most common organisms isolated
in the latter study were Haemophilus influenzae (55%) and Pseudomonas aeruginosa
(26%). More recently, a prospective study of 89 patients over a five year period found
79% to be chronically infected with bacterial pathogens in their sputum when clinically
stable (King et al., 2007). On initial assessment the two most common infecting
pathogens isolated from sputum samples were Haemophilus influenzae (47%) and
Pseudomonas aeruginosa (12%). Other pathogens identified included Moraxella
catarrhalis (8%), Streptococcus pneumoniae (7%), Staphylococcus aureus (4%),
Escherichia coli (2%), Mycobacterium avium complex (2%) and no pathogens in 21%.
Five years later, 74% continued to be chronically infected with 56% isolating the same
organism in their sputum.
The potential clinical relevance of the predominant infecting pathogen has been
explored in a limited number of studies, with the greatest emphasis on the two most
common infecting pathogens, Haemophilus influenzae and Pseudomonas aeruginosa.
Studies initially reviewed the impact of isolation of Haemophilus influenzae from
sputum, based on its greater incidence (and thus presumed importance) in the early
microbiological studies, as eloquently described by Allison in 1943
"...the conclusion is inescapable that nonencapsulated Haemophilus influenzae is
responsible for keeping the chronic inflammatory process smouldering in bronchiectatic
individuals... " (Allison PR, 1943, Allison, 1943).
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In 1966, the persistent presence of Haemophilus influenzae was observed to be
associated with a reduction in total lung capacity in a study of 42 patients with
cylindrical and saccular bronchiectasis of whom 32 were followed for at least 3 years
(Cherniack and Carton, 1966). Patients with Haemophilus influenzae infection were
later recognised to also have a poorer health related quality of life compared with those
not chronically infected with pathogens in their sputum (Wilson et al., 1997b).
Pseudomonas aeruginosa colonisation is associated with more severe bronchiectasis. In
an early study comparing 12 patients with a diagnosis of chronic bronchitis and
Pseudomonas aeruginosa infection with 12 patients who had chronic bronchitis alone,
computed tomography scans demonstrated that in the group infected with
Pseudomonas, there was a greater presence and extent of bronchiectasis and a greater
degree of bronchial wall thickening (Nagaki et ah, 1992). These observations were
echoed in a later study of 22 patients with chronic Pseudomonas aeruginosa infection
with more extensive bronchiectasis, increased bronchial wall thickening and luminal
dilatation as well as a greater area of reduced attenuation on CT chest scans than in
patients not colonised with Pseudomonas (Miszkiel et ah, 1997). Pseudomonas
aeruginosa infection in a later study was also associated with poorer lung function
compared with patients colonised by other organisms (Evans et ah, 1996). A larger
study of 100 patients of whom one third had chronic Pseudomonas aeruginosa infection
similarly found that these patients had a lower FEVi/FVC ratio and also expectorated
larger volumes of sputum than patients colonised with other organisms (Ho et ah,
1998). The chronicity of Pseudomonas infection and potential impact on lung function
was demonstrated in a study of 163 patients with bronchiectasis of whom 67 had never
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been infected, 82 were intermittently infected and 14 were chronically infected with
Pseudomonas, with the latter group having the lowest FEVi (Davies et al., 2006).
However, it is questionable as to whether colonisation with Pseudomonas is a marker of
disease severity rather than an entity responsible for decline in respiratory health (Evans
et al., 1996). Patients with a history of chronic Pseudomonas aeruginosa infection have
a worse health related quality of life than patients infected with Haemophilus influenzae
or indeed other pathogens (Wilson et al., 1997b).
Specific studies of other pathogens that chronically infect the airways in bronchiectasis
are limited. Moraxella catarrhalis is frequently isolated and although it has been
demonstrated that the strain of the organism may vary over time, the type of strain has
not been proven to correlate with exacerbations or antibiotic therapy (Klingman et al.,
1995). Chronic Staphylococcus aureus infection is frequently associated with
bronchiectasis affecting the upper lobes and in patients with allergic bronchopulmonary
aspergillosis infection (Shah et al., 1999).
Non-tuberculous mycobacteria (NTM) may also be isolated and such infection is
recognised as a cause as well as a complication (chronic airways infection) of
bronchiectasis. Initially only a very few studies attempted to assess the extent of NTM
infection in bronchiectasis, finding the incidence to be low (Bates, 1967, Wolinsky,
1979). In a later study of 91 patients with bronchiectasis followed for over 6 years, there
was a 13% (n=12) incidence of positive Mycobacterial cultures, of which 3 were due to
non-tuberculous Mycobacteria (Chan et al., 1992). More recently, a prospective study of
100 patients with bronchiectasis in 2005 found the prevalence of NTM to be 2%, but
with only 1% requiring treatment (Wickremasinghe et al., 2005). A later study similarly
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found a prevalence of 9% (7 out of 80 patients) with only 2.5% requiring treatment
(Fowler et al., 2006). Little is known regarding the clinical impact of chronic infection
with MAC and longitudinal clinical and radiological studies are needed.
Bacterial infection in the airways provokes a defensive inflammatory response. With
chronic airway bacterial colonisation and invasion of the respiratory mucosa, a
persistent, disproportionate inflammatory response occurs and there is progressive lung
damage (Wilson et al., 1996).
Airways Inflammation
The role of neutrophilic inflammation in bronchiectasis is well recognised from findings
of early sputum studies, imaging studies and studies of bronchial washings and mucosa
(Stockley et al., 1984b, Currie et al., 1987c, Gaga et al., 1998).
An early study of uptake of radiolabelled polymorphonuclear leucocytes in 18 patients
with severe, stable bronchiectasis demonstrated almost exclusive accumulation in
bronchiectatic areas of the lungs in nearly 90% (n=16) within 24hours (Currie et al.,
1987c). A later study of bronchial mucosa observed significantly greater numbers of
leukocytes, particularly neutrophils and macrophages in the airways of patients with
stable bronchiectasis compared with healthy controls (Gaga et al., 1998). Endobronchial
biopsies in a separate study had similar findings using monoclonal antibodies to stain
neutrophils, macrophages and cells positive for TNFa with high densities of all
observed in the lamina propria (Zheng et al., 2001). Early sputum studies found high
quantities of the neutrophil protease elastase with strong correlation between elastase
activity and sputum purulence (Stockley et al., 1984b). Bronchoalveolar lavage studies
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have also found greater concentrations elastase and neutrophil degradation products
such as myeloperoxidase in patients with bronchiectasis than in patients with other
inflammatory lung conditions such as pneumonia and idiopathic pulmonary fibrosis
(Schaaf et al., 2000).
Neutrophil recruitment
There is persistent polymorphonuclear leukocyte recruitment to the diseased airways in
bronchiectasis (Stockley et ah, 1988). Various chemoattractants are required for this
migratory process, such as interleukin-8 (IL8), interleukin 1(3 (ILip), leukotriene B4
(LTB4), tumour necrosis factor a (TNFa), transforming growth factor ip (TGF1P) and
have been explored in the sputum of patients with bronchiectasis. IL8 and LTB4 have
been found in high levels and with a strongly positive correlation with purulent sputum
in bronchiectasis (Mikami et ah, 1998). Bronchial mucosal biopsies have shown greater
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quantities of IL8 than controls (47cells/mm compared with 15cells/mm in healthy
controls) (Gaga et ah, 1998) and also TNFa (Zheng et ah, 2001). TGFip has been
observed in higher concentration in the bronchial washings of patients with stable
bronchiectasis compared with controls with a median(range) of 1,812.5(1226.4-
4114.5)pg/litre compared with 1,342.4(940.3-2371.7)pg/litre. Dysregulation of such
pro-inflammatory cytokines leading to their excessive release as indicated in the
aforementioned studies, or improper countenance of their release by anti-inflammatory
cytokines, leads to neutrophil recruitment and activation disproportionate to the
offending pathogen with subsequent local airways damage.
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Neutrophil activity
Neutrophils recruited to the airways become activated, releasing proteases and free
radicals as well as inducing cytokine release resulting in further and persistent
stimulation of the inflammatory process. Airway secretions from bronchiectasis patients
have been explored for a variety of such neutrophil products.
Neutrophil elastase is a serine proteinase produced during the early stages of neutrophil
differentiation. It is released when the neutrophil becomes activated causing epithelial
damage (Amitani et al., 1991), reducing ciliary beat frequency (Smallman et al., 1984),
producing mucus gland hyperplasia (Snider et al., 1985) and stimulating mucus
secretion (Sommerhoff et al., 1990). It damages immunoglobulins and
opsonophagocytic receptors and promotes neutrophil influx by stimulating epithelial
cells to produce chemoattractants (Tosi et al., 1990). High levels are found in the
sputum of patients with bronchiectasis even when clinically stable (Tsang et al., 2000).
Elastase content in sputum has been shown to positively correlate with increased
24hrsputum volume and number of lobes affected by bronchiectasis and in the same
study had a negative correlation with FEVipercent predicted and FVC percent predicted
(Tsang et al., 2000). Elastase activity has also been demonstrated to be higher with
increasing sputum purulence (Stockley et al., 1984b, Lloberes et al., 1992).
Myeloperoxidase is a separate product of neutrophilic inflammation relevant to
bronchiectasis. Initially named verdoperoxidase due to its intense green colour (Agner,
1941), it is a haem protein, abundantly expressed in neutrophils representing 5% of their
total protein content (Klebanoff, 2005). It is released from cytoplasmic granules of
neutrophils and catalyses the conversion of hydrogen peroxidise with chloride ions into
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hypochlorous acid, a potent oxidant with cell damaging properties (Klebanoff, 1999).
Myeloperoxidase also has proinflammatory properties independent of its enzymatic
activity, activating CDll-b and CD 18 on the outer membrane of neutrophils
contributing to further neutrophilic recruitment (Lau et al., 2005). Excessive neutrophil
accumulation can lead to inefficient clearance of apoptotic neutrophils by overwhelmed
macrophages leading to secondary necrosis of neutrophils during which they release
their lysosomal constituents with damaging effects to neighbouring host cells (Medan et
al., 2002).
Other cells involved in the innate inflammatory process in the airways have been
studied in patients with bronchiectasis, such as monocytes and mast cells. Higher
spontaneous adherence of monocytes to fibronectin in the extracellular matrix in the
airways of patients with bronchiectasis compared with healthy controls has been
demonstrated, with increasing purulence associated with greater adherence (in healthy
controls 20±2% adherence, patients with mucoid sputum 40±8% adherence and patients
with purulent sputum 65±5% adherence) (Owen et al., 1992). Tryptase levels as a
marker of mast cell activity have also been studied, with significantly higher levels
detected in the bronchial washings of 36 patients with bronchiectasis compared with 14
healthy controls [4.7( 1.4-20.1 )pmol/litre versus 2.0(0.1-3.55)pmol/litre respectively).
With increasing severity of bronchiectasis, there was noted to be a progressively higher
concentration of tryptase: patients with mild disease had 3.8(0.9-10.8)pmol/litre,
moderate disease had 4.3(3.0-12.6)pmol/litre and severe disease had 9.6(1.2-
20.1)pmol/litre (Sepper et al., 1998).
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Bacterial infection and inflammation
Inflammation in the airways is continuously stimulated by persistent bacterial
colonisation of the airways. The bacterial density in the airways has been shown to
correlate with the degree of airways inflammation. A study of 160 patients with chronic
bronchitis that included 43 patients with idiopathic bronchiectasis observed that
concentrations of the neutrophil chemoattractants IL8 and LTB4 and the neutrophilic
degradation product myeloperoxidase in sputum increased with increasing bacterial
density in the sputum (Hill et al., 2000). The concentration of
myeloperoxidase(units/ml) increased from 0.3(0.1-0.5) in patients who were not
chronically infected, to 0.5(0.2-0.7) with airway bacterial loads of 105-106colony
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forming units(cfu)/ml, to 0.5(0.3-1.2) with airway bacterial loads of 10 -10 cfu/ml, to
0.7(0.3-1.2) with airway bacterial loads of 107-108 and with airway bacterial loads of
>108, myeloperoxidase concentrations were 2.4(0.7-4.8). Bacterial species also
influenced myeloperoxidase concentration, with patients infected with Pseudomonas
aeruginosa having the greatest quantity of myeloperoxidase compared with those
colonised with Haemophilus influenzae and Moraxella catarrhalis respectively. A later
study of bronchial washings taken from 49 patients exclusively with bronchiectasis who
were all clinically stable compared with 9 healthy controls echoed these findings, with a
greater percentage of neutrophils [37(0-98)% versus 1(0-4)%], greater levels of elastase
[90.5(8-2,930)|ag/l versus 34(9-44)pg/l] greater levels of myeloperoxidase [9.1(0-376)
u/1 versus 0.3(0.1-1.4)u/l], higher levels of TNFa [4(0-186)pg/ml versus 0(0-7)pg/ml],
higher levels of IL8 [195(0-5,520)pg/ml versus 3(0-3 l)pg/ml] and higher levels of IL6
[6(0-115)pg/ml versus 0(0-3)pg/ml] respectively (Angrill et al., 2001). With increasing
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bacterial density in the airways of patients with bronchiectasis, there is an exaggerated
inflammatory response with greater numbers of neutrophils and higher concentrations
of neutrophil degradation products and other inflammatory markers.
Systemic inflammation
Studies of systemic inflammation in bronchiectasis are limited. Various markers of
systemic inflammation have been investigated including serum markers and clinical
features. Patients with bronchiectasis have been noted in one study to have a lower body
weight and the same study also found that these patients had a lower serum albumin, but
higher levels of serum antiproteases (a 1 antitrypsin), serum globulins and leukocytes (Ip
et al., 1991). A later study found that serum C-reactive protein was more sensitive than
serum albumin in detecting a higher degree of airways inflammation as expressed by the
concentration of neutrophil elastase in sputum (Lloberes et al., 1992). A further study
found that peripheral leucocyte count, neutrophil number and the erythrocyte
sedimentation rate all correlated with more extensive disease and poorer lung function
in patients with bronchiectasis, but no relationship was found between these markers
and sputum bacteriology (Wilson et al., 1998). In bronchiectasis, there is marked




The impaired host defences in the damaged bronchiectatic airways, with persistent
bacterial invasion and colonisation of the respiratory mucosa resulting in an
inflammatory response that is continuous, exaggerated and poorly regulated has resulted
in the hypothesis that a vicious cycle of perpetual infection, inflammation and
destruction exists in the airways (Cole, 1986), Figure 5.
It is widely acknowledged that this vicious cycle of infection and inflammation is
responsible for the persistent symptoms, frequent exacerbations and on-going airways
damage in bronchiectasis. Acute infective exacerbations provoke intense episodes of
inflammation with subsequent further disruption to the integrity of the airways and
worsening of the vicious cycle in the airways.
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1.8 Current Management of Bronchiectasis
The aims of management of bronchiectasis are to reduce symptoms (reduce cough
frequency and severity, improve sputum volume and purulence, reduce breathlessness,
chest pain and fatigue), reduce exacerbation frequency and severity, preserve lung
function and improve health related quality of life. The impact of bronchiectasis on
mortality is unclear but studies have explored factors that may predict mortality and
these should be considered in the management of bronchiectasis.
There has been one long term follow-up study of risk factors for mortality in
bronchiectasis (Loebinger et al., 2009b). Over a 13 year period, 91 patients with
bronchiectasis were studied and increased age, a history of Pseudomonas aeruginosa
colonisation, reduced total lung capacity, reduced residual volume to total lung capacity
ratio, reduced transfer factor coefficient and a poorer score in the activities section of
the St George's Respiratory Questionnaire (SGRQ) were all identified as risk factors for
increased mortality. Acute exacerbations of bronchiectasis requiring inpatient
management may also be a risk factor for mortality as Roberts et al observed that 21%
of patients had died within 12 months of an admission with an exacerbation of
bronchiectasis to a New Zealand hospital in 2002 (Roberts et al., 2011). A separate
study explored predictors for mortality in 43 patients who had been hospitalised with an
acute exacerbation of bronchiectasis and found a hospital mortality of 9% and a one
year mortality of 30% (Finklea et al., 2010). Factors associated with increased mortality
included male sex, reduced FEV i %predicted, smoking history, use of systemic steroids,
elevated serum creatinine concentration and a need for mechanical ventilation.
Potentially treatable risk factors or higher risk patients requiring more aggressive
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management that should be targeted therefore include those colonised with
Pseudomonas aeruginosa, those with reduced total lung capacity and gas transfer factor
on pulmonary function testing and patients with exacerbations requiring hospitalisation.
The approach to management is multifaceted. Current strategies include medical
management such as patient education, advice on airway clearance and management of
exacerbations as well as consideration of long term treatment strategies such as anti¬
inflammatory and or antimicrobial therapies. Surgical intervention, once the only
management available for patients with bronchiectasis also continues to offer a potential
therapeutic option.
Patient Education
Patients should understand the diagnosis of bronchiectasis, its natural history and
implications particularly the importance of limiting further damage to their airways.
Smoking is a major insult to the airways. Inhalation of tobacco causes mucosal gland
hypertrophy (Megahed et al., 1967), mucus hypersecretion and the recruitment of
inflammatory cells into the lungs with the uncontrolled release of toxic free radicals.
Such activity is destructive to the integrity of the already damaged airway walls.
Furthermore, chronic smoking has been demonstrated to independently induce
polymorphic ultrastructural axonemal abnormalities in bronchoepithelium cilia which
may impair tracheobronchial clearance of secretions (Verra et al., 1995). Smoking has
also been found to be a risk factor for increased mortality in bronchiectasis (Finklea et
al., 2010). Advice on smoking cessation should be given to all patients with
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bronchiectasis both to limit any further damage to the airways, reduce exacerbation
frequency and to improve mortality.
Limiting infective insults to the airways through early recognition and treatment of
exacerbations is important and patients should be educated to have an awareness of any
deterioration in their symptoms and know to seek help. Prevention of pneumonia and
viral insults may be limited by receiving the annual seasonal influenza vaccination and
the pneumococcal vaccine. Studies are however, limited. Furumoto et al (Furumoto et
al., 2008) studied 167 patients with chronic lung disease including bronchiectasis and
found that patients receiving both the 23-valent pneumococcal vaccine and the influenza
vaccine had significantly fewer acute infective exacerbations over a two year period
than patients receiving the influenza vaccine alone. There was however, no significant
difference found in episodes of pneumonia.
Airway Clearance
The normal mucociliary clearance mechanism in bronchiectatic airways is impaired,
mucus stagnates and the airway walls become further inflamed and damaged. Effective
mobilisation and clearance of secretions may be promoted with chest physiotherapy.
Other techniques for airway clearance have been proposed either as independent
treatments or more frequently as adjunctive measures to physiotherapy including
airways humidification, nebulised isotonic and hypertonic saline, nebulised P2 agonists,
inhaled mannitol, nebulised recombinant deoxyribonuclease and mucolytics.
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Physiotherapy
Breathing and exercise were proposed as important adjuncts to medical and surgical
treatments by Macmahon in 1915 (Macmahon, 1915). Over the past century, different
techniques and devices for chest physiotherapy have evolved and are used in the
ongoing management of bronchiectasis including postural drainage, the active cycle of
breathing techniques (ACBT), inspiratory muscle training, positive expiratory pressure
(PEP) and oscillatory positive expiratory pressure devices. A UK survey of routine
practice in 2002 found the most commonly practised techniques to be ACBT and
postural drainage (O'Neill et al., 2002).
Postural drainage was first suggested by Quincke in 1898 and essentially describes
gravity assisted drainage of secretions. Quincke postulated that postural drainage had 4
main mechanisms of action: firstly, the mechanical influence of gravitation to drain the
mucus; secondly, the subsequent movement of mucus through the airways provided a
stimulus for the cough reflex; thirdly, previously airless parts of the lung could then
expand and finally the pressure of the intra-abdominal organs on the diaphragm would
also facilitate expectoration (Quincke, 1898). Ewart in 1901 reported two case studies
and advised the technique should be used continuously for bronchiectasis and "chronic
bronchial affections". He conceded that only if poorly tolerated then it could be
practised intermittently, for at least 3hours per day (Ewart, 1901). Postural drainage
remained the technique of choice throughout the following five decades with further
studies including Nelson in 1934 who proposed that a position of fifteen degrees of the
Trendelenburg position would assist with middle lobe drainage and at twenty degrees of
the Trendelenburg position the lower lobes would drain (Nelson, 1934). The technique
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does not require any equipment and given adequate space can be practised unassisted
anywhere. Disadvantages include possible promotion of gastro-oesophageal reflux and
breathlessness. Chronic or increased gastro-oesophageal reflux may be a risk factor for
bronchiectasis and should the technique causes occurrence or worsening of such
symptoms then its practice would not be recommended. Dyspnoea with postural
drainage may also limit compliance (Cecins et al., 1999). In the 1960s, alternative
physiotherapy strategies to postural drainage began to emerge including different
exercise techniques and the use of specialised devices. The active cycle of breathing
techniques originated in New Zealand and involves a pattern of tidal breathing at the
patient's own rate followed by thoracic expansion exercises then forced expiration
(huffs) and a cough. Huffing generates both a shearing force within the airways and an
oscillatory movement of the airway wall itself helping to reduce mucus viscosity and
mobilise peripheral secretions to the more proximal and larger airways where the final
cough will clear them. Devices such as the Flutter create a positive expiratory pressure
and an oscillatory vibration of air within the airways, loosening and mobilising
secretions to the larger proximal airways for clearance with cough. Several short term
small studies have compared the various techniques and to date, no single method has
been found to be superior.
Postural drainage was formally studied by Mazzocco et al in 1985 in thirteen outpatients
with bronchiectasis. A single ten minute session of postural drainage (at ten degrees of
the Trendelenburg position) was compared with a ten minute session of postural
drainage and chest percussion (Mazzocco et al., 1985). No difference was seen in FEVi,
FVC, peak expiratory flow, oxygen saturations or sputum volume. Following both
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techniques, the authors observed that between 2-50% of the patients' total daily sputum
volume was expectorated. Cecins later revisited the benefits of postural drainage with
the active cycle of breathing technique (Cecins et ah, 1999). In their study, nineteen
patients each underwent a single session of ACBT alone; ACBT with a twenty degree
tilt; ACBT with a one hundred and eighty degree tilt. Each session was separated by a
twenty four hour washout period. No session was superior, with no significant
difference seen in FEVi, oxygen saturations or sputum weight measured immediately
after each session. However, using a visual analogue scale, a significant number of
patients reported increased dyspnoea following the session with a twenty degree tilt and
only one patient reported a preference for the twenty degree tilt session.
The longest study to date of chest physiotherapy in bronchiectasis compared four weeks
ofACBT with four weeks of twice daily usage of the flutter device in seventeen patients
with bronchiectasis and found no significant difference between the techniques in
sputum weight, dyspnoea score using the BORG scale or in health related quality of life
using the Chronic Respiratory Disease Questionnaire. A statistical improvement was
seen in FEVi but this was not thought to be clinically significant (Thompson et ah,
2002). Other studies have involved outcome assessment following single physiotherapy
sessions with different techniques and have found no difference in spirometry, oxygen
saturation or sputum weight (Patterson et ah, 2005, Eaton et ah, 2007, Patterson et ah,
2004).
Acceptability of a technique is recognised as critical for regular compliance. As no
single technique has been proven to be superior, the prescribed physiotherapy regimen
should be individualised and guided by patient preference.
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Pulmonary rehabilitation
Pulmonary rehabilitation involves a combination of exercise training sessions (such as
treadmill walking, stair climbing, cycling) and multidisciplinary education delivered on
a regular basis over a 6 to 8 week period. Its efficacy in COPD is well established (Nici
et ah, 2006). A randomised controlled trial of 32 patients with bronchiectasis
investigated the effect of pulmonary rehabilitation and inspiratory muscle training
(IMT) with pulmonary rehabilitation and an IMT sham with a control group. At 8 weeks
an improvement was seen in both groups (although there was no significant difference
between the groups) but at 12 weeks the improvement in exercise capacity had only
been maintained in the IMT group. The study did not find the addition of IMT to the
pulmonary rehabilitation programme provided any further significant benefit (Newall et
ah, 2005). More recently, a retrospective study of 95 patients with bronchiectasis
demonstrated significant improvements in both exercise capacity (assessed using the 6
minute walking distance test) and in health related quality of life (assessed using the
Chronic Respiratory Disease Questionnaire). 37 of these patients were followed up 12
months after the pulmonary rehabilitation programme and still had a better total exercise
capacity than at entry to the pulmonary rehabilitation programme (Ong et ah, 2011).
Airways humidification
Adequate hydration of the periciliary layer is necessary for optimal ciliary transport
capacity (Litt, 1970) and cough efficiency is known to improve with greater depth of the
periciliary fluid layer and reduced mucus viscosity (Scherer, 1981). Bronchiectatic
airways have a damaged epithelial layer and periciliary hydration may be suboptimal.
The rationale for humidification of the airways is that it may increase periciliary fluid
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depth and reduce mucus viscosity thus enhancing ciliary movement and mucus flow in
the airways. Evidence is, however, limited. One study has attempted to quantify the
effect of thirty minutes of cold water jet nebulisation to the airways as an adjunct to
postural drainage (with a twenty degree tilt) and huffing (Conway et al., 1992). Seven
patients with bronchiectasis underwent a single session of such humidification and
physiotherapy and one week later a session of physiotherapy alone. Sputum clearance
was assessed using labelled Technetium with gamma camera imaging. Sputum weight
and FEVi also observed. A significant increase in sputum weight (median increase of
six grams) and sputum clearance (median increase of 8.7%) was observed following
both humidification and physiotherapy compared with physiotherapy alone. Similar
improved mucociliary clearance was seen following seven days of domiciliary
humidification (daily three hours' inhalation of saturated air at 37°C) in ten patients
with bronchiectasis with the area under the tracheobronchial retention curve reducing
from 319±50%/hr to 271±46%/hr (Hasani et al., 2008). The largest clinical study to
date, although not exclusively in patients with bronchiectasis, was a randomised
controlled trial of 108 patients with COPD or bronchiectasis which found that following
twelve months' domiciliary humidification treatment patients had fewer and shorter
exacerbations with a greater length of time to their first exacerbation compared with
patients receiving routine care (Rea et al., 2010). No other formal studies of airways
humidification in bronchiectasis have been undertaken and although it may confer some
benefits, the current evidence is insufficient to recommend it for routine use,
particularly given the potential risk of infection from the delivery systems with
opportunistic organisms especially Mycobacteria.
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Nebulised saline and /f agonists
Efficiency of the mucociliary transport mechanism is intrinsically related to the
constituents and properties of the mucus. The rationale for nebulised saline as an
adjunct to physiotherapy is that it may alter the concentration of the main constituent of
mucus (i.e. water) thus improving transportability (Shibuya et al., 2003). Clinical
studies are, however, limited. In 1988 Sutton investigated whether isotonic (0.9%
saline) or nebulised P2 agonists were useful adjuncts to ACBT physiotherapy. Their
study involved only 8 patients undergoing single treatment sessions but did find that
with both nebulised adjunctive treatments sputum yield was greater than with ACBT
alone. In 2005 Kellett et al allocated 24 patients with bronchiectasis to receive four
separate sessions of ACBT physiotherapy with three of the sessions involving
adjunctive treatment with a nebulised P2 agonist and either nebulised 0.9% saline or
nebulised 7% saline (Kellett et ah, 2005). With nebulised 7% saline, the weight of
sputum expectorated was greater than with 0.9% saline and there was a notable linear
trend towards reduced sputum viscosity with the hypertonic saline. However patients
reported greater ease in expectoration with 7% saline. These studies provide sufficient
evidence to support a larger, longer-term study into the role of nebulised saline as an
adjunctive therapy to regular physiotherapy but at present such nebulised treatments are
not routinely used in clinical practice.
Inhaled hyperosmolar agents
Mannitol is a naturally occurring sugar alcohol that acts as a non-ionic osmotic agent
when inhaled as a dry powder into the airways. The mannitol increases the osmolarity
within the airway lumen causing water to leave the epithelial cells with their subsequent
80
shrinkage causing several cell volume regulatory actions to occur, including
intracellular influx of calcium (Komgreen and Priel, 1994). Increased intracellular
calcium increases ciliary activity and will thus aid the mucociliary transport mechanism
(Eveloff and Warnock, 1987). Hyperosmolarity within the airways is also thought to
trigger mast cell degranulation with release of histamine which may also contribute to
increased ciliary beat frequency (Silber et al., 1988).
Mannitol has been demonstrated clinically to improve mucociliary clearance in
bronchiectasis. An open label study using a radioaerosol technique to assess mucus
clearance in 11 patients with bronchiectasis observed that 34.0±5.0% mucus clearance
was achieved 75minutes following inhalation of a mean(standard deviation) dose of
320±81mg of dry powder mannitol compared with 17.4±3.8% clearance with control
(Daviskas et ah, 1999). A later study using the same technique in 8 patients found that a
single inhaled dose of 400mg of dry powder mannitol reduced the extent of mucus
retained within the lung 24hours after inhalation suggesting that mannitol has useful
long-acting effects in addition to its acute impact (Daviskas et ah, 2001). Clinically, an
open label study of 12 days treatment with daily 400mg inhaled dry powdered mannitol
improved small airways function (using midexpiratory flow FEF25-75), improved cough
transportability and had a beneficial effect on health related quality of life (Daviskas et
ah, 2005). A multicentre clinical study has recently been completed and the outcomes
are currently awaited. At present, there is insufficient evidence to support its routine
use.
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Recombinant human deoxyribonuclease 1
Purulent airway secretions contain excessive quantities of deoxyribonucleic acid (DNA)
released by persistent and uncontrolled neutrophilic activity in the chronically inflamed
and infected airways. DNA is an extremely viscous polymer and a major contributor to
the tenacity of purulent secretions. Inhalation of recombinant human deoxyribonuclease
(rhDNase) should cleave the DNA, reducing sputum viscosity, improving
expectoration, airway clearance and lung function. However, its routine use in
bronchiectasis is not advised after a randomised double blind placebo controlled trial of
rhDNase in 349 patients for 24 weeks found that patients randomised to twice daily
treatment with rhDNase had a higher rate of exacerbations, increased use of antibiotics
and a greater rate of hospitalisations as well as a significant reduction in FEVi
(O'Donnell et al., 1998).
Mucolytics
There are very few studies exploring the efficacy of other mucolytics in bronchiectasis.
Erdosteine has been demonstrated to significantly improve mucociliary transport
velocity in ex-smokers with chronic bronchitis and hypersecretion (Olivieri et ah,
1991). A more recent study assessed the efficacy of oral erdosteine in 30 patients in a
prospective parallel open label pilot study of twice daily erdosteine and physiotherapy
versus physiotherapy alone. Although both groups demonstrated improvements in the 6
minute walk test and visual analogue scores of cough, dyspnoea, sputum volume, colour
and purulence, the erdosteine group had a significant improvement in FEVi and FVC
(Crisafulli et ah, 2007). There is currently insufficient evidence to support the routine
use ofmucolytics in the management of stable bronchiectasis.
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Anti-inflammatory strategies
Limiting the perpetual inflammation in bronchiectasis may reduce the persistent damage
to the airway walls and disrupt the vicious cycle of inflammation and infection.
Anti-inflammatory strategies include inhaled corticosteroid therapy and more recently
the immunomodulatory effects of macrolide antibiotic therapy have been proposed as
potential treatment strategies.
Inhaled corticosteroids
The precise mechanism of action of inhaled corticosteroids in bronchiectasis is not
known. However, both sputum studies and studies of bronchial epithelium have
demonstrated a reduction in inflammatory cells with inhaled corticosteroid use. Patients
with bronchiectasis have high total leucocyte counts within the bronchial epithelium and
evidence of mucus gland hypertrophy (Gaga et al., 1998). In a study of endobronchial
biopsies in 12 patients with bronchiectasis, 6 of whom were on regular inhaled
corticosteroid treatment, there were significantly fewer CD3+ and CD4+ T lymphocytes
in the patients receiving inhaled corticosteroids (CD3+ 197cells/mm2 versus
369cells/mm2 respectively and CD4+ 82cells/mm2 versus 190cells/mm2 respectively).
Additionally, there were fewer cells positive on staining for interleukin-8 (30cells/mm2
versus 60cells/mm2) (Gaga et al., 1998). A four week double blind randomised
controlled trial of twice daily 500|ig fluticasone versus placebo in 24 patients with
bronchiectasis found a significant reduction in sputum leucocyte density, interleukin
(IL)-8, IL-lp and leukotriene B4 in the treatment group (Tsang et al., 1998a). It is
therefore postulated that inhaled corticosteroids may exhibit an effect in bronchiectatic
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airways by a reduction in inflammatory cell recruitment with subsequently less
proinflammatory mediator release and activity. There have been only a few studies of
the clinical benefits of inhaled corticosteroids in bronchiectasis. A double blind placebo
controlled crossover study of 20 patients explored the effect of 750pg of beclometasone
administered twice daily for six weeks on sputum production, lung function and
respiratory symptoms. There was an 18% reduction in daily sputum production, an
improvement in cough on symptom scoring and a statistically significant increase in
peak expiratory flow rate and FEV i (although the authors queried the clinical relevance
of these latter improvements) with regular inhaled corticosteroid use (Elborn et al.,
1992). A larger and longer term study of 500pg fluticasone twice daily versus placebo
in 86 patients over a 12 month period found that with treatment, 24hour sputum volume
reduced but there was no difference in sputum purulence, lung function or exacerbation
frequency (Tsang et al., 2005a). A further study explored the effect of inhaled
corticosteroid dosage in a six month randomised controlled trial of 93 patients who
received either 250pg fluticasone twice daily or 500pg fluticasone twice daily or
placebo (Martinez-Garcia et al., 2006). Patients receiving 500pg fluticasone twice daily
reported less cough, had less daily sputum [-9.7(12.8)mls per day], a reduction in their
dyspnoea and had an improved score on the health related quality of life questionnaire
the SGRQ [improved from a score of 45.5(14.2) to 40.5(13.9) after 6 months treatment].
No significant changes were seen in any group in pulmonary function or exacerbation
frequency. The evidence to support long term use of inhaled corticosteroids in
bronchiectasis is limited and their use must be balanced against the risk of adverse
effects. A study of 50 patients with bronchiectasis of whom 33 were receiving regular
inhaled corticosteroids found that 48.5% had adrenal suppression and a poorer health
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related quality of life score when investigated with a short synacthen test and
completion of the SGRQ compared with only 23.5% of those not regularly receiving
inhaled corticosteroids (Holme et ah, 2008). However, patients may warrant a trial of
therapy particularly those with excessive sputum volume.
Macrolide therapy
Macrolides were originally discovered as antibacterials that act through the inhibition of
RNA dependent protein synthesis by reversibly binding to the 50S ribosomal unit of a
susceptible microorganism. Interest in potential immunomodulatory properties of the
14-member (erythromycin and clarithromycin) and 15-member (azithromycin)
macrolides occurred in the 1960s and clinically these effects were first reported in
asthma by Spector et al in 1974 (Spector and Farr, 1974). Since then, their role has been
studied in other chronic inflammatory pulmonary diseases such as diffuse
panbronchiolitis, COPD and cystic fibrosis but to date there have only been four studies
in adults with bronchiectasis. The mechanism of action is thought to be
immunomodulatory rather than immunosuppressive and includes: inhibition of
inflammatory cell chemotaxis through suppression of cytokine production such as IL-8,
IL-6 and intracellular adhesion molecule (ICAM)-l (Takizawa et al., 1997, Kusano et
al., 1995); impairment of superoxide generation by activated neutrophils (Kadir et al.,
2000) as well as inhibition of mucus hypersecretion (Goswami et al., 1990, Tamaoki et
al., 1995).
The first clinical study of macrolide use in bronchiectasis was an 8 week randomised
double-blind placebo controlled trial of erythromycin 500mg twice daily versus placebo
in 21 patients. A significant improvement in FEV| and FVC was seen with a significant
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reduction in 24hrsputum volume from a baseline of mean (95%confidence interval)
33.7(23-49.3)ml to 23.8(15.7-36.l)ml after 8 weeks' treatment. No changes were seen
in sputum bacterial density or perhaps somewhat surprisingly in the inflammatory
mediators IL-8, IL-la, TNF-a and leukotriene-B4. Azithromycin 250mg was used
thrice weekly for four months in 39 patients with bronchiectasis in a study in 2004 with
significant improvements seen in exacerbation frequency, use of intravenous antibiotic
therapy, symptoms and gas transfer diffusing factor coefficient (Davies and Wilson,
2004). An open label randomised crossover trial of twice weekly 500mg azithromycin
treatment in 11 patients found significant reductions in sputum volume and exacerbation
frequency with treatment (Cymbala et al., 2005). The most recent study was an
uncontrolled study of once daily 250mg erythromycin given for 12 months in 24
patients with bronchiectasis (Serisier and Martin, 2011). In comparison with the 12
months preceding entry into the study the median number of infective exacerbations
halved [median(range) 2(0-8)exacerbations compared with 4(2-11) exacerbations
respectively, P<0.0001] and the number of days of antibiotic use per year also
significantly reduced [median(range) 21(0-78)days compared with 44(15-138)days
respectively, P0.0001].
The regular long term use of macrolides is associated with potential adverse effects
including perhaps most importantly macrolide resistance. The risk of macrolide
resistance in nontuberculous mycobacteria that may be more prevalent in patients with
bronchiectasis needs explored. Other adverse effects include gastrointestinal upset
(diarrhoea occurred in 25% of Cymbala's study population with treatment),
derangement of liver function tests (Davies and Wilson, 2004) and rash (Tsang et al.,
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1999b, Davies and Wilson, 2004) and potential middle ear problems with balance
difficulties and deafness. However, both their potential immunomodulatory and
antibacterial effect are intriguing and potentially offer a long term therapeutic option in
bronchiectasis, although further randomised controlled studies are needed.
Antimicrobial strategies
The rationale for prescribing long term antibiotics (oral or nebulised) in clinically stable
bronchiectasis is to reduce the bacterial burden in the airways therefore limiting
inflammation and promoting healing of the bronchial tree. Disrupting the vicious cycle
of infection and inflammation should reduce daily symptoms and exacerbation
frequency. The evidence for long term antibiotics is, however, limited. Studies have
been conducted using both oral antibiotics and nebulised antibiotics, but the study
designs have varied, used different criterion for selecting patients and different
durations and doses of antibiotics with various outcome measures to assess response
making comparisons between regimens difficult subsequently limiting clinical
application. National guidelines published by the British Thoracic Society in 2010
recommended that patients suffering three or more exacerbations per year or those with
fewer exacerbations but significant morbidity should be considered for long term
antibiotics (Pasteur et al., 2010).
The first randomised controlled trial of long term oral antibiotic therapy was designed to
study the effect of prolonged antibiotic therapy in severe cases of bronchiectasis
characterised by abundant mucopurulent or purulent sputum. It was conducted in 112
patients from seven different UK centres over 12 months by the MRC in 1957 and
compared 2g of tetracycline daily with 2g of penicillin daily or 2g of lactose daily. It
87
found that 2g of oral tetracycline per day improved sputum purulence and reduced
sputum volume significantly (from 76.7ml to 49ml per day) as well as reducing the
number of absent days from work due to respiratory ill health (118 days of absenteeism
compared with 381 days in the penicillin group and 446 days in the lactose group)
(1957). Tetracycline and penicillin continued to be studied as a potential long term oral
antibiotics in studies conducted over the following few decades. Chemiack et al in 1959
found that with 2g tetracycline per day used for at least 3 months, there were fewer
exacerbations and exacerbations that occurred were of shorter duration compared with
placebo (Cherniack et al., 1959). In 1960, a randomised controlled trial of tetracycline
2g daily compared with penicillin lg daily, compared with an oleandomycin/penicillin
combination and placebo in 89 patients focussed on the impact of the treatments on
sputum bacteriology. Tetracycline was effective in reducing infection with Haemophilus
influenzae, Streptococcus pneumoniae and Staphylococcus aureus but there was
increased infection with Pseudomonas aeruginosa. Penicillin was effective in reducing
Streptococcus pneumoniae infection but not Klebsiella species and the
oleandomycin/penicillin combination was found to be effective in reducing infection
with Haemophilus influenzae, Streptococcus pneumoniae and Staphylococcus aureus,
but not Proteus species (Dowling et al., 1960). The effect of antibiotic therapy on
sputum inflammatory indices was explored by Stockley in 1984, although the
amoxicillin administered to the 15 patients in the open label study was for 14 days only.
However, in the 67% patients who clinically responded with macroscopic clearing of
sputum purulence and eradication of the sputum pathogen, there was a significant
reduction in sputum elastase and albumin leakage (Stockley et al., 1984a). Later studies
explored the effect of long term antibiotics on other clinical endpoints such as lung
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function and found minimal improvements (Hill and Stockley, 1986). Three decades on,
another randomised controlled trial was conducted to explore the impact of high dose
daily oral amoxicillin (3g BD) over 8 months in 32 patients. It found that amoxicillin
treatment led to clinical improvement, reduction in 24 hour sputum volume and
purulence as well as fewer absent days from work, with the treatment well tolerated
(Currie et al., 1990). Tolerability of long term oral antibiotics is a clear factor that may
affect compliance and was recognised early on in antibiotic studies. Sobel et al assessed
the adverse effects with long term usage of oral tetracycline, oral penicillin and oral
olandeomycin/penicillin combination preparations (Sobel et al., 1962). Tetracycline was
associated with reported diarrhoea in 27% and with both penicillin and
olandeomycin/penicillin combinations upper gastrointestinal symptoms occurred
(reported in 27% and 20% respectively). Aerosolised antibiotics began to be formally
studied as potential means of delivering long term antibacterial therapy to the diseased
airways in the 1980s. With direct delivery to the lungs, systemic absorption could be
anticipated to be minimal with a lower risk of such adverse systemic effects.
Nebulised antibiotics offer a targeted therapy with limited systemic side effects, but are
expensive and may be less well tolerated due to bronchospasm- even with adjunctive
treatment with a p2 agonist. An open label study in 1985 assessed the impact of 4
months treatment with nebulised amoxicillin in six patients who had failed to respond to
oral amoxicillin (Stockley et al., 1985). The randomised controlled trials of long term
nebulised antibiotics began to be conducted in the late 1990s in patients chronically
colonised with Pseudomonas aeruginosa. Orriols et al compared the impact of
nebulised ceftazidime and nebulised tobramycin with placebo over 12 months in 15
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patients and found that with nebulised antibiotic therapy there were fewer and shorter
hospital admissions for exacerbations and no increase in antibiotic resistance (Orriols et
al., 1999). Two larger randomised controlled trials followed comparing twice daily
nebulised tobramycin with placebo, one cyclically (4 weeks treatment, 2 weeks off) and
the other daily for 6 months. Both found a reduction in bacterial density in the sputum
but there was a small increased incidence of bronchospasm in the treatment arms
(Barker et al., 2000, Drobnic et al., 2005). Further support for the role of nebulised
tobramycin in patients colonised with Pseudomonas aeruginosa was demonstrated in an
open label study in 2005 of 41 patients who received three cycles each of fourteen days
of twice daily 300mg tobramycin separated by fourteen days with no treatment. Patients
reported an improved health related quality of life and 22% achieved complete
eradication of Pseudomonas aeruginosa from their sputum. However, 5% developed
resistance to tobramycin and 22% stopped treatment early due to adverse effects
(Scheinberg and Shore, 2005).
Further studies are needed to define who would benefit from long term antibiotics and
the optimum mode and type of treatment.
Eradication
There have been no studies in non-cystic fibrosis bronchiectasis evaluating whether a
targeted antibiotic regime should be commenced following first isolation of organisms
such as Pseudomonas aeruginosa and Methicillin resistant Staphylococcus aureus from
the airways in otherwise clinically stable disease. The rationale for attempting bacterial
clearance is founded upon these organisms infecting the airways of patients with more
severe bronchiectasis with a poorer prognosis (Ho et al., 1998, Loebinger et al., 2009a,
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Wilson et al., 1997b). Such an approach is used in cystic fibrosis bronchiectasis, but its
effect and long term impact in non-cystic fibrosis bronchiectasis is unknown. The
current UK national guidelines do however advise that eradication may be attempted as
a pragmatic approach to management of the condition, although this advice is based on
consensus expert opinion only and long term, randomised controlled studies are needed
(Pasteur et al., 2010).
Surgery
Prior to the introduction of antibiotic therapy, the most effective management of
bronchiectasis was surgery.
"The only means of "curing" bronchiectasis in the sense ofcausing the disappearance
of the dilated bronchi is by surgical removal.... " (Warner, 1932).
Currently, surgical management is reserved for specific indications including major
haemoptysis or localised disease causing significant morbidity refractory to medical
management. Surgery has traditionally been performed via thoracotomy and reported
outcomes from retrospective case reviews are good. An analysis of 92 patients who
underwent thoracotomy between 2002-2007 including ten pneumonectomies, 36
lobectomies, 2 bi-lobectomies and segmentectomies and 12 segmentectomies) had a
morbidity rate of 16% and mortality of 1%. With a mean follow-up of 15.3 months in
75 patients, 84% were asymptomatic and 10.7% had had a significant clinical
improvement (Gursoy et al., 2010). A larger retrospective analysis of 277 patients
undergoing thoracotomy (42.2% a unilateral lobectomy) for bronchiectasis had a
mortality of 0.7% and morbidity of 15.8% with 68.5% of patients being symptom free
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over a mean follow up of four and a half years (Bagheri et al., 2010). Risk factors
affecting surgical outcome were explored in a retrospective analysis of 143 patients and
included a previous history of tuberculosis infection, an FEVi of less than 60%
predicted, incomplete resection and patients who had not undergone a preoperative
bronchoscopy (Eren et al., 2007). More recently, outcomes from video assisted
thoracoscopic surgery have been compared with thoracotomy. A study of 52 patients
undergoing video assisted thoracoscopic surgery (VATS) compared with 52 undergoing
thoracotomy found that the VATS group had a shorter length of stay post-operatively,
had fewer post-operative complications and 94% achieved complete recovery compared
to an 88% complete recovery in the thoracotomy (Zhang et al., 2011). In current
practice, referral for surgery is not common and to date there have been no randomised
controlled trials of surgical and nonsurgical management of bronchiectasis.
Management ofexacerbations
Exacerbations of bronchiectasis requiring antibiotic therapy are typically defined as a
persistent (more than 24 hours) deterioration in respiratory symptoms (increased cough,
increased sputum volume, increased sputum purulence, breathlessness or wheeze) with
or without systemic disturbance. They are responsible for both significant patient
morbidity and socioeconomic cost as patients frequently utilise both primary and
secondary health care resources. UK hospital data for 2007-2008 identified
bronchiectasis as the primary diagnosis for 1 in 1800 inpatient admissions. In the United
States between 1993 to 2006, the average annual age-adjusted hospitalisation rate was
16.5 per 100 000 of the population (Seitz et al., 2010). Kelly et al observed 410 patients
for 6 months during which time 30 patients required a hospital admission, a further 12
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required domiciliary intravenous antibiotic therapy and 77 received oral antibiotic
therapy (Kelly et ah, 2003). The associated days of absence from work have a wider
societal impact.
More frequent severe exacerbations have been shown to be an independent factor for
decline in lung function. In a study of 76 patients over 24 months the mean annual rate
of severe exacerbations (those requiring treatment with systemic corticosteroids, or with
respiratory failure or those requiring hospitalisation) was 1.5(range 0-8) (Martinez-
Garcia et al., 2007). There are no randomised placebo controlled trials evaluating the
efficacy of antibiotic treatment of infective exacerbations although studies have shown
that treatment can improve patients' health related quality of life. A study of 18 patients
requiring intravenous antibiotics for an infective exacerbation had a significant
improvement in their quality of life score (improvements were seen in dyspnoea,
emotional and mastery subsections) following completion of treatment (Courtney et al.,
2008). Despite such morbidity and the cost of exacerbations to the patient and society,
there is little evidence to guide selection of antibiotic(s), mode of delivery, duration of
treatment or indeed the role of adjunctive therapies.
Antibiotic therapy
The first studies of antibiotic treatment for exacerbations were for exacerbations that
had not responded to an initial course of antibiotics. Douglas et al randomised 131
patients who had not responded to penicillin (1 or 2 megaunits, administered
intramuscularly for between 5 to 14 days) to receive either chloramphenicol (2 grammes
per day, orally) or oxytetracycline (2 grammes per day, orally) for between 5 to 7 days.
78% of those treated with chloramphenicol developed mucoid sputum compared with
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38% in the oxytetracycline group (Douglas et al., 1957). Further studies suggested that
higher doses of antibiotics and longer treatment duration may have a greater impact. A
randomised controlled trial of 14 days of penicillin and streptomycin compared with
cephaloridine (2g daily or 4g daily or 6g daily) in 197 patients who had failed to
respond to an initial course of antibiotics found that 6g of cephaloridine achieved
conversion to mucoid sputum in 56% which was superior to penicillin and streptomycin
which achieved mucoid sputum in only 34%. Subsequent to this study, Pines et al
conducted a further randomised controlled trial comparing 4 separate antibiotic
regimens in patients known to be chronically colonised with Pseudomonas aeruginosa
with exacerbations and found greatest success with combinations of intramuscular or
intravenous antibiotics and inhaled antibiotics administered for a 7 to 14 day period
(Pines et al., 1970). These findings proposed that longer duration of antibiotic therapy,
dual therapy and both local and systemic treatment may be a more effective approach to
management of exacerbations. Later studies have ranged in duration of treatment from 7
to 14 days, but there have been no randomised controlled trials comparing treatment
efficacy between 7 and 14 days. Mode of delivery of antibiotic was explored in 1994 in
a study of 27 patients randomised to either intravenous antibiotics alone or intravenous
and inhaled antibiotics for seven days. The combination of intravenous and inhaled
therapy was superior, with an improved FEVi, FVC, PEFR and a more than 6 fold
reduction in sputum volume (el-Din et al., 1994). More recently, a double blind,
multicentre trial comparing 14 days treatment with either inhaled tobramycin and oral
ciprofloxacin with oral ciprofloxacin alone in 53 patients known to be chronically
colonised with Pseudomonas aeruginosa suffering an acute exacerbation found that
with inhaled tobramycin, there was a greater reduction in sputum bacterial density,
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although improvements in other clinical outcomes measured were not found to be
superior (Bilton et al., 2006).
The studies to date have generally used empirical, broad spectrum antibiotic therapy
proven for Pseudomonas aeruginosa, Haemophilus influenzae and Staphylococcus
aureus. To date, there are no randomised controlled trials comparing antibiotics with
placebo in the treatment of acute exacerbations of bronchiectasis, but consensus opinion
for selection is suggested in Table 3 below.
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Table 3. Recommended antibiotic therapy for exacerbations of bronchiectasis according
to pathogenic organism (adapted from BTS Guideline (Pasteur et al., 2010).
Organism First Line Treatment Length of Second Line Length of
Treatment Treatment Treatment
Streptococcus Amoxicillin 500mg 14 days Clarithromycin 14 days
pneumoniae TDS 500mg BD
Haemophilus Amoxicillin 500mg- 14 days Clarithromycin 14 days
influenzae 1G TDS 500mg BD
(P lactamase (3G BD in severe Ciprofloxacin
negative) disease) 500mg BD
Ceftriaxone l-2g
OD (IV)
Haemophilus Co-amoxiclav 625mg 14 days Clarithromycin 14 days





Moraxella Co-amoxiclav 625mg 14 days Ciprofloxacin 14 days
catarrhalis TDS 500mg BD
Staphylococcus Flucloxacillin 500mg 14 days Clarithromycin 14 days
aureus QDS 500mg BD
Methicillin <50Kg: Rifampicin 14 days <50Kg: 14 days
resistant 450mg + trimethoprim Rifampicin 450mg
Staphylococcus 200mg BD + doxycycline
aureus >50Kg: Rifampicin 200mg OD







Organism First Line Treatment Length of Second Line Length of
Treatment Treatment Treatment







Coliforms Ciprofloxacin 500mg 14 days Ceftriaxone l-2g 14 days
(eg Klebsiella, BD (IV)
Enterobacter)
Pseudomonas Ciprofloxacin 500mg 14 days Monotherapy 14 days
aeruginosa BD (IV):
Ceftazidime 2g
(Or, in severe TDS
infections Or































Adjunctive therapies in acute exacerbations
There are few studies that have explored the role of adjunctive therapies in acute
exacerbations of bronchiectasis.
There have been no randomised placebo controlled trials evaluating the efficacy of chest
physiotherapy in acute exacerbations but studies have compared different chest
physiotherapy techniques during exacerbations. A single blind trial randomised 15
patients with an acute exacerbation to either postural drainage and breath/cough
manoeuvres, the flutter device and breath/cough manoeuvres or to breath/cough
manoeuvres alone and found no difference in sputum weight, FEVj, FVC or PEFR
between any of the groups (Tsang, 2003). A later study randomised 20 patients to either
the Acapella device or to continue their usual physiotherapy technique again found no
significant difference between the groups in terms of sputum volume produced, patient
perception of dyspnoea or spirometry (Patterson et al., 2007).
There has been one study exploring bromhexidene as a mucolytic adjunctive in the
management of inpatient exacerbations. A randomised double blind placebo controlled
trial of bromhexidene 300mg three times daily in addition to intravenous ceftazidime
improved ease of expectoration and increased sputum production (Olivieri et ah, 1991).
The outcomes of patients with exacerbations of bronchiectasis and acute respiratory
failure requiring management with either non-invasive ventilation or invasive
mechanical ventilation have been reviewed in two retrospective studies (Dupont et ah,
2004, Phua et ah, 2010). In the first study, 48 patients with acute exacerbations of
bronchiectasis and acute respiratory failure were admitted to intensive care over the ten
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year study review period between 1990 and 2000, 13 of whom required non-invasive
ventilation and 26 of whom required invasive mechanical ventilation. The intensive care
unit mortality was 19% and one year mortality was 40%, with factors associated with
reduced survival including prior use of long term domiciliary oxygen therapy and age
greater than 65 years (Dupont et al., 2004). The more recent study found similar
outcomes in 57 patients admitted to the intensive care unit over an 8 year period. 31
patients were managed with non-invasive ventilation and 26 with invasive mechanical
ventilation. There was no difference in mortality between the groups (25.8% in the non¬
invasive ventilation group and 26.9% in the invasive mechanical ventilation group) and
this was predicted by the APACHE II score. There have been no randomised controlled
trials to evaluate the role of non-invasive ventilation with invasive mechanical
ventilation in acute exacerbations of bronchiectasis.
The role of other therapeutic strategies have not been studied in acute exacerbations,
particularly the use of corticosteroids (either systemic or inhaled), other airway
clearance techniques such as hypertonic nebulised saline, airways humidification and
oxygen and further studies are needed.
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1.9 Assessing response to treatment
Treatment efficacy is typically measured by the ability to halt the pathogenesis of the
disease. In chronic conditions, defining treatment efficacy necessitates encompassing
the intent of treatment: to slow disease progression and to improve patients' health
related quality of life. In bronchiectasis, treatment goals frequently include improving
symptoms, reducing exacerbation frequency and severity as well as limiting the
bacterial burden and inflammatory insult in the airways.
Currently, few clinical or laboratory markers specifically validated for bronchiectasis
exist and it is poorly understood how best to assess the disease and its response to
treatment. Early studies relied predominantly on subjective non-quantitative measures
such as "the foetor of the breath and sputum" to assess treatment success (Grainger-
Stewart, 1893). More recent interventional studies have used a variety of clinical and
laboratory parameters to monitor response to treatment, many of which have been
selected based on their utility in other chronic respiratory disease processes. Laboratory
markers used in studies have included qualitative and quantitative sputum bacteriology
as well as sputum and serum inflammatory measures. Clinical indices used include
24hour sputum volume, sputum purulence, lung function (typically FEV), FVC and
PEFR), symptoms scores and in longer-term studies, frequency and severity of
exacerbations. To date, there are only two validated measures in non-cystic fibrosis
bronchiectasis that have been proven to be responsive to change- the St George's
Respiratory Questionnaire and the Leicester Cough Questionnaire (LCQ) (Wilson et al.,
1997a, Murray et al., 2009d).
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Laboratory markers
Bronchiectasis is characterised by neutrophilic airways inflammation and it has been
hypothesised that direct measures of lung inflammation using markers in exhaled breath
and sputum may be useful in assessing disease activity and response to treatment.
Interventional studies of antibiotic therapy have explored the effect of treatment on
various markers of neutrophilic inflammation including sputum neutrophil elastase,
myeloperoxidase and pro-inflammatory cytokines such as ILla, IL8, TNFa and LTB4
(Stockley et ah, 1984a, Hill et ah, 1988). Sputum elastase levels have been shown to
reduce with one week of antibiotic treatment in acute exacerbations and also in stable
disease treated with longer term antibiotics (Stockley et ah, 1984a, Hill et ah, 1988).
Myeloperoxidase levels were also found to reduce with a short course of nebulised
antibiotic treatment in stable disease (Lin et ah, 1997). A longer study exploring the
impact of 8 weeks of erythromycin treatment in stable disease found no effect on the
proinflammatory cytokines ILla, IL8, TNFa and LTB4 (Tsang et ah, 1999b). The full
potential of such markers requires exploration however, as none have been validated as
measures of response to treatment. Their clinical utility as cost effective, reliable and
pertinent markers also requires full assessment.
Studies have investigated other markers of airways inflammation that may have a role in
assessing disease activity in bronchiectasis, particularly those with proven utility in
other chronic inflammatory respiratory diseases including exhaled hydrogen peroxide,
exhaled nitric oxide and serum procalcitonin, although there have been no formal
validation studies of any such markers. Exhaled breath hydrogen peroxide was analysed
in a cross-sectional study of 30 patients with bronchiectasis and found to be present in
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higher concentrations than in healthy controls [1.1(0.87-1.29)pMol versus 0.3(0.19-
0.36) pMol] (Loukides et al., 2002). Within the bronchiectasis patients, higher levels
were found in those chronically infected with Pseudomonas aeruginosa and in those
requiring management with long term antibiotics. Significant positive correlations were
seen with the concentration of hydrogen peroxide and symptoms score, percentage of
neutrophils in the sputum and radiological extent of disease as well as a negative
correlation with FEVi. Despite these findings suggesting that exhaled breath hydrogen
peroxide could be a useful measure in bronchiectasis, its utility has not been further
explored in interventional studies.
Peripheral airway nitric oxide has been found to be a useful direct measure of
inflammation in other chronic respiratory diseases such as asthma (Barnes et al., 2010).
A recent study has explored its potential utility in bronchiectasis, finding higher levels
in patients with bronchiectasis than in controls [3.6(2.l)ppb versus 2.7(1.5)ppb
respectively] (Shoemark et al., 2011). The levels of fractional exhaled nitric oxide
(FeNO) were found to correlate with the severity of bronchiectasis using lung function,
radiological parameters and quality of life scores. Its role as a marker of response to
treatment is less clear, as no difference was found in levels of FeNO following
treatment for an acute exacerbation in 20 patients (Shoemark et al., 2011).
Procalcitonin, the peptide precursor to the hormone calcitonin is a useful marker of
severity in pneumonia and other sepsis syndromes. However, a study of its utility in
exacerbations of bronchiectasis found that it is unlikely to be useful with generally low
serum levels and in patients requiring inpatient management, there was no correlation
between serum procalcitonin and other inflammatory markers (Loebinger et al., 2008).
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Only a limited number of possible biomarkers for monitoring disease and response to
treatment in bronchiectasis have been studied. A recent study involving 19 patients with
bronchiectasis used the mass spectrometry technique surface enhanced laser desorption
ionisation time of flight (SELDI-TOF) to actively select proteins from sputum using
adherence to chromatographic surfaces with subsequent mass spectrometry and found
377 potential biomarkers may exist within sputum from patients with bronchiectasis
compared with healthy controls (Gray et al., 2008). A later study analysed 16 samples
of sputum for trace metals and found significantly higher levels of zinc, iron and
manganese compared with controls (Gray et ah, 2010). More work is needed to identify
markers specific to bronchiectasis, relevant to pathogenesis and responsive to changes
in disease activity.
The airways in bronchiectasis are frequently chronically infected with pathogenic
bacteria and interventional studies have therefore used sputum bacterial clearance as an
important marker of treatment efficacy (Davies et ah, 1983, Lam et ah, 1989, Pines et
ah, 1974, Drobnic et ah, 2005, Currie et ah, 1990). The majority of antibiotic studies
have relied upon qualitative sputum bacteriology (described as bacterial eradication or
clearance) as an outcome measure but in a disease characterised by chronic airways
colonisation, treatment response may be more sensitively measured by quantitative
bacteriology which has only been used to a limited extent in interventional studies to
date (Tsang et ah, 1999b). Bacterial density in the airways in bronchiectasis is crucial to
disease pathogenesis with increasing load associated with a significant increase in
airways inflammation (Angrill et ah, 2001, Hill et ah, 2000). Further studies are needed
to test this hypothesis and validate quantitative bacteriology as an important measure of
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treatment response, superior to solely using qualitative bacteriology and bacterial
clearance particularly to warrant the associated greater clinical cost.
Clinical Markers
Interventional studies in bronchiectasis have typically used a variety of clinical outcome
measures to assess treatment response. Despite this, there remains no single uniformly
agreed optimum measure in terms of reliability, relevance and cost. One of the most
frequently used clinical outcome measures is sputum colour with the majority of
interventional antibiotic studies using conversion of purulent to mucopurulent or
mucoid sputum as a reflection of treatment efficacy (Stockley et al., 1984a, Lam et ah,
1986, 1957, Pines et ah, 1967). A reduction in sputum volume has also been used as a
marker of treatment success in antibiotic studies although conversely physiotherapy
studies have suggested that increased sputum volume is a useful marker of treatment
response. Lung function indices (most commonly FEVi, FVC, PEFR and TLCO) have
also been used as outcomes in antibiotic, inhaled corticosteroid and physiotherapy
studies but their response to these interventions has been variable with studies
frequently observing minimal change or indeed statistical changes that may have little
clinical relevance (Thompson et ah, 2002, Tsang et ah, 2005a). Respiratory muscle
pressures in bronchiectasis have recently been studied in 20 patients with clinically
stable disease, with maximal inspiratory pressure demonstrated to have reliability,
suggesting that there may be a role for it as a clinical outcome measure, but further
studies are needed (Moran et ah, 2010). Exercise capacity has also been used as a
potentially useful marker in interventional studies (Lin et ah, 1997) and the 6minute
walking test has been demonstrated to be strongly associated with health related quality
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of life in bronchiectasis and radiological extent of disease (defined by the generations of
bronchial divisions affected) but again has not been validated for use as a parameter of
treatment response (Lee et al., 2009).
In longer term studies the number, frequency and severity of acute exacerbations has
been used to measure treatment success. This encompasses one of the main aims of
disease management in bronchiectasis, reducing further insults to the airways that may
contribute to disease progression. Studies have also used symptoms as a guide to
treatment efficacy. The earliest interventional studies relied on patient reporting which
was difficult to quantify and use for comparison between studies (Davies et al., 1983,
Lam et al., 1986). The only currently validated measures of treatment response in
bronchiectasis are both measures of health related quality of life- the St George's
Respiratory Questionnaire and the Leicester Cough Questionnaire.
The St George's Respiratory Questionnaire is a 50 item self-administered health related
quality of life questionnaire assessing the impact of multiple chronic respiratory
symptoms on HRQL, originally intended for use in COPD (Jones et al., 1992). It
consists of 3 components- symptoms (8 items), activity (16 items) and impacts (26
items) and assesses the impact of symptoms over the preceding 4 weeks. In
bronchiectasis it has been shown to have repeatability over a 2 week period with an
intraclass correlation coefficient of 0.97. Responsiveness of the SGRQ was validated by
assessing change in score compared with parameters such as the level achieved in the
shuttle walk test, MRC dyspnoea score and Short Form 36 HRQL score over a 6 month
period (Wilson et al., 1997a).
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The Leicester Cough Questionnaire is a 19 item self-completed quality of life measure
of chronic cough (Birring et ah, 2003).It has 3 domains: physical (8 items),
psychological (7 items) and social (4 items). The total severity score ranges from 3-21,
with a lower score indicating greater impairment of health status due to cough. It
assesses the impact of symptoms over the preceding two weeks. The validation of the
questionnaire was undertaken prior to the commencement of the studies reported in this
thesis and is described in the General Methods section (Murray et al., 2009d).
For a parameter to be useful in disease management, it is must be pertinent to the
condition, non-invasive, inexpensive, easily accessible, reliable and responsive to
change. There are few such markers currently available for non-cystic fibrosis
bronchiectasis and much work is needed to allow any progress to be made in the
development and implementation of potential therapies.
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1.10 Aims
There were two main aims to this thesis:
1. To explore whether the vicious cycle of inflammation and infection in
bronchiectasis can be disrupted and whether this impacts clinically on the
symptoms of bronchiectasis.
2. To identify potentially useful clinical markers for monitoring treatment response
in patients with non-cystic fibrosis bronchiectasis.
The first aim involved designing and conducting three separate studies.
1. Currently, regular chest physiotherapy is advised as a mainstay of management
in bronchiectasis. The rationale for its use is to help mobilise and clear
secretions with their debris and bacteria from the damaged airways. Although
various physiotherapy techniques are practised, evidence for its efficacy is
limited. The first study was designed to assess the efficacy of regular chest
physiotherapy as treatment strategy in its own right- does augmentation of the
impaired mucociliary transport escalator disrupt the vicious cycle of infection
and inflammation and can it improve the symptoms of bronchiectasis?
2. The second study was designed to assess the impact of reducing bacterial
infection in the airways on both clinical and laboratory outcomes during acute
exacerbations of bronchiectasis- can infection and inflammation be reduced and
clinical improvement achieved?
3. The third study was designed to assess whether limiting the bacterial burden in
the airways on a long-term basis can reduce airways inflammation, disrupting
the vicious cycle of inflammation and infection in the airways. The second
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question this study sought to address was if the vicious cycle of infection and
inflammation can be disrupted does this lead to clinical and symptomatic
benefits? A randomised controlled trial of nebulised antibiotics administered
over a 12 month period was therefore conducted.
The second aim sought to explore whether there are any key parameter- either clinical
or laboratory markers- that can be used to assess treatment response in the management
of bronchiectasis. The endpoints used in the first and third studies conducted as part of





2.1 Ethical approval and consent
All studies included in this thesis had approval from the local research ethics committee
for NHS Lothian or where applicable, the Scottish Multi-Centre Research Ethics
Committee. All patients provided written consent.
2.2 Patients
All patients were recruited from the specialist bronchiectasis clinic, Royal Infirmary of
Edinburgh, NHS Lothian. All had both a clinical and radiological diagnosis of
bronchiectasis.
Clinical diagnosis
Patients had a history of a chronic cough with daily sputum expectoration and suffered
at least two exacerbations requiring antibiotics in the preceding year. All had
chronically infected sputum which was defined as the culture of pathogenic organisms
in at least three sputum samples when clinically stable in the preceding twelve months.
Radiological diagnosis
All patients had a high resolution computed tomography (HRCT) scan of the thorax
with bronchiectasis diagnosed if there was evidence of bronchial dilatation, defined as
the diameter of the bronchial lumen being greater than the luminal diameter of the
adjacent pulmonary artery, with a lack of tapering on sequential slices (Naidich et al.,
1982).
For the studies reported in this thesis, any patient with a clinical and radiological
diagnosis of bronchiectasis but who also had any of the following, were excluded:
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current smokers; ex-smokers of less than two years; cystic fibrosis (cystic fibrosis
transmembrane receptor sequences present on genotyping); active pulmonary
mycobacterial infection; active sarcoidosis; active allergic bronchopulmonary
aspergillosis (ABPA); chronic obstructive pulmonary disease (COPD) (Celli and
MacNee, 2004); poorly controlled asthma (poorly controlled asthma was defined
objectively as a 20% or more diurnal variation in peak expiratory flows despite
treatment); long term regular oral corticosteroid treatment; long term regular antibiotic
treatment (oral or inhaled).
For the first two studies reported in this thesis, patients were required to be clinically
stable at the point of entry to the study. In the four weeks preceding entry to the study,
there had to be no changes in routine respiratory medication and no requirement for
antibiotics or corticosteroid treatment.
2.3 Sputum collection
Two different types of sputum collection were used throughout the studies, early
morning samples and 24 hour collections.
Early morning samples: all sputum expectorated in the first four hours on rising from
bed on the day of assessment was collected in a sterile, transparent container.
24 hour sputum collections: all sputum expectorated in the 24hours preceding the study
visit was collected in a sterile, transparent, pre-calibrated container.




Each sputum sample was assessed for both colour and volume.
Sputum colour
A sputum colour chart specific to bronchiectasis was used to describe the three typical
gradations of sputum colour: mucoid (clear), mucopurulent (pale yellow/pale green) and
purulent (dark yellow/dark green) (Murray et al., 2009b) (Appendix 9.1). The chart was
developed and piloted in the bronchiectasis clinic at the Royal Infirmary of Edinburgh
prior to the commencement of the studies reported in this thesis to ensure consistency of
reporting between staff and patients as well as to ensure patients were confident in using
it to describe their symptoms. 141 individual patients' sputum samples were graded
using the colour chart by both doctor and patient. Agreement was 80.9% in the mucoid
group, 90.3% in the mucopurulent group and 76.3% in the purulent group. In all cases
of disagreement except in 5 (21.7%), the doctor interpretation was of greater purulence
than the patient interpretation. The intraclass correlation coefficient was 0.83, 95%
confidence interval 0.76-0.87, P<0.0001 and Cronbach's alpha coefficient for
comparing the Doctor interpretation with Patient interpretation was 0.91.
Sputum volume
Sputum was collected in sterile, transparent, calibrated containers. The containers were
calibrated using water. The total volume was read directly from the meniscus. The
volume was recorded for both early morning samples and 24 hour collections. This
method has not been externally validated but is accepted as standard in clinical practice.
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2.5 Sputum analysis
All sputum samples were processed as soon as possible following collection.
Prior to the commencement of the studies reported in this thesis, a study was performed
to investigate the effects of storage and processing of sputum samples (Murray et al.,
2010). This pilot study was conducted in 10 patients colonised with Pseudomonas
aeruginosa. Figure 6 demonstrates that there was no significant difference (P=0.4) in
Ps. aeruginosa density when processing the sputum at lhr, 2hrs, 4hrs and 6hrs from
expectoration. The mean difference (standard deviation) with 95% limits of agreement
between processing at lhr compared with 2hrs was -0.04(0.31), -0.65 to 0.57 logio
colony forming units/millilitre (logio cfu/ml); between 1 hr and 4hrs was -0.1(0.54), -1.2
to 0.97 and between lhr and 6hrs was -0.06(0.35), -0.7 to 0.6.
Figure 6. Change in sputum bacterial density with processing of sputum up to six hours
post expectoration.
The figure shows a Bland-Altman plot of sputum bacterial density over 2hrs, 4hrs and
6hrs. The solid line represents the mean difference between the density at lhour post
expectoration and 2hrs, 4hrs and 6hrs respectively. The perforated lines represent the









































































































2.6 Sputum Gram staining
A lOpl sterile loop was used to transfer sputum to a clean, dry, frosted glass slide. lOpl
of sterile saline was gently pipetted onto the sputum and the sample smeared uniformly
and thinly across the slide. The sample was air dried and subsequently heat fixed by
passing the slide through a low flame several times until all moisture had evaporated.
The slide was then flooded with the primary staining reagent methyl violet for one
minute followed by gentle rinsing in deionized water. The mordant iodine was then
used to flood the slide for one minute followed by further gentle rinsing in deionized
water. Following draining, acetone was used as a decolourising agent, flooding the slide
until the fluid appeared colourless (approximately ten seconds). The slide was
immediately rinsed in deionized water. The counterstain basic fuschin was then used to
flood the slide for one minute before further rinsing in deionized water. The slide was
gentle blotted using paper towel and allowed to air dry. The results of the staining
procedure were observed under oil immersion microscopy. At low (xlOO)
magnification, the number of squamous cells and polymorphonuclear leukocytes per
field were counted. At high (xlOOO) magnification, bacterial cell colour was described
as purple (Gram positive) or pink (Gram negative) and morphology was noted (rods or
cocci).
All sputum samples were considered to be valid sputum if there were >25
polymorphonuclear leukocytes and <10squamous cells on Gram stain per low-power
(xlOO magnification) field (Gleckman et al., 1988).
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2.7 Quantitative sputum bacteriology
Sputum was prepared for quantitative bacteriology. A minimum of one millilitre of
fresh sputum was used. An equal volume (1:1) of 0.1% dithiothreitol was added to the
sputum sample and vortexed vigorously. The liquefied, homogenised sample was
serially diluted using 0.9% sterile saline to achieve dilutional factors of 10"' to 10"4.
lOOul aliquots of diluted homogenised sputum (neat, 1/100 and 1/10000) were then
inoculated across the entire surface of the following agar selective or enrichment media
using a sterile "hockey stick" spreader (Pye et ah, 1995): Cetrimide (Difco)
Pseudomonas isolation agar, chocolate with bacitracin agar and horse blood agar. The
inoculated cetrimide and horse blood agars were incubated aerobically at 37°C for
48hours and the inoculated chocolate with bacitracin agars were incubated at 5% CO2 at
37°C for 48hours. Colony forming units for each pathogen were identified and counted
at 48hours for each pathogen. The sputum bacterial density was expressed as log 10
colony forming units per millilitre (logio cfu/ml).
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2.8 Qualitative sputum bacteriology
Viable pathogens were identified following incubation based on colonial morphology,
Gram's stain and further, specific standardised identification tests. The identification
methods used for the most common organisms cultured is described.
Haemophilus influenzae
The primary isolation media used for Haemophilus influenzae was chocolate with
bacitracin agar incubated at 37°C at 5%C02. Colonies are small, round and convex and
typically appear after 24hrs incubation. The species appear negative on Gram staining
as spherical, oval or rod shaped cells of less than 1 pm diameter. Colonies suspected to
be Haemophilus species from morphology and Gram's stain appearance were further
identified based on their requirement for X and V factors. One or more colonies were
selected using a sterile straight wire loop and emulsified in distilled water to produce a
light suspension. lOOpl of suspension was inoculated onto nutrient agar and spread
evenly using a sterile hockey stick spreader. Three filter paper discs incorporating X
factor (comprising protoporphyrin IX and haemin), Y factor (comprising nicotinamide
adenine dinucleotide) and X and Y factors together respectively, were positioned on the
inoculated agar surface in the configuration of an equilateral triangle with a minimum of
3.5cm distance between the discs. Following overnight incubation at 37°C, the agar
plate was examined for growth around the discs. Haemophilus influenzae was
distinguished from Haemophilus parainfluenzae as detailed in Table 4.
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Table 4. Identification ofHaemophilus influenzae and Haemophilus parainfluenzae.
Factor Haemophilus influenzae Haemophilus
parainfluenzae
X Negative for growth around
disc
Negative for growth around
disc
V Negative for growth around
disc
Positive for growth around
disc
Xand V Positive for growth around
disc
Negative for growth around
disc
X and V test results for Haemophilus influenzae and Haemophilus parainfluenzae.
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Moraxella catarrhalis
The primary isolation media used for Moraxella species was horse blood agar. Colonies
are white or buff and convex in shape. The species appear as negative cocci on Gram's
stain, are approximately 0.6-1.0pm diameter, and occurr either singly or in pairs.
Colonies suspected to be Moraxella species from morphology and Gram's stain
appearance were tested for a positive oxidase reaction. Filter paper was soaked in the
test reagent N, N, N', N'-tetra-methyl-p-phenylenediamine dihydrochloride. A sterile
wooden stick was used to select at least one suspicious colony and rub it onto the pre-
soaked filter paper. A reaction was looked for within ten seconds. A positive result was
confirmed with the development of a blue colour, indicating oxidase production. A
negative result was indicated by an absence of colour.
Streptococcus pneumoniae
The primary isolation media used for Streptococcus species was horse blood agar.
Colonies appear white, l-2mm in diameter and may have a classic draughtsman
appearance due to autolysis after incubation. Streptococcus species are positive on
Gram's staining, appear round and are in pairs, chains or clusters. Colonies suspected
from morphology and Gram's stain appearance to be Streptococcus pneumoniae were
further identified by assessing their sensitivity to ethylhydrocupreine hydrochloride
(optochin test). Ethylhydrocupreine hydrochloride causes changes in surface tension of
the cell membrane causing Streptococcus pneumoniae to lyse. Fresh suspicious colonies
were selected using a sterile straight wire loop and streaked across a horse blood agar
plate. An optochin disc (filter paper disc impregnated with 5pg of ethylhydrocupreine
hydrochloride) was placed in the centre of the inoculated agar and incubated at 37°C at
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5%CC>2 for 24hours. Following incubation, the inoculated agar was examined for zones
of inhibition. A positive result was defined as a radial zone of inhibition measuring
5mm or more from the edge of the disc. A negative result was defined as either no zone
of inhibition or a zone of inhibition less than 5mm radius from the edge of the disc.
Staphylococcus aureus
The primary isolation media used for Staphylococcus aureus was horse blood agar.
Colonies are opaque with either a creamy white colour or a yellow-orange colour. Gram
staining shows Gram positive cocci occurring either singly, in pairs or in irregular
clusters. Colonies suspected to be Staphylococcus aureus were confirmed using the
commercial test kit Dryspot Staphytect Plus, a latex slide agglutination test according to
the manufacturer's instructions (Oxoid Limited, Basingstoke, Hampshire).
Pseudomonas aeruginosa
Cetrimide (Difco) Pseudomonas isolation agar was used as the primary selective media
for Pseudomonas aeruginosa. Morphological identification of colonies may have
included several characteristics. The most common type of colony is a large, low oval
convex shape with a rough appearance. There may be a characteristic smell of
aminoacetophenone and colonies may have a blue-green appearance due to the
production of pyocyanin (blue) and pyoverdin (yellow). The production of this pigment
is indicative of Pseudomonas aeruginosa, although some strains particularly mucoid
strains may not produce pyocyanin. Further identification of colonies was confirmed
using the commercially available API20NE kit (bioMerieux UK Linited, Basingstoke,
Hampshire) according to the manufacturers' instructions. Briefly, approximately one to
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four colonies were selected using a sterile straight wire loop and emulsified with 2ml of
0.85% sterile saline to produce a suspension approximating a 0.5McFarland standard.
The API20NE test strip consists of twenty microtubes containing dehydrated
substances. These microtubes were inoculated with the bacterial suspension and
incubated for 24 or 48 hours at 30°C with the addition of reagants and interpretation of
reactions done according to the manufacturer's directions. The biochemical reactions
were converted accordingly into an octal profile number and decoded using the
Analytical Profile Index (API Database Vn6.0, APILAB Software Vn3.3.3, Apilab Plus;
bioMerieux).
Enterobacteriaceae
Enterobacteriaceae were selected from horse blood agar. The colonies are 2-3mm in
diameter, are low, convex, grey and maybe smooth or mucoid. The cells appear as Gram
negative rods. Further identification of suspicious colonies was initially with a negative
oxidase test as described previously and then the commercial kit API20E was used
(bioMerieux UK Linited, Basingstoke, Hampshire). The principle and preparation of the
API20E strip is similar to the API20NE strip described above, with incubation for only
24hours at 30°C.
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2.9 Sputum biochemical assays
Sputum was ultra centrifuged at 50,000xg for 90 minutes at 4°C. The sol phase was
removed and immediately frozen at -70°C until required for analysis.
Sputum myeloperoxidase
Sputum myeloperoxidase (MPO) acivity was used as a measure of neutrophil influx.
MPO activity was measured from sputum sol phase by chromogenic substrate assay.
Standards and samples were diluted as necessary in phosphate buffered solution.
Twenty-five microlitres of standard or sample were added to the wells of a microtitre
plate (Serotec), followed by twenty-five microlitres of tetramethylbenzidine (TMB).
The plate was then incubated for 5minutes at 25°C. Fifty microlitres of sulphuric acid
solution was added to each well at the end of the incubation period and absorbance was
measured using a dual wavelength of 450 and 560nm and the MPO concentration
interpolated from the standard curve and expressed as pg/ml. The MPO concentration
was determined in duplicate for each sample or standard and the mean determined for
each.
The standards, sample dilution used, and the lower detection of the assay is illustrated in
Table 5. The standard curve is shown in Figure 7.
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Table 5. Sputum neutrophil myeloperoxidase assay.
Standards Typical Sample Dilution Lower Limit ofDetection
0.008-8.25units/ml 1 in 20 to 1 in 500 0.016units/ml
The standards, sample di utions and lower limits of detection used for the
myeloperoxidase assay.




Sputum neutrophil elastase was used as a measure of neutrophil influx. Neutrophil
elastase activity present in the samples was measured spectrophotometrically as the rate
of change of optical density at 405nm at 37°C using the chromogenic peptide substrate
methoxysuccinyl-ala-ala-pro-val-paranitroanilide (MeoSAAPvN, Elastin Products,
UK). This rate of change was compared with a standard curve for the rate of change in
optical density, obtained by incubating known concentrations of human neutrophil
elastase (Sigma Aldrich, UK) with the same chromogen. The human neutrophil elastase
lyophilized powder was reconstituted in sodium actetate 50mM, pH5.56 + 200mM
NaCl. Standards and samples were diluted as necessary in 50mM [4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid] (HEPES) + 150mM NaCl + 0.05% Igepal CA630,
pH8. Forty microlitres of standard or sample were added to each well of a 96 well
microtitre plate (Nunc). 40pl of MeoSAAPvn was then added to each well and the
samples immediately read at 37°C for a minimum of thirty minutes with readings every
two minutes. The rate of change in optical density was converted into elastase activity
and expressed in units per milligram. The elastase concentration for each sample was
determined in duplicate and the mean determined for each.
The standards, sample dilution used, and the lower detection of the assay are illustrated
in Table 6. The standard curve is shown in Figure 8.
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Table 6. Sputum neutrophil elastase assay.
Standards Typical Sample Dilution Lower Limit ofDetection
0.002-3.0 units/mg 1 in 20 to 1 in 500 0.18units/mg
The standards, sample dilutions and lower limits of detection used for the neutrophil
elastase assay.





15mls of venous blood was collected and analysed for total leucocyte count (WCC)
expressed as xl09cells/l; normal range 4-1 Ixl09/1; erythrocyte sedimentation rate (ESR)
measured in mm/hr with normal range for males calculated as age/2 and for females age
+ 10/2, and C-reactive protein (CRP) measured in mg/1, with the accepted normal range
<7mg/l.
Routine monitoring
The interventional nature of the studies conducted for this thesis required monitoring for
potential adverse systemic effects. All patients therefore routinely had venous blood
taken for measurement of blood biochemistry including: urea [mmol/1; normal range
2.5-6.6); creatinine (umol/1; normal range 60-120], sodium (mmol/1; normal range OS-
MS) and potassium (mmol/1; normal range 3.6-5.0) and monitoring of haematological
indices: haemoglobin (g/1; normal range for males 130-180 and for females 115-160)
and platelet count (xl09/l; normal range 150-350). Other monitoring tests conducted
routinely specific to the interventions are reported in the methods section of the
individual chapters.
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2.11 HRCT thorax scoring
Assessment of bronchiectasis was by evaluation of the bronchi on a lobar basis (for the
purposes of the studies included in this thesis the lingula was counted as a separate
lobe). The number of lobes affected was recorded and severity of bronchial dilatation
was graded 1-3 according to the Reiff criteria: grade one: less than twice the diameter of
adjacent pulmonary artery (described as cylindrical); grade two: two to three times the
diameter of adjacent pulmonary artery (described as varicose); grade three: greater than
three diameter of the adjacent pulmonary artery (described as cystic), giving a
maximum possible total score for six lobes of eighteen (Reiff et al., 1995).
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2.12 Pulmonary Function Tests
Forced Expiratory Volume in One Second (FEVi), Forced Vital Capacity (FVC) and
mid-expiratory flows (FEF25-75) were measured according to standardised guidelines
(ERJ 2005) using a MicroMedical Microloop ML3535 (Viasys Healthcare).
FEVi is the maximal volume of air exhaled in the first second of forced expiration
following a forced expiration from a position of full inspiration and is expressed in
litres. FVC is the maximal volume of air exhaled with maximally forced effort from a
maximal inspiration and is expressed in litres. The highest of three technically
satisfactory measurements (within 10%) was recorded for each and the FEVi/FVC ratio
was calculated. FEF25-75% is the mean forced expiratory flow between 25% and 75% of
the FVC and was calculated from the blow with the largest sum of FVC and FEVi. It is
expressed as litres/second. Actual values were recorded and were also expressed as %
predicted for the patients age, sex, and height.
Respiratory muscle strength was assessed by measuring the Maximum Inspiratory
Pressure (MIP) and Maximum Expiratory Pressure (MEP) using the MicroRPM
(Respiratory Pressure Meter) (Viasys Healthcare) with the highest of three technically
satisfactory measurements recorded for each. The MIP was measured following
complete exhalation to near residual volume followed by maximal deep inspiration
against the occluded airway (Mueller manoeuvre) and expressed as cm^O. The MEP
was measured following deep inspiration to near total lung capacity followed by strong
expiration (Valsalva manoeuvre) and expressed as cnfl^O. Actual values were recorded
and were also expressed as % predicted for the patients age, sex, and height.
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2.13 Exercise capacity
The incremental shuttle walk test (ISWT) was used to assess functional exercise
capacity. It has been proven in patients with COPD to provide an objective measure of
disability and can be used for direct comparison of patients' performances (Singh et al.,
1992).
The ISWT comprises a 10 metre shuttle course with the walking speed externally paced
or controlled using pre-recorded audio signals from a computerised disc. It consists of
twelve incremental levels, with each level lasting one minute. It is a symptom limited
test with the endpoint of the test determined when the patient becomes too breathless to
continue or when the patient becomes unable to complete the shuttle in the paced time
(defined as being 0.5metres or further from the marker). All patients were instructed to
walk at a steady pace walk aiming to turn around at each end of the course at the sound
of the audio signal. All were advised to continue to walk until they felt unable to
maintain the required speed without becoming unduly breathless. The level achieved
was recorded and total distance covered calculated. At the start and end of the ISWT all
patients had their heart rate, oxygen saturations and dysnoea score according to the
modified BORG dyspnoea scale (Borg, 1982) in accordance with standardised
guidelines (2002).
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2.14 Health related quality of life
Two health related quality of life (HRQL) questionnaires were used.
St Georges Respiratory Questionnaire
The St George's Respiratory Questionnaire is a 50 item self-administered health related
quality of life questionnaire assessing the impact of multiple chronic respiratory
symptoms on HRQL (Jones et al., 1992). It consists of 3 components- symptoms (8
items), activity (16 items) and impacts (26 items)- and has previously been validated to
reflect impaired health related quality of life in bronchiectasis patients (Wilson et ah,
1997a). The total score ranges from 0-100, with a higher score indicating a poorer
health related quality of life. It assesses the impact of symptoms over the preceding four




The Leicester Cough Questionnaire (LCQ) is a 19 item self-completed quality of life
measure of chronic cough (Birring et ah, 2003). It has 3 domains: physical (8 items),
psychological (7 items) and social (4 items). The total severity score ranges from 3-21,
with a lower score indicating greater impairment of health status due to cough. It
assesses the impact of symptoms over the preceding two weeks.
The LCQ focuses purely on the impact of cough severity on HRQL rather than
encompassing multiple respiratory symptoms and has been validated for use in
bronchiectasis by exploring its reliability, responsiveness and validity in a two year
prospective cohort study (Murray et ah, 2009d). The ability of the LCQ to discriminate
between mild and severe disease was explored in 120 patients - 51 with severe disease,
29 with moderate disease and 40 with mild disease. In predicting severe bronchiectasis,
the LCQ was found to perform well, with an area under the receiver operator curve
(AUC) score of 0.84 (0.80-0.88, P<0.0001) (Figure 9) and the lower the LCQ score the
greater the likelihood ratio for severe disease (Table 7).
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Figure 9. Predicting severe and mild bronchiectasis.
The utility of the LCQ in indicating severe and mild disease was assessed using the area
under the receiver operator curve (AUC). For interpretation of AUC values the
following is widely accepted: AUC 0.50-0.59= no value of test; 0.6-0.69= poor
discrimination value; 0.70-0.79= moderate discriminatory value; 0.80-0.89= good
discriminatory value; 0.9-1.0= excellent discriminatory value. A= severe •=mild.
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Table 7. The utility of the LCQ as a predictor of severe bronchiectasis.
LCQ
Score










<10 29.4 98.5 19.6 0.7 14.5 93.7 65.4
<11 39.2 95.6 8.9 0.6 6.6 87 68
<12 47 94.2 8.1 0.5 6.0 85.7 71
<13 52.9 86.9 4.0 0.5 3.0 75 71
<14 64.7 84.0 4.0 0.4 3.0 75 76
<15 74.5 79.7 3.7 0.3 2.7 73 81
The prevalence of severe disease in the study cohort of 120 patients was 42.5%. The
pretest odds ratio was 0.74.
LR+ = the likelihood ratio for a positive test result and LR- = the likelihood ratio for a
negative test result.
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In predicting mild bronchiectasis, the LCQ performed well, with an AUC of 0.80 (0.76-
0.84, PO.OOOl) (Figure 9) and the higher the LCQ score the greater the likelihood ratio
for mild disease (Table 8).
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Table 8. The utility of the LCQ as a predictor ofmild bronchiectasis.
LCQ
Score










>20 57.5 91.2 6.5 0.5 3.3 76.7 81.1
>19 65 85 4.3 0.4 2.2 68.4 82.9
>18 75 76.2 3.15 0.3 1.6 61.2 85.9
>17 87.5 68.7 2.8 0.18 1.4 58.3 91.7
The prevalence of mild disease in the study cohort of 120 patients was 33.33%. The
pretest odds ratio was 0.5.
LR+ = the likelihood ratio for a positive test result and LR- = the likelihood ratio for a
negative test result.
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The same prospective cohort study showed it to be a repeatable questionnaire in stable
disease when completed by 67 patients over a six month period with an intraclass
correlation of 0.96 (95% confidence interval 0.93-0.97) and a mean difference between
the total scores of 0.1 (-0.4 to 1.0).
Importantly, the LCQ has been proven to be responsive to change and the minimum
clinically important difference for change (MCID) has been shown to be 1.3units (Raj et
al., 2009).
SGRQ and LCQ
The LCQ has been shown to have a significant inverse correlation with the SGRQ in
stable disease with a Spearman rank correlation coefficient was -0.7, (95% confidence
interval -0.58 to -0.78, P<0.0001). In exacerbations, the LCQ also has a significant
inverse correlation with the SGRQ [Spearman rank correlation coefficient of -0.69 (95%
confidence interval -0.53 to -0.81, P0.0001], Figure 10 (Murray et al., 2009d).
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Figure 10. Correlation of the LCQ with the SGRQ in bronchiectasis.
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2.15 Exacerbation Frequency
An exacerbation was defined as a clinical deterioration with all of the following:
increasing cough, increasing sputum volume and worsening sputum purulence
(Anthonisen et al., 1987). All patients who experienced an exacerbation during the
study were reviewed and received fourteen days of antibiotics (prescribed according to
sputum bacteriology culture and sensitivities). All were reviewed following completion
of antibiotics to ensure recovery. Patients were all supplied with a diary card for
recording their exacerbations, particularly in case they were unable to attend for review.
The diary card asked patients to document the following information: date of onset of
symptoms; presence or absence of cough, sputum, chest pain, breathlessness or fever;
the colour of the sputum according to the previously described colour chart (included
within the diary); the date of commencement of any antibiotic treatment for their
symptoms; the name of the antibiotic and duration of treatment; the actual date of
feeling back to normal health. A copy of the diary card is enclosed (Appendix 9.2).
Further specific instructions relevant to the individual studies are discussed in the
individual studies' methods section.
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CHAPTER THREE:




Chest physiotherapy aims to mobilise bronchopulmonary secretions and facilitate
effective expectoration, providing control of cough and improving airway clearance. It
is widely advocated as a mainstay of management for bronchiectasis (O'Neill et al.,
2002). To date however, there are no randomised controlled trials of chest
physiotherapy exclusively in patients with non-cystic fibrosis bronchiectasis (Jones and
Rowe, 2000).
Several different techniques or regimens for airway clearance exist such as postural
drainage, autogenic drainage, the active cycle of breathing technique, positive
expiratory pressure (PEP), oscillatory PEP devices and high frequency chest wall
percussion. Previous small studies in non-cystic fibrosis bronchiectasis have compared
various techniques and found no single method to be superior, although patient
preference for technique has varied (Eaton et al., 2007, Thompson et al., 2002).
The aim of this randomised crossover study was to establish the efficacy of routine
chest physiotherapy in non-cystic fibrosis bronchiectasis, comparing the effect of twice
daily physiotherapy using an oscillatory PEP device with no chest physiotherapy in
patients not previously practising regular chest physiotherapy.
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3.2 Methods
This was a randomised crossover trial of 3 months of twice daily chest physiotherapy
followed by a one month washout period compared with 3 months of no chest
physiotherapy in adults with non-cystic fibrosis bronchiectasis not routinely practising
chest physiotherapy. Randomisation was determined by computer generation. The
primary outcome was patient perceived cough severity measured using the Leicester
Cough Questionnaire (LCQ) (Birring et al., 2003). Secondary outcomes included 24
hour sputum volume, FEV) FVC, mid-expiratory flows (FEF25-75), maximum
inspiratory pressure (MIP), maximum expiratory pressure (MEP), exercise capacity
using the ISWT (Singh et al., 1992), sputum microbiology and the St George's
Respiratory Questionnaire (Jones et al., 1992).
Patients
Patients were recruited according to the criteria described in the General Methods
section. All patients were clinically stable at the point of entry to the study (defined as
no change in routine respiratory medication and no requirements for antibiotics or
corticosteroid therapy in the 4 weeks preceding the study entry date). Patients who were
ex-smokers of less than two years or ex-smokers with a greater than ten pack year
history of smoking and emphysema on high resolution CT scan were excluded.
Physiotherapy
Chest physiotherapy was carried out using the oscillatory PEP device "Acapella
Choice®" (Smiths Medical ASD, Inc., NH03431, USA). Each patient was trained to
complete 3 sets of the following cycle for each treatment session: 10 breaths (each
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inhaling to three-quarters of the maximum inspiratory capacity then a 3 second breath
hold followed by exhalation to functional residual capacity) and then 2-3 forced
expiratory techniques (huffs) or coughs. The frequency/resistance dial (range 1-5) was
set at 3 for all participants. This setting was the maximum tolerated by all participants.
Patients completed 2 treatment sessions each day (morning and evening, typical
duration 20-30 minutes). Compliance and occurrence of any adverse effects
(specifically, any haemoptysis or increased use of short acting bronchodilator therapy)
were assessed using a diary card which was reviewed monthly during the treatment
phase. Technique was reviewed at monthly intervals during the treatment phase and the
devices were retained at the Royal Infirmary of Edinburgh during the non-treatment
phase.
Other interventions
Exacerbations requiring antibiotic therapy: exacerbations were diagnosed and managed
as described in the General Methods section. No additional chest physiotherapy was
advised.
Routine therapy: any changes made to the patients' usual respiratory medication during
the study period were noted.
Endpoints
The study design and assessment timepoints are shown in Figure 11. The following
were assessed as described in the General Methods section at each timepoint: 24hr
sputum volume; qualitative and quantitative sputum bacteriology; FEVi, FVC, FEF25-75,
MIP and MEP; exercise capacity using the incremental shuttle walk test; health related
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quality of life using the Leicester Cough Questionnaire and the St George's Respiratory
Questionnaire.
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Assessments were performed at the start and end of each treatment period with A, B, C
and D representing the assessment time points.
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Statistics
Statistical analysis was performed using SPSS for Windows, Version 17 (SPSS inc,
Illinois). The primary aim was to detect an improvement in LCQ score. Using the
original validation of the LCQ, with 20 patients, a 5% level of significance (2 tailed), a
common standard deviation of 0.94 and a power of 80% this would detect a mean
difference in LCQ score of 0.63 (Birring et al., 2003). Using the validation of the LCQ
in non-cystic fibrosis bronchiectasis, with 20 patients, a 5% level of significance (2
tailed), a common standard deviation of 1.1 and a power of 80% this would detect a
mean difference in LCQ score of 0.73 (Murray et al., 2009d). Data was analysed
according to the method of Kenward and Jones (Jones B, 1989). The treatment effect
was estimated using the differences of the matched pairs of observations from each
patient and is presented as median (interquartile range). Treatment differences between
regular chest physiotherapy and no chest physiotherapy were compared using the




20 outpatients were recruited. Baseline demographics and patient characteristics are
detailed in Table 9.
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Table 9. Patients included in the randomised crossover study of chest physiotherapy.
Characteristic n(%) or median(IQR)




Chronic cardiac disease 3(15)
Neurological disease 1(5)
Chronic renal impairment 1(5)
Diabetes Mellitus 0
Inhaled corticosteroid therapy 12(60)
Systemic corticosteroid therapy 0
Long term antibiotic therapy 2(10)
Infective exacerbations requiring antibiotic treatment
in preceding 12 months
2(1.5-3)
Lobes affected with bronchiectasis on HRCT 4(3-4.75)
Varicose or cystic dilatation affecting >1 lobe 15(75)











Inactive allergic bronchopulmonary aspergillosis 1(5)
Inflammatory Bowel Disease 1(5)
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Study Entry- baseline andpost-washout
The baseline characteristics for the clinical and laboratory endpoints at entry to each
phase of the study are detailed in Table 10. There was no significant difference in total
LCQ score, 24 hour sputum volume, FEV), FVC, FEF25-75, MIP, MEP, exercise
capacity, sputum microbiology and SGRQ score (Table 10) between entry to the first
arm of the study (Figure 10, Point 'A') and at the end of the washout period (Figure 10,
Point 'C'), prior to entry to the second arm of the study.
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Table 10. Comparison of clinical and laboratory assessments of patients at point of
entry to each phase of the crossover study.
Characteristic Median(IQR)
Study Start
(Figure 1, Point 'A')
Median(IQR) End of
Washout Period






























































Completion and adverse events
All patients completed the study and no adverse effects with the oscillatory PEP device
occurred. There were 12 exacerbations affecting 11 patients during the study period
(Table 11). No other interventions or changes to patients' care were required throughout
the duration of the study.
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Treatment differences
There was a significant improvement in all of the domains and the total LCQ score
(Table 11 and Figure 12).
Figure 12. Effect of regular chest physiotherapy on the LCQ.
















Physical Psychological Social Total
Physiotherapy
No physiotherapy
LCQ Domains and Total
*P=0.002 **P<0.0001 #P=0.02
The change in LCQ individual domain and total scores with physiotherapy and with no
physiotherapy is shown. The horizontal lines represent the median and interquartile
ranges for each group and the whiskers represent the maximum and minimum. The
median(IQR) score improved with regular chest physiotherapy from 4.5(4.1-5.8)units
to 5.1(4.9-6.2)units in the Physical domain; from 5.1 (4.6-6.l)units to 6.3(5.4-6.7)units
in the Psychological domain; from 5.7(4.2-6.l)units to 6.2(5.0-7.0)units in the Social
domain and from 15.3(13.5-17.9) to 18.2(15.4-19.4) in the Total score. *P=0.002
**P<0.0001 #P=0.02.
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24 hour sputum volume significantly increased with regular chest physiotherapy
compared with no chest physiotherapy (Figure 13).
Figure 13. Effect of regular chest physiotherapy on 24 hour sputum volume.














The change in 24 hour sputum volume with physiotherapy and with no physiotherapy is
shown. The horizontal lines represent the median and interquartile ranges and the
whiskers represent the maximum and minimum. *P=0.02.
With regular chest physiotherapy, the median (IQR) 24 hour sputum volume increased
from 5(2-15)mls to 12.5(2.5-20)mls.
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The total SGRQ score improved significantly with regular chest physiotherapy but the
only significant improvement seen in the individual domains of the SGRQ score was in
the activity domain (Figure 14).
Figure 14. Effect of regular chest physiotherapy on the SGRQ.
Change in SGRQ Score
Physiotherapy
No physiotherapy
-» Symptoms Activities Impacts Total
SGRQ Domains and Total
*P=0.02 **P=0.005
The change in SGRQ individual domain and total scores with physiotherapy and with
no physiotherapy is shown. The horizontal lines represent the median and interquartile
ranges for each group and the whiskers represent the maximum and minimum. *P=0.02
**P=0.005.
Regular chest physiotherapy significantly improved the Activities domain score from
47.6(32.6-59.4)units to 47.3(17.4-59.4)units and the Total score from 41.1(24.6-
49.1)units to 32.8(13.9-41.0)units. There were no statistically significant improvements
seen in the other domains, with the Symptoms score improving from 50.8(33.5-74)units
to 42.8(27.2-53.3)units and the Impacts score improving from 30.2(15.5-41.5)units to
23.9(7.2-28.7)units.
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Exercise capacity also improved significantly with regular chest physiotherapy (Figure
15) but there were no significant differences seen in sputum bacteriology, FEVi, FVC,
FEF25-75, MIP or MEP, or exacerbation frequency (Table 11).
Figure 15. Effect of regular chest physiotherapy on exercise capacity.





















The change in exercise capacity with physiotherapy and with no physiotherapy is
shown. The horizontal lines represent the median and interquartile ranges for each
group and the whiskers represent the maximum and minimum. *P=0.001.
Exercise capacity improved from 220(125-355)metres to 330(200-430)metres with
regular chest physiotherapy.
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FEV, (L) -0.01(-0.06-0.08) -O.Ol(-O.l-O.ll) 0.7
FVC (L) -0.01(-0.09-0.28) 0.06(-0.08-0.21) 0.9
FEF25-75 (L-s ') -0.02(-0.17-0.16) 0.04(-0.1-0.34) 0.6
MIP (cmH20) -1 (-9-7) 5.5(-10-12.5) 0.7





















This randomised crossover trial found that twice daily chest physiotherapy in patients
with non-cystic fibrosis bronchiectasis not normally practising regular physiotherapy,
significantly improves perceived cough severity, increases 24 hour sputum volume,
improves exercise capacity and SGRQ score, but has no effect on sputum microbiology,
FEVi, FVC, FEF25-75, MIP, MEP or exacerbation frequency.
Clearance of bronchopulmonary secretions is impaired in patients with bronchiectasis
(Currie et al., 1987b). Mazzocco et al (Mazzocco et al., 1985) first explored potential
benefits of chest physiotherapy in bronchiectasis patients over 2 decades ago but despite
further studies investigating various physiotherapy techniques to aid clearance, there
have been no randomised controlled studies exploring the efficacy of regular chest
physiotherapy. The primary outcome measured was selected to reflect one of the major
goals of management of chronic disease- an improvement in HRQL. Specifically, the
aim was to assess the impact of the predominant symptom of bronchiectasis- cough
severity.
The study population had clinically significant bronchiectasis. They had an average of
2(1.5-3) exacerbations in the preceding 12 months, over two-thirds were chronically
colonised with pathogenic organisms in their sputum and radiologically, 4(3-4.75)lobes
were affected with bronchiectasis on CT chest scan and 75% had varicose or cystic
dilatation in at least one lobe. Despite this, they did not carry out regular chest
physiotherapy prior to the study.
The study was conducted with twice daily chest physiotherapy over 3 months, as an
outpatient. The Acapella Choice® device was selected as the airway clearance
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technique both for ease of use and based on patient preference from previous studies
(Thompson et al., 2002, Currie et ah, 1986). Currently, there is no clear evidence for the
optimum frequency or duration of airway clearance. However, it is recognised that
airway clearance regimens need to be effective without affecting other activities of daily
living. A twice daily physiotherapy regimen was selected to account for this and as
previous studies assessing different physiotherapy techniques for non-cystic fibrosis
bronchiectasis have achieved compliance with this frequency (Thompson et ah, 2002,
Patterson et ah, 2007). Further studies are needed to specifically address the optimal
frequency and duration of physiotherapy.
Several adjuncts to physiotherapy currently exist including: bronchodilator therapy
which may minimise bronchial hyperactivity and improve airway clearance; inhaled
hyperosmolar agents (nebulised hypertonic saline has been shown to yield greater
sputum weights and inhaled mannitol which has been shown in small studies to date to
aid mucociliary clearance (Kellett et ah, 2005, Daviskas et ah, 2008)); pulmonary
rehabilitation and inspiratory muscle training has previously been shown to improve
exercise tolerance (Newall et ah, 2005). Inhaled mucolytics (recombinant human
DNase) on the other hand, although of benefit in cystic fibrosis, is not recommended in
non-cystic fibrosis bronchiectasis because it has a significant negative impact on FEV i
(O'Donnell et ah, 1998). This study did not employ any such adjuncts. Further studies
are needed to assess efficacy of such techniques in addition to regular chest
physiotherapy.
This study did not have a sham arm and instead twice daily chest physiotherapy using
an oscillatory PEP device was compared with no chest physiotherapy. This design was
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intentional as any type of sham would involve some form of airway clearance. A
limitation of this study design, however, is the potential for a placebo effect. The
crossover design was used to offer all patients a period of regular chest physiotherapy
during the study. There was no carry over effect with the 1 month washout phase.
One of the main goals of long term management of chronic respiratory disease is to
improve HRQL and with regular, controlled airway clearance, patient perception of
cough severity improved with an increase in score seen in all domains of the LCQ.
Since the completion of this study, a 1.3 unit difference in the total LCQ score has been
established as a clinically significant change (Raj et al., 2009) and a median increase of
1.3 units following 3 months of twice daily chest physiotherapy was indeed observed in
this study. A previous open label study by Mutalithas et al found a mean improvement
of 3.1 units in total LCQ score with bronchopulmonary hygiene physical therapy
(Mutalithas et al., 2008). Importantly, although this current study was not powered to
detect a change in SGRQ score, this also improved, with the total score improving
beyond its established minimal clinically significant change of 4 units (median
improvement of 7.8 units) (Wilson et al., 1997a).
A major rationale for chest physiotherapy is to loosen secretions and enhance
expectoration. According to previous work by Cecins et al, this study was sufficiently
powered to detect a 15% change in 24hour sputum volume and we found that with twice
daily chest physiotherapy the mean volume of sputum expectorated over 24 hours
increased by 2(0-6)ml (Cecins et al., 1999). Although the value of 24 hour sputum
collections in clinically stable outpatients may be limited by patient compliance and
confounded by factors such as swallowed secretions, it is a highly pertinent, non-
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invasive marker and has been selected as a relevant outcome measure in previous
studies assessing other potential long term therapeutic strategies in bronchiectasis
including inhaled steroids and long term antibiotics (Tsang et al., 2005a, Tsang et ah,
1999b, el-Din et ah, 1994, Cymbala et ah, 2005).
An increase in the distance achieved during the ISWT following 3 months of twice
daily chest physiotherapy was also observed. Based on a previous study by Newall et al
the patient sample size was powerful enough to detect a significant effect on exercise
capacity (Newall et ah, 2005). This perhaps emphasises the improvement in the
activities domain of the SGRQ and that with greater control of cough and clearance of
mucus from the airways, exercise capacity also improves.
The benefits observed with regular chest physiotherapy were small however, and we did
not find any improvements in the remaining study endpoints. Despite increased sputum
expectoration, we observed no change in sputum bacterial load or any improvement in
FEVi, FVC, FEF25-75, MIP, MEP or exacerbation frequency. One previous study of
airway clearance techniques in bronchiectasis comparing the Flutter device with the
active cycle of breathing technique found a significant improvement in FEV1 (0.08L,
95% Confidence Interval 0.01 to 0.15 using the Flutter device), however, this
improvement in FEVi was not thought to be clinically significant (Thompson et al.,
2002). The patient cohort in the current study had a median age of 73(72-77)years and
with increasing age, there is less airway reversibility, perhaps further limiting the
opportunity for any benefit from chest physiotherapy on FEVi or FVC. In addition,
there were no improvements in the assessment of small airways or inspiratory and
expiratory pressures. This may however, be due to the intrinsic variability of such
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measurements. A previous study by Newall et al in non-cystic fibrosis bronchiectasis
patients found MEPs to be impaired but MIPs were within normal range (Newall et al.,
2005). The current study population was however, older than that of Newall's study
which may explain the difference. Despite the lack of improvements in these measures,
exercise capacity significantly increased.
In conclusion, this randomised crossover study found that regular chest physiotherapy
in non-cystic fibrosis bronchiectasis has significant benefits compared with no chest
physiotherapy. Despite the differences being small, achieving an improvement in
functional ability and HRQL is highly relevant to the management of this long-term
illness. Larger studies are needed to explore potential benefits on other outcome
measures.
The next study was designed to assess the impact of reducing bacterial infection in the
airways on both clinical and laboratory outcomes during acute exacerbations of








Infective exacerbations are a significant cause of morbidity in non-cystic fibrosis
bronchiectasis and often necessitate utilisation of health care resources including
inpatient admissions for intravenous antibiotic therapy (Kelly et al., 2003). The criteria
used to define exacerbations requiring antibiotic therapy have been described in chronic
obstructive pulmonary disease and include increasing dyspnoea, increasing sputum
production and worsening sputum purulence (Anthonisen et al., 1987). Similarly, in
bronchiectasis, antibiotics are prescribed in exacerbations in patients with increasing
cough, increasing sputum volume and worsening sputum purulence. Little is known
about how best to assess the effect of antibiotic treatment in the management of such
exacerbations. Currently, a successful outcome is qualitative only, relying on the
patient's subjective assessment of symptom resolution. Validated, easily accessible and
relevant outcome measures are needed (Chang and Bilton, 2008).
It is not known if the outcome of an exacerbation is influenced by the pathogenic
organism. It has been shown that patients who are chronically colonised with
Pseudomonas aeruginosa have more severe bronchiectasis, a poorer health related
quality of life and may have an accelerated decline in FEVi(Martinez-Garcia et al.,
2007, Evans et al., 1996, Wilson et al., 1997b, Ho et al., 1998).
The aim of this prospective cohort study was to assess the effect of two weeks
intravenous antibiotic therapy for exacerbations of non-cystic fibrosis bronchiectasis on
a variety of both clinical and laboratory endpoints including 24 hour sputum volume,
FEVi FVC, exercise capacity, systemic inflammation, sputum microbiology and health
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related quality of life. In addition, the aim was to determine whether these outcomes
were influenced by the pathogenic organism isolated.
4.2 Methods
This was a prospective cohort study of adults with infective exacerbations of non-cystic
fibrosis bronchiectasis requiring intravenous antibiotics.
Patients with an exacerbation were selected according to the criteria described in the
General Methods. Patients with mixed normal flora isolated from their sputum at the
start of the exacerbation were excluded from the study. Criteria for intravenous
antibiotic therapy included failure of oral antibiotics, culture of pathogenic organisms
sensitive only to intravenous agents or severe exacerbations necessitating acute inpatient
admission.
All patients received 14 days of intravenous antibiotic therapy; the antibiotics chosen
were based on sputum microbiology prior to commencing treatment or, if necessary,
previous sputum microbiology history. All were advised to continue their routine
respiratory medications and chest physiotherapy. Any patient on long term oral
corticosteroid therapy had their dose doubled for the first seven days of the
exacerbation. No other adjunctive treatments were used to manage the exacerbation.
The following endpoints were assessed as described in the General Methods at the start
of the exacerbation prior to commencement of treatment (Day 0) and on completion of
antibiotics (Day 14): 24hr sputum volume; qualitative sputum bacteriology; FEVi and
FVC; exercise capacity using the incremental shuttle walk test (ISWT); total leukocyte
count (WCC); erythrocyte sedimentation rate (ESR); C-reactive protein (CRP); St
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George's Respiratory Questionnaire Score (SGRQ). The SGRQ was completed at the
start of the exacerbation and one week following antibiotic completion. The
questionnaire was adapted for the end of exacerbation assessment to ask about
symptoms in the preceding week (i.e. the single week following antibiotic completion).
This version of the SGRQ has not been externally validated.
Statistics
Statistical analysis was performed using SPSS for Windows, Version 16 (SPSS inc,
Illinois) and GraphPad Prism Version 5.0 (GraphPad Software, California). The data
were normally distributed and is presented as mean ± standard deviation. For comparing
means, the paired t-test was used. Patients that isolated Pseudomonas aeruginosa were
compared with those that isolated other potential pathogenic microorganisms (other
PPMs) at the start of the exacerbation. Fishers exact test was used to compare groups. A
2 tailed P value of <0.05 was considered to be statistically significant. Additional sub
analysis was conducted to ensure that the reason for needing intravenous therapy or




There were 58 exacerbations of non-cystic fibrosis bronchiectasis managed with 2
weeks of intravenous antibiotic therapy during the study period. 13 patients had more
than 1 exacerbation during the study period, but only the first exacerbation for each
patient was used. Five patients were excluded as mixed normal flora was isolated at the
start of the exacerbation and one patient was excluded as they had mucoid sputum at
presentation. The final analysis was conducted in 32 individual patients.
Table 12 details baseline patient characteristics, including parameters of disease
severity, and table 13 provides details of the aetiology of the bronchiectasis. All patients
had advanced bronchiectasis with 29 patients (90.6%) being chronically colonised with
pathogenic bacteria in the sputum when clinically stable (65.6% had Pseudomonas
aeruginosa) and having multiple exacerbations in the past year (Table 12). 62.5%
needed intravenous antibiotics because of failure of oral antibiotics, 34.4% had severe
exacerbations necessitating acute inpatient admission and 3.1% required intravenous
antibiotics as the pathogenic organisms isolated were sensitive only to agents available
as intravenous preparations.
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Table 12. Clinical characteristics of patients included in the study of intravenous
antibiotics for exacerbations of bronchiectasis.
Characteristic n (%) or Mean ± Standard Deviation
Number 32
Male 10(31.3)
Age (years) 62.8 ±9.8
Non smokers 23 (71.9)
Ex-smokers 9(28.1)
Ex-smoker pack year history 34.5 ± 17.2
COPD 3 (9.4)
Asthma 18 (56.3)
Inhaled Corticosteroid Therapy 28 (87.5)
Nebulised Bronchodilator Therapy 7(21.9)
FEV, (L) 1.57 ±0.58
(% Predicted) (66.5 ±27.3)
FVC (L) 2.49 ±0.78
(% Predicted) (85.3 ±33.2)
Infective exacerbations in preceding 7.4 ±6.0
year
Number of lobes involved on HRCT 4.1 ± 1.7
chest
Cystic bronchiectasis 10(31.2)
Chronically colonised 29 (90.6)
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Table 13. Aetiology of bronchiectasis of patients included in the study of intravenous
antibiotics for exacerbations of bronchiectasis.
Aetiology n (%)
Inactive allergic bronchopulmonary aspergillosis 11 (34.4)











At the start of the exacerbation Pseudomonas aeruginosa was isolated in 19 patients; 10
had non-mucoid and 9 had mucoid Pseudomonas aeruginosa. 13 patients isolated other
PPMs which included Haemophilus influenzae (n=4), Streptococcus pneumoniae (n=3),
Staphylococcus aureus (n=2), Moraxella catarrhalis (n=2), Escherichia coli (n=l) and
Serratia species (n=l).
Antibiotic Therapy
All patients completed 14 days of antibiotic therapy and doses used were as
recommended for bronchiectasis/cystic fibrosis in British National Formulary
(JointFormularyCommittee., 2008). In the Pseudomonas aeruginosa group 13 received
intravenous ceftazidime (2g, three times daily) and gentamicin (dose per ideal body
weight and creatinine clearance); 2 patients with a previous history of gentamicin
toxicity received intravenous ceftazidime (2g, three times daily) and colistin (2MU three
times daily) and three with known impaired renal function received intravenous
ceftazidime (2g, twice daily) and oral ciprofloxacin (500mg twice daily). The remaining
patient who had a known intolerance of ceftazidime received intravenous piperacillin
with tazobactam (4.5g, three times daily) and oral ciprofloxacin (500mg twice daily).
In the patients that isolated other PPMs, those who isolated Haemophilus influenzae,
Streptococcus pneumoniae and Moraxella catarrhalis all received single agent
ceftriaxone (2g once daily). 2 patients isolated Staphylococcus aureus (one methicillin
sensitive Staphylococcus aureus and one methicillin resistant Staphylococcus aureus)
and received intravenous flucoxacillin (500mg, four times daily) and vancomycin (dose
per ideal body weight and creatinine clearance) respectively. The remaining two
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patients isolated Serratia species and Escherichia coli respectively and both were
managed with intravenous ceftazidime (2g, three times daily) and gentamicin (dose per
ideal body weight and creatinine clearance).
Corticosteroids
4 patients were receiving long term oral corticosteroid therapy and had their dose
doubled for 7 days. No patients otherwise received oral corticosteroid therapy.
Side effects
No adverse effects were reported and no changes to treatment regimens occurred and all
patients successfully completed 14 days treatment.
Outcomes: clinical assessments
24 hour sputum volume
Following 14 days' antibiotics all patients' 24 hour sputum volume reduced with a
mean reduction of 21.8±19.9ml (PO.OOOl) (Table 14).
All patients had a reduction in their 24 hour sputum volume: 5% had <25%
improvement, 15% had 25-49% reduction and 80% had >50% reduction in 24 hour
sputum volume (Figure 16).
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Pulmonaryfunction tests
The FEVi did not significantly improve, with a mean increase of 0.07±0.2L
(5.4±12.5%), P=0.07 (Table 14). The FVC did however, improve by a mean of
0.09±0.44L (2.9±22.2%), P = 0.01 (Table 14).
29% of patients did not have any improvement in FEV), 36% had an improvement of
<10%, 19% had an improvement of 11-17% and 16% improved their FEV) by > 18%
(Figure 16).
Exercise capacity
The distance achieved in the ISWT significantly improved by 58.3±51.0m
(48.9±54.8%), PO.OOOl (Table 14) following 2 weeks' antibiotic treatment.
12% of patients did not show an improvement in exercise capacity, 28% had <25%




There was a significant improvement in WCC, ESR and CRP (Table 14). WCC reduced
by a mean of 3.7±3.7 xl09/L, ESR reduced by a mean of 17.7±21mm/hr and CRP
reduced by a mean of 59.5±69.6mg/L (Table 14).
WCC did not improve in 9.7% of patients, 29% had 50-74% improvement and no
patients had a >75% improvement in WCC (Figure 16).
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ESR did not improve in 30% of patients, 40% had a 50-74% improvement and 7% had a
> 75% improvement in ESR (Figure 16).
CRP did not improve in 9.3% of patients, 15.6% had a 50-74% improvement and 62.5%
had a >75% improvement in CRP (Figure 16).
Sputum microbiology
Qualitative bacterial clearance was achieved in 78.1% of patients (PO.OOOl) (Figure
15). All patients infected with other PPMs achieved bacterial clearance. 12 out of 19
patients infected with Pseudomonas aeruginosa achieved bacterial clearance. Of the 7
with Pseudomonas aeruginosa who did not achieve bacterial clearance, 5 of these had a
mucoid strain.
Health related quality oflife
The SGRQ total score significantly improved with a mean reduction of 13.8±12.9 units
(P=0.01) after completion of antibiotics (Table 14).
7.1% did not show any improvement in SGRQ score, 3.6% had an improvement of <4
units and 89.3% had an improvement of > 4 units.
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Table 14. Outcome measures at the start and the end of the exacerbation.
Variable Start of exacerbation End of exacerbation P
24 hr sputum
volume (mis)
30.4 ±21.9 8.5 ±8.4 <0.0001
FEVi(L) 1.45 ±0.57 1.52 ±0.58 0.07
FVC (L) 2.35 ±0.78 2.5 ±0.86 0.01
FEVi/FVC (L) 61.4 ± 12.3 60.4 ± 11.5 0.5
Exercise
Capacity (m)




10.8 ±7.1 7.2 ±2.5 <0.0001
CRP (mg/L) 66.9 ±70.7 7.4 ± 11.2 <0.0001
ESR (mm/hr) 40.1 ±27.4 22.3 ± 14.1 <0.0001
SGRQ score 57.9 ± 17.5 45.7 ±20.0 <0.0001
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The response to treatment was compared between patients with PA and other PPM. The
responses were not significantly different with the exception of FEVi and FVC. Patients
infected with Pseudomonas aeruginosa showed no improvement in either FEV i (mean
value at start of exacerbation was 1.52±0.61 improving to only 1.53±0.58 at the end,
P=0.9) or in FVC (mean value at start of exacerbation 2.38 ± 0.88 improving to 2.44 ±
0.81L, P=0.3). Those patients infected with other PPMs did however, have a significant
improvement in both FEVi (improving from 1.32±0.48L to 1.51±0.61, P=0.01) and
FVC (improving from 2.25±0.62L to 2.58±0.96L, P=0.02).
Needfor Intravenous Antibiotics
11 patients required intravenous antibiotics because of failure of oral antibiotics, 1
patient due to culture of pathogenic organisms sensitive only to intravenous agents and
20 patients due to severe exacerbations necessitating acute inpatient admission.
At the start of the exacerbation, the need for hospitalisation group had worse exercise
capacity (mean difference -196 ± 59.3m, p = 0.003), higher CRP (mean difference 49.8
± 23.4mg/L, p = 0.04) and white cell count (mean difference 2.8 ± 1.3 x 109' p 0.04)
and worse SGRQ score (mean difference 14.4 ± 5.8 units, p = 0.02). There was no
significant difference in the other endpoints.
Both groups showed a significant improvement in all parameters except in FEVi and
FVC.
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Single versus multiple exacerbations
19 patients had one exacerbation necessitating intravenous antibiotics and 13 required
more than one course of intravenous antibiotics (3.6 ±1.5 courses). At the start of the
exacerbation there was no difference in the endpoints between groups. Patients with a
single exacerbation had a significant improvement in all parameters except in FEV i and




This prospective cohort study identified useful clinical and laboratory markers for
assessing the response to 2 weeks' intravenous antibiotic treatment in adults with
exacerbations of non-cystic fibrosis bronchiectasis. Improvements were observed in 24
hour sputum volume, sputum bacterial clearance, systemic inflammation, exercise
capacity and health related quality of life, independent of pathogenic organism. No
improvement was observed in FEVi. 24 hour sputum volume, microbial clearance, CRP
and SGRQ were the most responsive markers identified.
All patients received 14 days of intravenous antibiotic therapy. The optimum duration
of treatment is not known and further trials will be needed to define this period but
previous studies have administered therapy for between 5 to 28 days (Darley et al.,
2000, Chan et ah, 1996, Ip et ah, 1993, Tsang et ah, 1999a).
All patients with Pseudomonas aeruginosa or Gram negative organisms were treated
with two anti-pseudomonal antibiotics to reduce the chance of developing antibiotic
resistance. Those with other PPMs were treated with monotherapy using intravenous
ceftriaxone. The optimum therapeutic agents are unknown. The agents used in this
study are known from in vitro sensitivities to be effective agents. The aim of the study
was not to assess the therapeutic regimen but to explore the outcome of two weeks'
effective antibiotic therapy on a variety of clinical and laboratory parameters.
There are no published international guidelines and no validated methods to allow
clinicians to assess response to treatment. Currently, a successful outcome relies
predominantly on the subjective assessment of symptom resolution. Objective outcome
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measures are needed (Chang and Bilton, 2008). This study sought to observe relevant,
minimally invasive and easily accessible endpoints to assess parameters that may be
clinically useful in monitoring response to therapy. Four particularly responsive markers
were identified: 24 hour sputum volume, qualitative sputum bacteriology, CRP and
SGRQ score.
All patients had a significant improvement in 24 hour sputum volume, with 80% having
a >50% reduction. 24 hour sputum volume is a potentially useful marker as it is highly
pertinent to the condition, non-invasive, easily accessible and inexpensive. It has been
used as a marker in previous studies that have assessed potential long term therapeutic
strategies including inhaled steroids and long term antibiotics (Tsang et ah, 2005a,
Cymbala et ah, 2005, el-Din et ah, 1994, Currie et ah, 1990). A recent study has shown
wet weight sputum to be as reliable dry sputum (Moran F, 2006). The potential
limitation of 24 hour sputum volume as an outcome measure is the reliance on patient
compliance for collection.
Sputum bacteriology as an endpoint could involve either complete bacterial clearance or
a reduction in bacterial load (colony forming units/ml). Direct counts of bacterial load is
time consuming, expensive and less likely to be available in the majority of routine (non
research) microbiology laboratories. In this study 78.1% had bacterial clearance. In the
remaining 22.9% there is no information on whether there was a reduction in bacterial
load as only qualitative cultures were carried out. However, these patients did show
improvements in the 3 other key parameters identified in this study: 24 hour sputum
volume (mean reduction 13.8±9.1mls), CRP (mean reduction 61.4±104.4 mg/ml) and
SGRQ score (mean reduction 14.8±7.2 units). Further studies using both qualitative and
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quantitative cultures would be helpful, although at present, the findings emphasise the
need for more than one endpoint to assess response to treatment.
A 9 fold fall in C-reactive protein (mean±SD fall 59.5±69.6mg/L) was observed, with
62.5% having a >75% improvement following antibiotic therapy. The other markers of
systemic inflammation observed were WCC and ESR. Although a significant
improvement was seen in WCC (1.6 fold fall with a mean±SD fall of 4.0±4.3 xl09/L),
the mean WCC at the start of the exacerbation was within normal range and the
reduction following antibiotics was small, suggesting WCC is a less relevant marker of
treatment response. The mean ESR also improved (1.8 fold fall with a mean±SD fall of
17.7±20.9mm/hr) however, only 7% of patients achieved >75% reduction in ESR.
89.7% of patients showed a clinically significant response (i.e. >4 unit improvement) in
SGRQ score. The use of such questionnaires remains predominantly within the research
setting as administration and analysis require specific resources and are time
consuming.
In keeping with the observed clinical improvements, exercise capacity improved by 1.2
fold with a mean±SD rise of 54.1±51.5m and 36% of patients increasing their distance
in the ISWT by > 50%. It may be a useful adjunct to other markers.
There was no significant improvement in FEV i but there was a small 1.06 fold rise in
FVC (mean±SD rise of 144±306ml). There was however, an improvement seen in FEVi
in patients infected with other PPMs which may reflect the complete bacterial clearance
achieved in this group. A recent review article of exacerbations in bronchiectasis noted
FEV i to be a less sensitive measure in acute exacerbations, particularly in contrast to
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cystic fibrosis bronchiectasis (Chang and Bilton, 2008). Similar findings were made by
the authors of a previous study who found that following 2 weeks of treatment with oral
amoxicillin there were small improvements in FEVi (mean improvement 8ml) and FVC
(mean improvement 180ml) but these changes were not felt to be clinically useful (Hill
and Stockley, 1986).
This study has identified multiple parameters which may be used to assess response to
antibiotics in adults with exacerbations of bronchiectasis, independent of the pathogenic
organism. 24 hour sputum volume, microbial clearance, CRP and SGRQ were most
responsive to change.
The next study was designed to assess whether limiting the bacterial burden in the
airways on a long-term basis can reduce airways inflammation, disrupting the vicious
cycle of inflammation and infection in the airways thus improving clinical status and
symptoms. A randomised controlled trial of nebulised antibiotics administered over a 12
month period was therefore conducted.
180
CHAPTER FIVE:




Long term antibiotics offer a real therapeutic option in bronchiectasis: reducing the
bacterial burden in the airways may reduce inflammation and promote healing of the
bronchial tree, limiting symptoms and potentially improving health related quality of
life. Targeted delivery of aerosolized antibiotics directly to the airways may have
significant benefit with minimal adverse systemic effects.
The purpose of this randomised controlled trial was to assess the efficacy of continuous
nebulised gentamicin therapy over one year in patients with non-cystic fibrosis
bronchiectasis chronically infected with a variety of pathogens and to assess whether
treatment effects are sustained over a three month treatment free follow up period. The
primary endpoint was a greater than or equal to one log unit reduction in sputum
bacterial load, regarded as the minimum important reduction necessary to have a
significant impact on airways inflammation (Angrill et al., 2001).
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5.2 Methods
This was a randomised controlled trial of 12 months twice daily nebulised gentamicin
compared with twice daily nebulised 0.9% saline, followed by a 3 month treatment-free
follow-up period in adults with non-cystic fibrosis bronchiectasis. The primary
outcome was >1 log unit reduction in sputum bacterial density. Secondary outcomes
included qualitative sputum bacteriology, emergence of gentamicin resistant
Pseudomonas strains, sputum myeloperoxidase and free neutrophil elastase, 24hr
sputum volume, sputum purulence, FEV), FVC, midexpiratory flows (FEF25.75),
exercise capacity, the Leicester Cough Questionnaire (LCQ) and St George's
Respiratory Questionnaire (SGRQ), exacerbations and side effects.
Patients
Patients were recruited according to the criteria described in the General Methods
section. All patients were clinically stable at the point of entry to the study (defined as
no change in routine respiratory medication and no requirements for antibiotics or
corticosteroid therapy in the 4 weeks preceding the study entry date). Patients who were
current smokers or ex-smokers of less than one year or ex-smokers with a greater than
twenty pack year history of smoking were excluded. In addition, patients had to be able
to tolerate nebulised gentamicin (defined as no bronchospasm or fall in FEVi >15% and
>200mls following nebulisation of 80mg gentamicin with or without prebronchodilation
using nebulised 2.5mg salbutamol). Furthermore, patients with any of the following
were excluded: creatinine clearance <30mls/minute; vestibular instability; previous
documented intolerance to aminoglycosides (ototoxicity or nephrotoxicity).
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Interventions
Study treatment: randomisation was to either twice daily nebulised 80mg gentamicin
(supplied as gentamicin injectable solution and reconstituted for nebulisation using
0.9% saline) or twice daily nebulised 5mls 0.9% saline. Porta-Neb Ventstream (Profile
Respiratory Systems Ltd, Bognor Regis, West Sussex) nebulisers were used for both
groups.
Nebulised gentamicin treatment: a regime of 80mg nebulised gentamicin twice daily
was prescribed.
Nebulised saline: twice daily 5mls 0.9% saline was administered.
Any patient with a serum gentamicin level >lmg/ml had their study treatment reduced
to once daily. Any patient reporting symptomatic bronchospasm (defined as increased
wheeze and/or breathlessness) had adjunctive treatment with a nebulised P2 agonist
(salbutamol 2.5mg) prior to their study treatment.
Study compliance: the twice daily treatment was self-administered at home. At each 3
monthly review, all patients were supplied with their study treatment as well as the
appropriate number of needles, syringes and filters necessary for nebulisation for the
following three months. They were asked to return any unused equipment or
medication. This was counted and in addition, all were questioned directly regarding
their compliance at each visit.
Exacerbations requiring antibiotic therapy: exacerbations were diagnosed and managed
as described in the General Methods. Regular study treatment continued during the
exacerbation.
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Routine therapy: any changes made to the patients' usual respiratory medication during
the study period were noted.
Assessments
All patients were reviewed at baseline entry to the study (month 0) and at months 3, 6,
9, 12 of treatment and then after a 3 month treatment free, follow-up period (monthl5),
Figure 17.
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Figure 17. Design of study of nebulised gentamicin versus nebulised saline in
bronchiectasis.
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At each review, the following assessments were conducted as described in the General
Methods: sputum colour; 24hr sputum volume; quantitative and qualitative sputum
bacteriology; sputum myeloperoxidase and elastase; total leucocyte count; erythrocyte
sedimentation rate (ESR); C-reactive protein (CRP); FEVi, FVC and FEF25-75; exercise
capacity using the incremental shuttle walk test (ISWT); health related quality of life
using the LCQ and the SGRQ.
In addition, gentamicin susceptibility testing was performed for all isolates of
Pseudomonas aeruginosa and Gram negative enteric bacteria at months 0, 12 and 15 in
the routine NHS laboratory, according to the Clinical and Laboratory Standards Institute
Guidelines (2006). The following zone diameters were used with lOpg gentamicin disk
to report susceptibility with Pseudomonas strains: resistance <12mm; indeterminate 13-
14mm; sensitive >15mm (2006).
Toxicity
Serum gentamicin levels as well as urea and electrolytes were measured at two weeks
following initiation of treatment and then at each three monthly assessment until
completion of the study and 3 months after completion of treatment. At the same time-




All statistics were performed using SPSS for Windows, Version 17 (SPSS inc, Illinois)
and GraphPad Prism Version 5.0 (Graphpad Software, La Jolla, California).
The primary aim was to detect a one log unit reduction in bacterial density (cfu/ml).
Using a 2 sided, 2 sample test with 80% power and 1% level of significance, 24 patients
per group were necessary and to allow for a 20% dropout rate we selected 30 patients
per group.
Only patients who completed the study were included in the final analysis. Analysis of
the results comprised a Mann-Whitney U test for unpaired numerical data and Wilcoxon
for paired numerical data were used. A Fishers exact test was used to compare
categorical variables. Data are presented as median (interquartile range). A two-tailed P




65 patients were recruited to the study, with 32 randomised to nebulised gentamicin and
33 to nebulised saline. In the gentamicin group, there were two unexpected sudden
deaths (previously undiagnosed metastatic colorectal cancer at month three and
myocardial infarction at month 5). There were no deaths in the saline group. In the
gentamicin group, there were three withdrawals: two felt unable to tolerate the
nebulised therapy (month 3 and month 6 respectively) and one felt unable to commit to
the study reviews (month 6). In the saline group, there were three withdrawals, two of
whom felt unable to tolerate the nebulised therapy (month 3 for both) and the third was
unable to commit to the study reviews (month 3). In total, 57 patients completed the
study, with 27 in the gentamicin group and 30 in the saline group (Figure 18).
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Figure 18. Consort diagram showing patient recruitment for nebulised gentamicin
versus nebulised saline in bronchiectasis.
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The baseline characteristics for each group in the analysis are shown in Table 15.
Table 15. Patient characteristics at entry to study of nebulised gentamicin versus
nebulised saline in bronchiectasis.
Characteristic Gentamicin Group n=27 Saline Group n=30 P
n(%) or median(IQR) n(%) or median(IQR)
Male Sex 9(33.3) 15(50) 0.2
Age (years) 58(53-67) 64(55.7-69) 0.2
Ex-smokers 8(29.6) 8(26.7) 0.8
Pack Year History 10(1.2-16) 7(4.2-16) 0.8
Inhaled Steroid 17(62.9) 19(63.3) 0.6
Therapy
Oral Corticosteroids 3(11.1) 3(10) 0.9
Inhaled p2 agonists
Short acting 19(70.4) 22(73.3) 0.8
Long acting 17(62.9) 19(63.3) 1.0
Inhaled
anticholinergics
Short acting 3(11.1) 0(0) 0.3
Long acting 1(3.7) 1(3.3) 0.2
Aetiology
-Idiopathic 8(29.6) 9(30) 1.0
-Post-infective 11(40.7) 11(36.7) 0.7
-Inactive ABPA 6(22.2) 6(20) 0.8
-Inactive Sarcoid 1(3.7) 1(3.3) 0.9
-Immunodeficiency 1(3.7) 1(3.3) 0.9
(IgG2 deficiency)
-Inflammatory Bowel 0 2(6.6) 0.2
Disease
CT Characteristics
-Cystic or varicose 25(92.6) 22(73.3) 0.06
dilatation
-Lobes involved 5(3-6) 5(3-6) 0.8




There was no significant difference in bacterial density between the groups at baseline
with a median of 8.02(7.63-8.3)logiocfu/ml in the gentamicin group and 7.88(7.34-
8.17)logi0cfu/ml in the saline group, P=0.29. At the end of 12 months' treatment, the
bacterial density had significantly reduced in the gentamicin group [2.96(1.0-5.9)
logiocfu/ml] compared with the saline group [7.67(7.34-8.17)logiocfu/ml], P<0.0001. At
follow up however, bacterial density was similar in both groups [gentamicin group
7.29(5.88-7.76)logiocfu/ml and saline group 7.49(6.46-8.19)logiocfu/ml, P=0.12],
Figure 19 shows the changes in bacterial density at each of the study timepoints for both
groups. For each assessment timepoint, the impact of nebulised gentamicin and
nebulised saline on sputum bacterial density compared with baseline bacterial density
for each group is shown. The impact is categorised as: no bacterial growth; > 1 log unit
reduction in bacterial density; < 1 log unit reduction or no change in bacterial density;
an increase in bacterial density. At each assessment timepoint, the difference between
each impact category was compared between the gentamicin and saline group using the
Fishers exact test. There was a significant difference in impact between the gentamicin
and saline groups at 3 months, 6 months, 9 months and 12 months. At month 15, there
was no significant difference in the change seen between the two groups.
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*P<0.0001.
Figure19: Gent=Gentamicinroup; Saline=SalineGroup. Allchangesinbacterialgrowthare
incomparisonwithsputum bacterialdensityattheseline visit,Month0.Betweengroup (GentamicinvsSaline) comparisonswe emadateach timepointusi gheF shersExact TestforBacteriallearanceand> 1logunitreduct onindensity versus<1logunitreduct onrno changeorincre sebact rial density. *P<0.0001.
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Qualitative bacteriology
There was no significant difference in the infecting pathogen between the groups at
baseline (Table 16a). Table 16b shows the change in sputum infection for both groups
throughout the study.
By one year, within the gentamicin group, 30.8% (4 of 13 patients) infected with
Pseudomonas aeruginosa achieved eradication and 3.7% (1 of 13 patients) cultured a
different pathogen, Staphylococcus aureus. 92.8% (13 of 14 patients) originally infected
with pathogens other than Pseudomonas aeruginosa achieved eradicaton. In those not
achieving eradication, there was still a significant reduction in bacterial density from a
median(IQR) 8.06(7.5-8.4)logiocfu/ml at baseline to 6.17(5.81-7.15)logiocfu/ml at the
end of treatment.
At entry to the study, all patients with Pseudomonas aeruginosa and Gram negative
enteric pathogens had strains fully susceptible to gentamicin. Of these, no patients in
either group at the end of treatment or at follow up had developed gentamicin
indeterminately resistant or resistant strains.
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Table 16a. Sputum qualitative bacteriology prior to commencement of nebulised
gentamicin and nebulised saline.





-Pseudomonas 13(48.1) 11(36.7) 0.5
aeruginosa
-Haemophilus 11(40.7) 15(50) 0.3
influenzae
-Staphylococcus 2(7.4) 1(3.3) 0.5
aureus
-Streptococcus 1(3.7) 0(0) 0.3
pneumoniae
-Moraxella 0(0) 2(6.7) 0.5
catarrhalis
-Other (coliforms) 0(0) 1(3.3) 0.3
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Table 16b. Comparison of nebulised gentamicin and nebulised saline on sputum
qualitative bacteriology throughout the study.
Month 0 Month 3 Month 6 Month 9 Month 12 Month 15










14(51.8) 4(14.8) 3(11.1) 3(11.1) 2(7.4)# 8(29.7)
Bacterial Growth 0 15(55.6) 17(62.1) 16(59.2) 18(66.7) 9(33.3)
Saline Group






18(60) 17(56.7) 19(63.3) 20(66.7) 20(66.7) 22(73.3)
Bacterial Growth 0 2(6.7) 1(3.3) 1(3.3) 1(3.3) 1(3.3)
Definition of abbreviations: PPMs= Potentially Pathogenic Microorganisms
(H. influenzae, S.pneumoniae, M.catarrhalis, S.aureus)-, MNF= mixed normal flora. #
3.7% (1 patient) was originally infected with Pseudomonas aeruginosa at entry to the
study.
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Sputum neutrophil myeloperoxidase andfree elastase
There was no significant difference in sputum myeloperoxidase or free elastase activity
at baseline between the two groups. At the end of treatment, concentrations of
myeloperoxidase and free elastase activity were significantly lower in the gentamicin
group compared with the saline group. At follow up however, concentrations of both
myeloperoxidase and free elastase activity was similar in both groups (Table 17).
Sputum purulence and volume
There was no significant difference in sputum purulence between the groups at baseline
or after 3 months treatment. At treatment months 6, 9 and 12 significantly fewer
patients in the gentamicin group had purulent sputum compared with the saline group.
At follow up, there was no difference in sputum purulence between the groups (Table
17).
There was no significant difference between the groups in 24hr sputum volume at any
timepoint (Table 17).
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Lungfunction and exercise capacity
There was no significant difference between the groups in FEVi, FVC or FEF25.75 at any
timepoint (Table 18 and Figure 19).
There was no significant difference in exercise capacity between the groups at baseline
or throughout the study until month 12 when exercise capacity had improved
significantly more in the gentamicin group compared with the saline group. At follow
up however, there was no significant difference between the groups (Table 18 and
Figure 20).
200
Table 18. Comparison of nebulised gentamicin and nebulised saline on lung function
and exercise capacity.
Month 0 Month 3 Month 6 Month 9 Month 12 Month 15
FEVi(L)
%predicted
Gentamicin 1.8 1.74 1.66 1.63 1.60 1.69
Group (1.34- (1.39- (1.32- (1.28- (1.34- (1.30-2.0)
Actual 2.31) 2.28) 2.03) 2.07) 2.08) 68.1
72.9 70.5 65.5 69.1 70 (55.7-
%Predicted (60-81.2) (56.7- (53.4- (53.3- (55-82) 77.4)
88.2) 88.2) 76.6)
1.67
Saline 1.61 1.68 1.66 1.61 1.62 (1.29-
Group (1.22- (1.28- (1.22- (1.24- (1.24- 2.16)
Actual 2.35) 2.23) 2.10) 2.15) 2.10) 64.3
63.4 64.9 66.2 67.3 61.5 (48.4-
%Predicted (45.5- (52-80.3) (45.9- (46.4- (52.6- 78.1)
80.4) 81.4) 76.8) 80.5)







Gentamicin 2.89 2.86 2.79 2.74 2.65 2.69
Group (2.21- (2.16- (2.2-3.28) (2.11- (2.18- (2.19-
Actual 3.41) 3.29) 87.1 3.33) 3.11) 3.17)
88.9 89.3 (77.5- 87.8 87 85.9
%Predicted (82.7- (78.9- 92.1) (75.6- (75.1- (80.7-
94.1) 95.1) 93.9) 92.7) 94.1)
Saline 2.93 2.83 2.87 2.68 2.68 2.67
Group (2.12- (2.14- (2.25- (2.11- (2.20- (2.21-
Actual 3.35) 3.35) 3.30) 3.33) 3.22) 3.20)
85 89.4 87.2 86.9 85.7 83..8
%Predicted (71.1- (67.7- (69.8- (71-94.2) (58- (66.3-
99.4) 96.9) 99.5) 103.4) 96.3)
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Gentamicin 350 390 445 450 510* 420
Group (270-530) (287.5- (272.5- (372.5- (350-690) (340-580)
562.5) 590) 642.5)
345 415 385
Saline (257.5- 340 340 360 (267.5- (232.5-
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The effect of nebulised gentamicin and nebulised saline on spirometry and exercise
capacity is shown in Figure 20.
The effect on FEV1% predicted, FVC% predicted and exercise capacity throughout the
study period in each group is shown. The horizontal lines represent the median and
interquartile ranges and the whiskers represent the 5-95th percentile.
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Health related quality oflife
At each 3 monthly interval during treatment, significantly more patients in the
gentamicin group achieved a clinically significant improvement in both LCQ score and
SGRQ score compared with patients in the saline group (Table 20). This effect was only
sustained at follow-up with the SGRQ score. There was no significant difference seen at
follow-up between the two groups with the LCQ score, P=0.5.
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Table 19. Comparison of nebulised gentamicin and nebulised saline on LCQ and
SGRQ.





54.5* 68.1* 65* 81.4* 48





78.2** 81.8** 1\ 4** 87.5** 60.8**
Saline Group 31.8 34.7 23.8 19.2 19
The percentage of patients with a clinically significant improvement in LCQ and SGRQ
score compared with their baseline score at entry to the study for each treatment
timepoint and at follow-up is shown. At each timepoint, the difference between the
groups was compared. *P<0.01 **P<0.004.
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Systemic inflammation
There was no significant difference in CRP, ESR or total leukocyte count between the
groups at baseline. At months 3 and 9, CRP was significantly lower in the gentamicin
group and at month 3 total leukocyte count was also lower in the gentamicin group. No
other significant differences were seen in CRP and total leukocyte count at any
timepoint during the study (Table 20). There was no significant difference between the
groups in ESR at any timepoint.
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Table 20. Comparison of nebulised gentamicin and nebulised saline on markers of
systemic inflammation.












































































































There were fewer exacerbations during the 12 months' treatment in the nebulised
gentamicin group compared with the saline group [0(0-l)exacerbations and 1.5(1-
2)exacerbations respectively, PO.OOOl].
33.3% of patients in the gentamicin group had an exacerbation during the 12months'
treatment compared with 80% in the saline group (P=0.0005). The median time to first
exacerbation during the 12months' treatment was 120(87-161.5) days in the gentamicin
group compared with 61.5(20.7-122.7) days in the saline group, P=0.02.
There was no significant difference in the number of exacerbations that occurred during
the 3 month treatment-free follow up period with 0(0-1) exacerbations occurring in the
gentamicin group and 0(0-1) exacerbations occurring in the saline group.
Gentamicin toxicity
Serum gentamicin levels at the end of treatment were 0.13(0-0.37)mg/ml. Only one
patient developed a serum gentamicin level >lmg/ml during the study. This occurred at
treatment month 9 (level 1.25mg/ml) and following reduction of study treatment to once
daily all subsequent levels (at weekly intervals for 3 weeks) were <lmg/ml for the
subject concerned.
Adverse Effects
In the total cohort originally allocated to nebulised gentamicin, 21.9% (7 of 32 patients)
reported bronchospasm and received adjunctive nebulised P2 agonist treatment. Despite
this, two patients required withdrawal from the study (one at month 3 and one at month
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6) as they remained unable to tolerate the treatment. The remaining 5 patients
successfully completed the study and were included in the final analysis.
In the total cohort originally allocated to nebulised saline, 6% (two of 33 patients)
reported bronchospasm and received adjunctive nebulised P2 agonist treatment. Despite
this, both required withdrawal from the study (both at month 3) as they remained unable
to tolerate the treatment. 16.7% (five patients) in the saline group who completed the
study reported a salty taste with nebulisation.
No nephrotoxicity was detected and no ototoxicity reported. 11.1% of patients in the
gentamicin group (three patients) reported an unpleasant taste following nebulisation.
Compliance
One patient in the gentamicin group had compliance issues. On counting of total drug
doses returned, by the end of the 12 months' treatment this study patient had taken only
67.9% of the total doses prescribed throughout the study. This patient was included in
the final analysis. There were no issues with compliance in the saline group.
Changes to routine respiratory medication
No changes were made to any patient's routine respiratory therapy during the study.
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5.4 Discussion
This randomised controlled trial has proven efficacy for nebulised gentamicin in non-
cystic fibrosis bronchiectasis. Regular, long-term nebulised gentamicin significantly
reduces sputum bacterial density and airways inflammation, with less sputum
purulence. Patients had greater exercise capacity, fewer exacerbations and an improved
health related quality of life.
The pathophysiological basis of bacterial infection and airways inflammation in
bronchiectasis was originally proposed by Cole et al approximately two decades ago
and offers a clear target for therapeutic intervention (Cole, 1986). Nebulising antibiotic
therapy allows direct treatment to the damaged airways and with localised treatment,
systemic side effects are limited (Palmer et al., 1998). Gentamicin was selected as it is
broad spectrum for the pathogens seen in non-cystic fibrosis bronchiectasis, inexpensive
(current cost for a 12 month 80mg twice daily course totals £1124.20) and has
previously been shown to achieve good sputum concentrations (Crowther Labiris et al.,
1999, Twiss et al., 2005a).
There have been no previous long term studies of nebulised gentamicin in
bronchiectasis and the optimum dose and regime is unknown. There has been one study
to date exploring the dosage of nebulised gentamicin in non-cystic fibrosis
bronchiectasis in adults (Crowther Labiris et al., 1999). Crowther Labiris et al found
that a single dose of 160mg of nebulised gentamicin, achieved good sputum
concentrations [97.2(0.3-194.2)pg/g sputum] two hours following nebulisation
(Crowther Labiris et al., 1999). There were however, reports of an unpleasant taste and
mouth irritation following nebulisation. Although there have been no previous long
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term studies, anecdotal opinions of nebulised gentamicin in bronchiectasis have
preferred 80mg twice daily dosing (Currie, 1997). In the 2 years prior to the
commencement of this study, a small pilot study (n=5) was conducted within the
bronchiectasis clinic at the Royal Infirmary of Edinburgh, using 80mg of nebulised
gentamicin twice daily and found it to be well tolerated with no reported
bronchoconstriction and no detectable serum concentrations. For this study, a regime of
80mg twice daily was selected as a dose likely to achieve adequate sputum
concentrations with minimal adverse effects and systemic toxicity, particularly for long
term administration.
The majority of patients with bronchiectasis are chronically infected with pathogenic
bacteria in their airways even when apparently clinically stable. Angrill et al, in their
study of 77 patients, found 64% to be colonised, most frequently with Haemophilus
influenzae (55%) followed by Pseudomonas aeruginosa (26%) (Angrill et al., 2002).
King et al conducted a prospective 5 year follow up study of 89 patients with
bronchiectasis, of whom 79% had pathogens in their sputum when clinically stable
{Haemophilus influenzae in 47%, Pseudomonas aeruginosa in 26%, with Moraxella
catarrhalis, Streptococcus pneumoniae and Staphylococcus aureus responsible for
infection the remaining 27%) and found that the infecting pathogen varied little over the
5 year follow-up period (King et al., 2007). Previous randomised controlled trials of
aerosolised antibiotics have included only patients colonised with Pseudomonas
aeruginosa- our study was unique to include patients infected with a variety of
pathogens and our baseline demographics support the previous studies in terms of
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incidence of infecting pathogen (Orriols et al., 1999, Barker et ah, 2000, Drobnic et ah,
2005).
Angrill et al in a separate study, evaluated the relationship between bacterial infection
and airways inflammation using bronchoalveolar lavage in both infected and non-
infected patients with bronchiectasis as well as control subjects (Angrill et ah, 2001).
Infected patients had an exaggerated inflammatory response (greater number of
neutrophils, higher concentrations of elastase, myeloperoxidase and other inflammatory
markers) compared with non-infected patients. The diagnostic cut-off value used to
define bacterial infection in bronchial washings in the study was 103cfu/ml, and with a
one log unit increase, at 104cfu/ml, there was a significant increase in airway
inflammatory markers. Hill et al found similar results using sputum in patients with
chronic bronchitis and bronchiectasis, specifically demonstrating a significant increase
in markers of airways inflammation with sputum bacterial loads of >106cfu/ml (Hill et
ah, 2000). Prior to entering the current study, all patients had significant bacterial
density in their sputum with a median of 8.021ogiocfu/ml in the gentamicin group and
7.881ogiocfu/ml in the saline group with high levels of MPO and free elastase activity
when clinically stable. The primary endpoint was a greater than or equal to one log unit
reduction in sputum bacterial load, regarded as the minimum important reduction
necessary to have a significant impact on airways inflammation. A significant reduction
in bacterial density was seen after 3 months of nebulised gentamicin, an effect sustained
throughout the 12 months' of treatment. Similar to Barker et al's study (Barker et ah,
2000), in the gentamicin group pathogen eradiction was achieved in 30.8% of patients
colonised with Pseudomonas aeruginosa and in those infected by other pathogens,
214
eradication was achieved in 92.8%. In those not achieving complete eradication of
pathogens, there was still a significant reduction in bacterial density seen. Furthermore,
parallel reductions in sputum MPO was seen, although not significantly so until
treatment month 6. Free elastase activity also significantly reduced after 3 months'
treatment. These treatment effects further corroborate Cole's hypothesis of infection and
inflammation in bronchiectasis (Cole, 1986). In the saline group, there was no change in
bacterial density or infecting pathogen and airways inflammation seen throughout the
study.
Emerging strains of antibiotic resistant bacteria is an increasing problem in lung
infection. In bronchiectasis, the potential virulence of the pathogens typically
responsible for chronic bronchial infection combined with the repeated courses of
antibiotics required for exacerbations makes the potential development of antimicrobial
resistance an almost expected phenomenon, but one that poses a real threat to a
chronically unwell population with significant disease burden. To date, there is little
data available regarding the impact of long term inhaled antibiotics on susceptibility
patterns in non-cystic fibrosis bronchiectasis. Three studies of nebulised tobramycin in
patients chronically infected with Pseudomonas aeruginosa have included observation
of emergence of tobramycin resistant Pseudomonas strains (Couch, 2001, Scheinberg
and Shore, 2005, Drobnic et al., 2005). Couch et al found resistance in 11% of patients
following 4 weeks' treatment, although 3% of those treated with placebo also developed
resistance (Couch, 2001). Scheinberg et al noted that after 12 weeks' nebulised
tobramycin, 7% developed a resistant Pseudomonas aeruginosa (Scheinberg and Shore,
2005). Drobnic et al in their inhaled tobramycin study found resistance developed
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during treatment in 10% of patients, but they also observed resistance developing during
the placebo period in 10%; reassuringly two months following completion of the study,
all patients had tobramycin susceptible strains of Pseudomonas aeruginosa (Drobnic et
al., 2005). In this current study, all patients chronically infected with Pseudomonas
aeruginosa or Gram negative enteric organisms were fully susceptible to gentamicin
prior to entry to the study and there was no emergence of resistant strains. No patient
had a gentamicin resistant Pseudomonas strain or Gram negative enteric bacterial
isolate at the end of the twelve months or indeed at follow up, three months following
completion of treatment. However, a recent study by Gillham et al found variation in
morphotype and antibiotic susceptibility in colonies of Pseudomonas aeruginosa
isolated from non-cystic fibrosis bronchiectasis sputum indicating that further studies
are needed to explore the relevance and clinical implications of in vitro susceptibilities
in these complex, chronically infected patients with recurrent exacerbations (Gillham et
al., 2009). A limitation of this study is that susceptibility testing was not done more
frequently throughout the 12 months' treatment, as it is possible that changes in zone
diameter not reaching defined resistance diameters may have occurred. Furthermore,
only Pseudomonas strains and Gram negative bacterial isolates were tested for
gentamicin susceptibility; gentamicin susceptibility was not routinely tested for in all
other potentially pathogenic microorganisms isolated.
Purulent sputum in stable bronchiectasis is associated with bacterial infection, varicose
or cystic airway dilatation and an FEVi<80% predicted (Murray et al., 2009b).
Increased sputum purulence is also associated with increased neutrophilic airways
inflammation in patients with chronic bronchitis and bronchiectasis (Stockley et al.,
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2001). In this study, two-thirds of patients in the gentamicin group had purulent sputum
at baseline but this had significantly reduced to 8.7% after 6 months' treatment and was
sustained for the remainder of the gentamicin treatment. No such similar effect was seen
in the saline group where 40% of patients had purulent sputum at baseline and 38.5%
after 12 months' treatment. No significant change was however observed in the volume
of sputum expectorated over 24hrs between the groups throughout the study. It is
questionable how reliable this endpoint is, as factors such as patient compliance,
swallowed secretions and collection of saliva may affect it.
The correlation between airways inflammation and systemic inflammation has
previously been shown to be poor (Angrill et al., 2001). In this study, despite good
improvement in bacterial clearance, there was no significant change in systemic
inflammation between the groups at the end of 12 months' treatment.
Exercise capacity has been used as a marker of treatment response in previous
interventional studies with regular chest physiotherapy and treatment of exacerbations
having significant improvement on distance achieved in the incremental shuttle walk
test (Murray et al., 2009a, Murray et al., 2009c). Lin et al in their randomised controlled
trial of nebulised gentamicin over 3 days found a significant improvement in patients' 6
minute walk test (Lin et al., 1997). In this study, after 12 months' treatment, patients
receiving nebulised gentamicin had significantly improved their exercise capacity
compared with those receiving nebulised saline. The distance achieved improved by a
median of 160m, compared with baseline. However, despite this improvement in
exercise capacity, no similar effects were seen in FEVi, FVC or mid-expiratory flows.
The value of spirometric makers as a measure of treatment effect in non-cystic fibrosis
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bronchiectasis is questionable. Orriols et al in their randomised controlled trial of
nebulised ceftazidime and tobramycin in 15 patients also observed no change in FEV i
or FVC (Orriols et al., 1999). Previous trials of other long term interventional studies
including inhaled corticosteroid therapy and regular chest physiotherapy have also not
observed any changes in FEVi (Tsang et al., 2005a, Murray et al., 2009a).
Infective exacerbations are a significant cause of morbidity and often necessitate
utilisation of both primary and secondary health care resources (Kelly et al., 2003).
Recurrent exacerbations are associated with a poor health related quality of life and add
further insult to the persistently damaged, inflamed airways. Reducing exacerbations is
a major goal ofmanagement in this chronic condition with previous long term antibiotic
studies evaluating the impact of treatment on exacerbations: Orriols et al found a
reduced number of hospital admissions and inpatient days with 12 months nebulised
ceftazidime and tobramycin; Drobnic et al found a reduced number of exacerbations
requiring hospital admission and for those admitted a shorter length of stay in their 6
month randomised controlled trial of nebulised tobramycin (Orriols et al., 1999,
Drobnic et al., 2005). In this study, patients receiving nebulised gentamicin had fewer
exacerbations during treatment and took twice as long to their first exacerbation during
the treatment phase than patients in the saline group.
With significant reductions in sputum bacterial density and inflammation as well as
improved exercise capacity and fewer exacerbations, significantly more patients in the
gentamicin group had a clinically significant improvement in health related quality of
life as assessed by both the LCQ and the SGRQ, arguably the most important goal of
management in chronic disease. Flowever, within the saline group a small percentage of
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patients also had an improvement in HRQL. This would suggest a small physiotherapy
effect or a potential placebo effect as a consequence of either a new treatment, the
impact of the frequent study reviews or immediate access to tertiary care support if they
felt unwell.
Nebulised gentamicin was a reasonably well tolerated therapy, with few adverse effects.
Despite no significant bronchospasm with the initial gentamicin challenge, seven of the
original 32 patients subsequently developed bronchospasm. These patients received
adjunctive nebulised beta-2-agonist and five were able to continue with the nebulised
gentamicin and complete the study. However, in Barker et al's study of 4 weeks of
nebulised tobramycin there was an overall increased incidence of reported wheeze,
cough, chest pain and dyspnoea with treatment- 70% of patients reported at least one
respiratory symptom (Barker et al., 2000). No patient suffered other adverse effects
commonly related to gentamicin, particularly there were no cases of nephrotoxicity or
ototoxicity. Only one patient developed a significantly detectable serum level of
gentamicin at month 9, requiring a reduction in treatment dose to 80mg once daily.
These findings would suggest that with close monitoring, nebulised gentamicin is a safe
treatment.
Despite significant benefits with nebulised gentamicin throughout 12 months'
treatment, it was disappointing that none of the treatment effects were sustained in the 3
month treatment free follow up period, with sputum characteristics returning to values
similar to baseline. Only one randomised controlled trial of nebulised antibiotics has
previously included a follow up period during which time eradication of Pseudomonas
aeruginosa from the sputum was sustained, but this was only over 2 weeks follow-up
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period and it is not known whether this effect would be sustained over a longer follow-
up period (Barker et al., 2000). Although our findings during the follow-up period are
disappointing, they provide clear guidance for clinicians that for treatment with
nebulised gentamicin to be effective, it must be continuous. Further studies are
however, needed to decide on the optimum regime.
There is a paucity of evidence for effective long term treatments in non-cystic fibrosis
bronchiectasis. This randomised controlled trial has shown that regular nebulised
gentamicin can significantly reduce sputum bacterial infection, reduce airways
inflammation, improve sputum purulence, improve exercise capacity, reduce
exacerbations and improve health related quality of life in chronically infected patients
with bronchiectasis, irrespective of infecting pathogen.
The final study sought to explore whether there are any key parameter- either clinical or
laboratory markers- that can be used to assess response to long term treatment strategies
in the management of bronchiectasis.
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CHAPTER SIX:
ASSESSING RESPONSE TO TREATMENT IN BRONCHIECTASIS
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6.1 Introduction
Bronchiectasis is a chronic, debilitating illness responsible for significant patient
morbidity and substantial socioeconomic cost (Martinez-Garcia et al., 2005, Weycker
D, 2005, Kelly et ah, 2003). Efficacious treatments are necessary but it is poorly
understood how best to monitor response. Few clinical or laboratory markers have been
specifically validated for the disease with previous interventional and observational
studies typically relying upon indices proven for other chronic respiratory conditions,
particularly chronic obstructive pulmonary disease (COPD) and cystic fibrosis. More
recently the reliability or relevance of such methods has been questioned (Athanazio et
ah, 2010).
There are currently two clinical outcome measures validated for use in bronchiectasis.
Both are health related quality of life questionnaires, the St George's Respiratory
Questionnaire (SGRQ) (Jones et ah, 1992, Wilson et ah, 1997a) and the Leicester
Cough Questionnaire (LCQ) (Birring et ah, 2003, Murray et ah, 2009d). Improving
health related quality of life is arguably the most important goal ofmanagement in non¬
fatal yet incurable chronic conditions, however objective assessment of health related
quality of life with such questionnaires may be time consuming and cumbersome for
both the patient to complete and the clinician to analyse, thus limiting its use in daily
practise. Other pertinent, non-invasive, inexpensive and reliable outcome measures are
urgently needed (Chang and Bilton, 2008).
The aim was to identify parameters that may be useful in assessing response to chronic
interventions in stable disease. A clinically significant improvement in the total St
George's Respiratory Questionnaire was considered an effective response to treatment
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and used to define a successful treatment outcome against which other currently non-
validated measures were assessed including: forced expiratory volume in one second
(FEVi), forced vital capacity (FVC), mid-expiratory flows (FEF25-75), incremental
shuttle walk test (ISWT), sputum bacteriology, sputum colour, total white cell count




An analysis of outcome measures used to assess response to chronic intervention in
stable disease (treatment with regular chest physiotherapy compared with no regular
chest physiotherapy over three months and treatment with regular nebulised gentamicin
compared with nebulised 0.9% saline over 12 months) was conducted.
Patients involved in the preceding studies were included in the analysis and classified as
"responders" or "non-responders".
Responders: Patients achieving an improvement of >4units in their SGRQ total score at
the end of the study when compared with their baseline SGRQ total score at the start of
the study. A change of >4 units is the minimal clinically important difference for change
(Wilson et al., 1997a).
Non responders: patients who failed to achieve an improvement of >4 units in their
SGRQ total score at the end of the study when compared with their baseline SGRQ total
score at the start of the study.
The following outcome measures were included in the analysis of response to treatment:
FEVi, FVC, FEF25-75, ISWT, quantitative sputum bacterial load, qualitative sputum
bacterial clearance, sputum colour, WCC, ESR, CRP and exacerbation frequency. Cut¬
offs were determined using the results from the previous study of infective
exacerbations described in Chapter Two.
All outcome measures were assessed as described in the General Methods section.
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Statistics
All statistics were performed using SPSS for Windows, Version 17 (SPSS inc, Illinois).
For comparisons between responders and non-responders, a Mann-Whitney U test was
performed. A multivariate forward logistic regression analysis was performed to assess
the predictors of response to long term treatment strategies in stable bronchiectasis. A P
value of <0.05 was used for entry into the model. Multicollinearity was assessed using
the variance inflation factor (VIF) with a VIF<2.5 regarded as excluding any significant
interaction. The dependant variable was an improvement in SGRQ of >4 units. The
independent variables were: >12% and >200ml increase in FEVi; >300ml increase in
FVC; >20% increase in FEF25-75; >50m improvement in the distance achieved in ISWT;
> 1 log cfu.ml reduction in bacterial load; >50% reduction in WCC; >50% reduction in
ESR; >75% reduction in CRP; >lpoint improvement in sputum colour chart
measurement; complete eradication of bacteria from the sputum; <2 exacerbations
during intervention. A second multivariate analysis was performed using the same
model but excluding complete eradication of bacteria from the sputum as an
independent variable to identify other independent predictive factors accounting for
patients with chronically infected sputum who may therefore be less likely to achieve
complete sputum bacterial eradication but may otherwise respond to treatment. A 2-
tailed P value of <0.05 was considered statistically significant.
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6.3 Results
Baseline comparison between responders and non-responders
There were 39 responders and 52 non-responders. There was no significant difference in
age, sex, % predicted FEVi, % predicted FVC, % predicted FEVi/FVC ratio or
radiological extent of disease between responders and non-responders when clinically
stable prior to the intervention (Table 21).
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Male sex 21(53.8) 28(53.8) 0.8
Age (years) 67(58-72) 71(64.2-75.0) 0.08
Ex-smoker 14(35.9) 20(38.5) 1.0
% Predicted FEVi 72.2(57.2-81.3) 69.0(47.9-88.5) 0.6










The characteristics of responders and non-responders when clinically stable prior to
entry into respective intervention studies are shown.
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Effect of intervention on variables in responders and non-responders
There was a significant difference between responders and non-responders to treatment
in FVC, ISWT, sputum colour, sputum bacterial eradication and sputum bacterial load
(Table 22).
Table 22. Effect of treatment on outcome variables for responders and non-responders
to treatment.
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Change in FEV1 (L) -0.08(-0.2-0.01) -0.02(-0.1-0.09) 0.07
Change in FVC (L) -0.11(-0.33-0.07) 0.06(-0.18-0.21) 0.02




























Independentfactors predictive ofa successful response to treatment
All factors had a VIF of <2.0. Independent factors were an improvement in the distance
achieved in the ISWT by >50m and eradication of bacteria from the sputum (Table 23).
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Table 23. Factors predictive of a response to treatment.
Factor Odds ratio








Multivariate logistic regression analysis of factors predictive of a successful response to
chronic treatment in bronchiectasis.
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Independent factors predicting a response to treatment with sputum bacterial eradication
excluded from the model were an improvement in the distance achieved in the ISWT by
>50m and improvement in sputum colour by > one point on the sputum colour chart
(Table 24).
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Table 24. Factors predictive of a response to treatment excluding sputum bacterial
eradication.
Factor Odds ratio








Multivariate logistic regression analysis of factors predictive of a successful response to
chronic treatment in bronchiectasis excluding complete sputum bacterial eradication.
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6.4 Discussion
Measures that may be important in the assessment of a successful response to long-term
treatments in bronchiectasis include an improvement in the incremental shuttle walk
test, eradication of bacteria from the sputum, a reduction in sputum bacterial density and
an improvement in sputum purulence. Independent outcome measures that may predict
a successful response to chronic treatment strategies (defined as >4 unit improvement in
SGRQ total score) include an improvement in the incremental shuttle walk test of >50m
and eradication of bacteria from sputum.
Patients who had a successful response to treatment achieved a significantly greater
distance in the ISWT than those who failed to respond to treatment. Exercise capacity is
highly relevant in bronchiectasis as it has long been recognised to promote airway
clearance (Macmahon, 1915) and more recently, a poor score in the activities section of
the SGRQ has been proven to be a predictor of mortality (Loebinger et al., 2009b).
Previous studies recognising exercise capacity as an important outcome include Lin's
study of twice daily inhaled gentamicin improving the distance achieved in the 6-minute
walk test and Newall et al in their study of exercise training and inspiratory muscle
training in patients with bronchiectasis used the ISWT as an outcome measure,
recognising the importance of exercise tolerance and health related quality of life
(Newall et al., 2005). In both models of the multivariate analysis, a minimum
improvement of 50m was found to be an independent predictor of a successful treatment
outcome. An improvement of 50m was selected based on the utility of the ISWT in
acute exacerbations (Murray et al., 2009c). The ISWT is an inexpensive, easily
conducted assessment with real pertinence to bronchiectasis in terms of both health
related quality of life and mortality. Further external validation studies are needed.
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Chronic airways infection is associated with increased airways inflammation, a poorer
health related quality of life, more frequent exacerbations and with chronic
Pseudomonas infection, a more rapid decline in lung function (Martinez-Garcia et al.,
2007, Angrill et al., 2001, Courtney et al., 2008). Limiting airways infection is a major
goal of long term management in bronchiectasis. Sputum bacteriology has been used as
an outcome measure in previous interventional studies for both acute management
strategies and in the evaluation of long term therapies (Stockley et al., 1984a, Tsang et
al., 1999a). This study included two different measures of sputum bacteriology as
potential predictors of treatment response. Qualitative bacteriology reports the presence
or absence of pathogens in sputum and is the most frequent technique utilised by
laboratories to measure airways infection. Quantitative bacteriology provides an
accurate assessment of bacterial density in the infected airways and in patients with
chronic infection unlikely to achieve complete pathogen eradication, quantitative
bacteriology measuring any impact or reduction in density may be a more useful
measure. Univariate analysis identified both measures as significant discriminators of
successful treatment response. On multivariate analysis, quantitative bacteriology
measuring complete eradication of bacterial pathogens from sputum emerged as the
more powerful measure as an independent marker of a successful treatment response.
With complete pathogen eradication, patients achieved an improved health related
quality of life and a successful treatment response.
Despite not achieving complete sputum pathogen eradication, particularly in patients
with chronic airways infection, a successful treatment response may still be achieved.
The patients included in the interventional studies analysed were all required to have
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evidence of chronic airways infection for eligibility for study entry. A second, separate
analysis of the model was therefore undertaken excluding complete pathogen
eradication as a potential independent predictor to assess for other measures that may
predict a successful treatment response. This identified a one point improvement in
sputum purulence in addition to an improvement in exercise capacity (>50m in the
ISWT) as independent predictors of treatment response.
Sputum purulence reflects airways inflammation and is positively associated with
bacterial infection (Stockley et al., 2001, Murray et al., 2009b). Changes in sputum
purulence have been utilised as measures of treatment response since the earliest
observational reports of management of bronchiectasis and in the earliest randomised
controlled treatment trials (1957, Cherniack et al., 1959, Hill et al., 1988, Currie et al.,
1990). In the multivariate analysis that excluded complete pathogen eradication as a
potential predictor of treatment response, an improvement in sputum purulence emerged
as an independent predictor of a successful treatment response. With clearer sputum,
there is less airways infection and inflammation and an improved health related quality
of life. Sputum purulence is a non-invasive, inexpensive and pertinent marker that can
be reliably measured and reported (Murray et al., 2009b).
Lung function- particularly FEVi and FVC- are frequently and reliably used as markers
of treatment efficacy in the management of other chronic respiratory diseases such as
cystic fibrosis and asthma. To date, studies in bronchiectasis have failed to provide
convincing support for lung function as a useful marker of treatment response. Orriols
et al in their randomised controlled trial of nebulised ceftazidime and tobramycin in 15
patients observed no change in FEVi or FVC (Orriols et al., 1999). Tsang et al observed
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no change with 12 months' inhaled corticosteroid treatment (Tsang et al., 2005a).
However, some studies of acute exacerbations have noticed significant improvements in
FEVi and FVC with an earlier open label study found that following 2 weeks of
treatment with oral amoxicillin there were small improvements in FEVi (mean
improvement 8mLs), FVC (mean improvement 180mLs), vital capacity (mean
improvement 170mLs), functional residual capacity (mean improvement 160mLs) and
total lung capacity (mean improvement 230mLs) although these changes were not felt
to be clinically useful (Hill and Stockley, 1986). The clinical relevance of any change in
FEVi and FVC was explored in the multivariate model using an improvement of
200mls and >12% increase from baseline in FEV( and an improvement of >300mls in
FVC based on the current American Thoracic Society/European Respiratory Society
guidelines for interpretation of lung function (Pellegrino et ah, 2005). These changes
were not found to be independent predictors of a successful treatment response and the
utility of FEVi and FVC in measuring treatment response remains unproven with little
evidence to currently support any further investigation of their role.
There was no significant difference in WCC, ESR or CRP observed between responders
and non-responders. Cut-off levels for a clinically relevant change in these markers
were based on the role of these markers in acute exacerbations (Murray et ah, 2009c),
however none were found to be useful predictors of a successful response to chronic
treatment strategies. These markers are more likely to have a role in assessing
interventions in the management of acute exacerbations of bronchiectasis which are
typically accompanied by a systemic inflammatory response (Murray et ah, 2009c).
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The analysis also included exacerbation frequency as a measure of treatment response.
Exacerbations are a stimulus to the vicious cycle of infection and inflammation in the
already damaged bronchiectatic airways and adversely impact on health related quality
of life- reducing their frequency is a major goal of management. On multivariate
analysis it was not an independent predictor of treatment response. This should however
be interpreted with caution as larger, multicentre trials would be necessary to address
this as an outcome measure.
Bronchiectasis is responsible for significant morbidity and frequent utilisation of health
care resources. Over the past decade it has become increasingly recognised that
effective, evidence-based treatment strategies are necessary. To effectively assess a
treatment strategy clear and validated endpoints are needed. Improvement in health
related quality of life is a key endpoint for all interventions. This study has found that
sputum microbial clearance and increasing exercise capacity as measured by an increase
of >50m in the ISWT as well as improved sputum purulence are independent predictors






7.1 Augmentation of the mucociliary system
In bronchiectasis the normal mucociliary clearance mechanism is impaired causing
disruption of both the integrity and sterility of the bronchial tree. Early studies of
inhaled labelled aerosols demonstrated abnormal and slow rates of clearance from the
airways of patients with bronchiectasis (Lourenco et al., 1972, Svartengren et ah, 1986,
Isawa et ah, 1990). Excessive, viscous and purulent secretions accumulate, causing an
increased risk of invasion and chronic colonisation of the bronchial mucosa by
potentially pathogenic microorganisms resulting in perpetual airways inflammation and
constant stimulation of the vicious cycle (Cole, 1986). The rationale for chest
physiotherapy is to loosen secretions and aid their movement through the bronchial tree
as well as enhancing expectoration. With fewer secretions in the airways there may be
less exposure of the bronchial mucosa to toxins and pathogens with less perpetuation of
the vicious cycle of infection and inflammation, improved symptom control and
improved disease parameters. Despite the plausibility of this rationale and the routine
recommendation for its use, there is a paucity of evidence for the efficacy of
physiotherapy in bronchiectasis.
The study in Chapter Three explored the impact of regular twice daily chest
physiotherapy with no chest physiotherapy in clinically stable patients with
bronchiectasis. The aim was to assess whether augmentation of the mucociliary
clearance mechanism could achieve one of the major goals of management in
bronchiectasis by improving patients' health related qualiiv of life and to assess its
impact on other disease parameters to help evaluate whether it is a treatment strategy
that may interrupt the vicious cycle of infection and inflammation.
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In this crossover study 20 patients who did not normally practise regular physiotherapy
were treated for 3 months with twice daily chest physiotherapy using an oscillatory
positive expiratory pressure device. Significant differences were observed with regular
chest physiotherapy including an improvement in perceived cough severity measured
with the LCQ score, an increase in 24 hour sputum volume, an improvement in exercise
capacity and an improved health related quality of life as quantified by SGRQ score.
There was no significant effect on sputum microbiology, FEVi, FVC, FEF25-75, MIP,
MEP or exacerbation frequency.
Regular chest physiotherapy achieves one of the main goals of management of
bronchiectasis, an improvement in health related quality of life. Improvements were
seen both in the impact of cough severity measured using the LCQ and in the effect of
general respiratory symptoms on health related quality life using the SGRQ. The
changes observed with regular chest physiotherapy were clinically significant with a
median improvement in LCQ total score of 1.3units, and a median improvement of 7.8
units in the SGRQ total score. It is of particular relevance that within the SGRQ score, a
significant improvement in the activities score was seen as this section of the SGRQ has
been identified as an independent risk factor for mortality (Loebinger et al., 2009b).
The rationale that chest physiotherapy should aid mobilisation of secretions is proven
clinically in this study with the increase in sputum volume expectorated over 24hours.
A median increase of 2mls in 24hour sputum volume expectoration with regular chest
physiotherapy was observed, implying better mobilisation of secretions. Although the
current study described in Chapter Three did not intend to explore the mechanistic
action of regular physiotherapy, the direct effect of physiotherapy on mucociliary
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transportation in bronchiectasis has been investigated in a recent 4 week crossover
study. 18 patients were exposed to a regime of a daily 30 minute physiotherapy session
with a high frequency oscillatory positive expiratory pressure device (the Flutter VRJP1)
followed by a washout period then a regime of a daily 30 minute session with positive
expiratory pressure physiotherapy. Sputum samples were collected on a weekly basis
and analysed in a cough simulated machine for contact angle measurement and relative
transport velocity. The combination of high frequency oscillation and positive
expiratory pressure resulted in a greater displacement of expectorated sputum with a
lower contact angle measurement, but no significant difference was seen in the relative
transport velocity (Tambascio et al., 2011). This contrasts with an earlier evaluation of
sputum expectorated following a single session of either the Flutter VPR1 or positive
expiratory pressure or no physiotherapy which found no change in ciliary or cough
transportability or contact angle measurements between all three groups (Valente,
2004). The difference in observations between the two studies suggests that regular,
long term practice of daily physiotherapy may be important for treatment efficacy.
It is intriguing that one of the aims of physiotherapy is to increase secretion
expectoration but that studies of other treatment strategies have typically always sought
a reduction in sputum expectoration as an indication of improved symptoms and a
measure of treatment efficacy. Longer studies are needed to establish whether
physiotherapy initially clears the airways of secretions causing perhaps a transient
increase in sputum volume followed by a reduced volume in the longer term.
The increased sputum clearance together with subjective better control of cough
reflected by the improvement in the LCQ may be sufficient to contribute to the
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improvement observed in exercise capacity but is not reflected in physiologic
improvement of airways obstruction with the absence of any improvement in mid
expiratory flows, FEV i or FVC.
Exercise capacity was assessed using the incremental shuttle walk test and a median
improvement of 40m with regular chest physiotherapy was seen. The greater distance
achieved is reflected in both the activities score of the SGRQ and the physical domain
of the LCQ. ft is perhaps surprising however that despite this improvement in exercise
capacity no changes were seen in either spirometry (including small airways) or in
muscle pressures as assessed by inspiratory and expiratory mouth pressures. The
median age of the study population was 73 years and with increasing age, there is less
airway reversibility, perhaps further limiting the opportunity for any benefit from chest
physiotherapy on FEV| or FVC. Only one of the previous studies of physiotherapy
techniques in bronchiectasis found a significant improvement in FEVi (0.08L using the
Flutter device) but the authors suggested that although this was a statistical
improvement and was unlikely to be clinically relevant. In view of the increased
prevalence of bronchiectasis in those over 75 years of age and the increasing life
expectancy of the general population worldwide, the sensitivity and utility of airways
reversibility as a measure of treatment efficacy requires further investigation and may
need to be reconsidered (Weycker D, 2005). However, the study described in Chapter
Three involves only 20 patients and as such is not sufficiently powered to show changes
in spirometry or small airways.
Although regular chest physiotherapy clearly has significant effects on functional
measures, no significant changes were seen in either quantitative or qualitative sputum
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bacteriology. Despite mobilisation and increased clearance of secretions from the
airways, chronic colonisation of the bronchial mucosa persists. No change in
exacerbation frequency was observed suggesting that patients remain vulnerable to
repetitive insults to the airways and disease progression although again the size of the
population studied and the duration of the study may have been insufficient to fully
evaluate this outcome. Larger multicentre studies are needed to explore the effect of
physiotherapy on bacterial colonisation, microbial load in the airways and exacerbation
frequency.
The current study provides evidence for the clinical efficacy of regular chest
physiotherapy in bronchiectasis but highlights major areas that still require research. In
particular, studies of longer duration that can assess the impact of physiotherapy on
exacerbation frequency and severity are needed and the efficacy of chest physiotherapy
in combination with other airway clearance techniques requires considered evaluation.
Other questions that need answered include whether the aetiology of bronchiectasis
affects the efficacy of physiotherapy; whether there is an optimum technique for
physiotherapy; how frequently and for how long should physiotherapy be practised and
whether it provides additional benefits during acute exacerbations. The present study
provides the initial evidence base from which these important questions need to be fully
answered.
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7.2 Successfully treating exacerbations to disrupt the vicious cycle
Infective exacerbations are a significant cause ofmorbidity in bronchiectasis. Although
there are no formal criteria specific to bronchiectasis that define an exacerbation,
consensus expert opinion agrees that an exacerbation involves an acute deterioration
(usually over several days) with worsening local symptoms (cough, increased sputum
volume or change of viscosity, increased sputum purulence with or without increasing
wheeze, breathlessness or haemoptysis) and/or systemic upset (Pasteur et al., 2010).
Infective exacerbations have a negative impact on health related quality of life, absent
days from work occur and hospital admission may be necessary. On a pathological
level, acute bacterial infection in the airways is associated with increased neutrophilic
inflammation and airway wall damage, and with repeated episodes perpetuating the
vicious cycle of infection and inflammation in the airways, there may be progressive
destruction of the integrity of the bronchial wall.
More frequent and severe exacerbations are associated with a progressive decline in
lung function and a poorer health related quality of life (Martinez-Garcia et al., 2007)
(Martinez-Garcia et al., 2005, Courtney et al., 2008). Although exacerbations have not
been explored as an independent risk factor for mortality, a New Zealand study
observed that 21% of 152 patients who had required a hospital admission for an
exacerbation of bronchiectasis had died within the next 12 months (Roberts et al., 2011)
and an American study of 43 patients with inpatient exacerbations of bronchiectasis
found a hospital mortality of 9% and a one year mortality of 30% (Finklea et al., 2010).
Exacerbations are commonly managed with in the community, although such outpatient
exacerbations are poorly quantified or indeed characterised in the literature (Kelly et al.,
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2003). More severe exacerbations typically require management as an inpatient in
hospital, often due to associated systemic sepsis or the need for intravenous antibiotic
agents if these are unable to be administered in the community. There has been a decline
in the number of inpatient admissions for exacerbations of bronchiectasis over the past
few decades with a Finnish study observing 87 admissions per million of the population
in 1992 compared with 143 admissions per million of the population in 1972 (annual
reduction of 1.3% with a 5.7% annual reduction of the number of necessary inpatient
days) (Saynajakangas et al., 1997). Various factors are likely to be responsible for this
decline including better understanding of bronchiectasis, increased availability of
preventative measures such as vaccination, development of more effective antibiotic
agents and improved community health care services. Despite this, exacerbations
necessitating inpatient management remain a significant problem. The average annual
age-adjusted hospitalisation rate of US inpatient admissions betweenl993-2006 was
16.5 per 100 000 of the population (Seitz et ah, 2010) and more recently a study of 152
patients observed 307 admissions over a 12month period (Roberts et ah, 2011).
Despite the morbidity and mortality associated with exacerbations of bronchiectasis,
little is known about how best to assess the effect of antibiotic treatment in the
management of such exacerbations, to define a successful treatment outcome.
The aim of the study described in Chapter Four was to assess the effect of two weeks of
intravenous antibiotic therapy for exacerbations on a variety of both clinical and
laboratory endpoints including 24 hour sputum volume, FEVi, FVC, exercise capacity,
systemic inflammation, sputum microbiology and health related quality of life. In
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addition, the aim was to determine whether these outcomes were influenced by the
pathogenic organism isolated.
Improvements were observed in 24 hour sputum volume, sputum bacterial clearance,
systemic inflammation, exercise capacity and health related quality of life, independent
of the infective organism. Four particularly responsive markers were identified: 24 hour
sputum volume, qualitative sputum bacteriology, CRP and SGRQ score.
Sputum expectoration is the defining symptom of bronchiectasis and as such is a
pertinent and non-invasive potential marker of bronchiectasis. Following 2 weeks of
intravenous antibiotic treatment, all patients had less sputum production with 80%
achieving >50% reduction in 24 hour sputum volume. Previous antibiotic studies have
utilised sputum volume as a parameter of efficacy (Hill et al., 1988, Currie et al., 1990,
Tsang et al., 1999b) and the current study supports this, finding 24 hour volume to be
the most responsive marker. However, for 24 hour sputum volume to be reliable it is
entirely dependent on patient compliance for accurate collection. Other more
independent objective markers of efficacy are likely to be necessary.
Treatment of exacerbations with 2 weeks of intravenous antibiotic therapy had a
positive impact on heath related quality of life with 89.7% of patients having a clinically
significant response in SGRQ score (greater than 4 unit change). A significant
improvement was seen in each domain assessed by the SGRQ (symptoms, activities and
impact) and the mean improvement of 13.8units in total score was more than three times
greater than the minimal important difference for change necessary with the SGRQ.
Achieving a better score in the activities section of the questionnaire may reflect an
improved prognosis in terms of mortality risk factors (Loebinger et al., 2009b).
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Improving health related quality of life is a major goal of management in chronic
disease and in non-cystic fibrosis bronchiectasis it's importance has been recognised
since the early studies of antibiotic treatment for exacerbations that reported various
features such as improved wellbeing and symptoms, fewer days confined to bed and
fewer days absent from work as outcomes of successful treatment (Hill et al., 1988,
Currie et ah, 1990, Davies and Wilson, 2004, Cymbala et ah, 2005). Health related
quality of life questionnaires have provided a powerful means to quantify such
important outcomes and have been widely used in more recent studies to both assess
treatment response and to compare interventions. A study of inflammatory indices in 18
patients receiving two weeks' intravenous antibiotic therapy for an infective
exacerbation also observed an improvement in the patients' health related quality of life
as measured by the Chronic Respiratory Disease Questionnaire and although this has
not been validated for use in non-cystic fibrosis bronchiectasis, significant
improvements were seen in three of the questionnaire subsections including the
dyspnoea, emotional and mastery scores (Courtney et ah, 2008). However, the utility of
such questionnaires remains predominantly within the research setting as administration
and analysis require specific resources and are time consuming.
The French mycologist Vuillenin used the phrase "antibiosis (Greek: and, against and
biosis, life)" to describe the activity of antibacterial substances. The term antibiotic was
derived from this phenomenon by Waksman in 1942 and clearly explains the rationale
for the use of such substances in the management of infection, to inhibit microbial
growth (Waksman, 1947). Studies of exacerbations of bronchiectasis have all used
antibiotics with the aim of limiting bacterial growth in the airways. In the current study,
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the effect of intravenous antibiotic therapy on the infecting pathogen was assessed using
qualitative sputum bacteriology. 78.1% achieved complete clearance of the infecting
pathogen at the end of 14 days of intravenous antibiotics. This is similar to previous
studies of intravenous antibiotics for exacerbations with one of the earliest studies using
intravenous ticarcillin or intravenous and nebulised ticarcillin for patients infected with
Pseudomonas aeruginosa achieving bacterial clearance in 76% (Pines et al., 1970).
Later studies using intravenous antibiotics alone have also achieved similar clearance
with a study of 9 patients treated with intravenous meropenem achieving complete
bacterial clearance in 83% and more recently a study of 18 patients receiving
intravenous antibiotics for 14 days achieved clearance in 72.2% (13 patients) at the end
of treatment (Darley et al., 2000, Courtney et al., 2008). In the remaining 22.9% in the
study in Chapter Four there is no information on whether there was a reduction in
bacterial load as only qualitative cultures were carried out. However, these patients did
show improvements in the 3 other key parameters identified in this study: 24 hour
sputum volume (mean reduction 13.8mls), CRP (mean reduction 61.4mg/ml) and
SGRQ score (mean reduction 14.8units). Further studies using both qualitative and
quantitative cultures would be helpful. The current study described in Chapter Four did
not follow the patients beyond the end of the 14 day treatment period and so it is
unknown as to whether the patients achieving bacterial clearance subsequently became
colonised or indeed reinfected with the same pathogen. Previous studies that have
reviewed sputum bacteriology subsequent to the immediate end of treatment of the
exacerbation have found variable rates of relapse between 15% (Courtney et al., 2008)
and 47-52% (Davies et al., 1983, Pines et al., 1974). Reinfection of the airways poses
many questions such as the type of infecting pathogen, resistance pattern of the
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infecting pathogen, the burden and impact of the pathogen in the airways and on the
vicious cycle of infection and inflammation and further studies are needed to address
these issues.
The current study used systemic markers of inflammation to assess treatment response
and observed a 9 fold fall in C reactive protein (mean fall 59.5mg/L), with 62.5%
having a >75% improvement following antibiotic therapy. The other markers of
systemic inflammation measured observed were WCC and ESR. Although a significant
improvement was seen in WCC (1.6 fold fall with a mean fall of 4.0xl09/L), the mean
WCC at the start of the exacerbation was within normal range and the reduction
following antibiotics was small, suggesting WCC is a less relevant marker of treatment
response. The mean ESR also improved (1.8 fold fall with a mean fall of 17.7mm/hr)
however, only 7% of patients achieved >75% reduction in ESR. The study also assessed
the effect of treatment on exercise capacity and lung function. In keeping with the
improvement in health related quality of life (particularly the activities domain of the
SGRQ), exercise capacity improved by 1.2 fold with a mean rise of 54.1m and 36% of
patients increased their distance in the ISWT by > 50%.
There was no significant improvement in FEV i however, and only a small 1.06 fold rise
in FVC (mean rise of 144ml). Similar findings were made by the authors of a previous
study who observed that following 2 weeks of treatment with oral amoxicillin there
were small improvements in FEVi (mean improvement 8mls) and FVC (mean
improvement 180mls) but these changes were not felt to be clinically useful (Hill and
Stockley, 1986). Interestingly, in the subanalysis of patients infected with pathogens
other than Pseudomonas aeruginosa, an improvement in FEVi (from 1.32L to 1.511)
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and FVC (from 2.25L to 2.58L) was observed, perhaps reflecting the complete bacterial
clearance achieved in this group. The utility of FEVi and FVC as markers of effective
treatment is debatable and a recent review article of exacerbations in bronchiectasis
noted FEV i to be a less sensitive measure in acute exacerbations, particularly in contrast
to cystic fibrosis bronchiectasis (Chang and Bilton, 2008).
Previous antibiotic studies have compared antibiotic dose and duration in patients
infected with either a variety of pathogens or in those exclusively infected with
Pseudomonas. The aim of the current study was to explore how best to assess treatment
efficacy in exacerbations irrespective of infecting pathogen.
The duration of antibiotic therapy for treatment of exacerbations of bronchiectasis in
this study was 14 days. The optimum duration of treatment is not known and there are
no randomised controlled trials of duration of antibiotic use in exacerbations. Studies
have included exacerbations using antibiotics for between 5 to 28 days and good
bacterial clearance has been proven in exacerbations managed with antibiotics for 7-14
days (Pines et al., 1967, Pines et al., 1970). Current national guidelines advise that
treatment is for 14 days based on consensus opinion but clearly further studies
evaluating the optimum period of treatment are needed (Pasteur et al., 2010). All
patients included in the study that were infected with Pseudomonas aeruginosa or Gram
negative organisms were treated with two anti-pseudomonal antibiotics to reduce the
chance of developing antibiotic resistance. Patients infected with other pathogens were
treated with monotherapy using intravenous ceftriaxone. The optimum therapeutic
agents for treating exacerbations are unknown, with previous studies of antibiotic
treatment for exacerbations finding variable results with different agents but no clearly
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superior antibiotic has been identified. Consensus expert opinion currently recommends
that treatment is initiated according to in vitro sensitivities of the most recent infecting
organism for each individual patient until the causative organism is identified from an
acute sputum sample cultured at the start of the exacerbation (Pasteur et al., 2010).
Many other questions regarding the optimal management of exacerbations remain
unanswered including the optimal route of antibiotic administration; whether dual
antibiotic treatment is superior to monotherapy regardless of the infecting pathogen; the
role of adjunctive therapies and the optimal duration of treatment. Exacerbations are a
further insult to the already damaged airways in bronchiectasis and a potent stimulus of
the vicious cycle of inflammation and infection. The current study identified multiple
parameters that may be useful for defining a successful treatment response in adults
with exacerbations of bronchiectasis and in particular found four highly responsive
markers of successful treatment: 24 hour sputum volume, qualitative sputum
bacteriology, CRP and SGRQ score. These outcome measures remained robust markers
of successful treatment irrespective of the infecting pathogen and may have an
important role as further strategies to limit exacerbations and their impact on the vicious
cycle of inflammation and infection in the airways are investigated.
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7.3 Reducing the chronic bacterial burden in the airways
Fundamental to the hypothesis of disease pathogenesis in bronchiectasis is chronic
bacterial invasion and colonisation of the airways persistently stimulating an
exaggerated neutrophilic inflammatory response (Cole, 1986). Previous studies have
found 64% to 79% of patients with bronchiectasis to be colonised with bacterial
pathogens in the airways when clinically stable (King et al., 2007, Angrill et al., 2002,
Pasteur et al., 2000) and bacterial density in the airways has been shown to correlate
with the degree of airways inflammation (King et al., 2007, Angrill et al., 2001, Hill et
al., 2000).
Long term antibiotic therapy could limit chronic bacterial infection in the airways thus
reducing neutrophilic inflammation and improving morbidity. Targeted delivery of
aerosolized antibiotics directly to the airways may have significant benefit with minimal
adverse systemic effects. The aim of the randomised controlled trial reported in Chapter
Five was to assess the efficacy of continuous nebulised gentamicin therapy over one
year in patients chronically infected with a variety of pathogens in their airways and to
assess whether any treatment effects could be sustained over a three month treatment
free follow up period.
The study was unique to include patients infected with a variety of pathogens as
previous randomised controlled trials of nebulised antibiotic therapy have been
conducted only in patients colonised with Pseudomonas aeruginosa (Orriols et al.,
1999, Drobnic et al., 2005, Barker et al., 2000). Although chronic Pseudomonas
aeruginosa infection is associated with more severe bronchiectasis in terms of the
radiological extent of disease, impaired lung function and a poorer health related quality
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of life (Miszkiel et al., 1997, Ho et al., 1998, Wilson et al., 1997b), chronic infection
with other pathogens is still associated with marked neutrophilic airways inflammation
and significant morbidity with exacerbations and poor health related quality of life
(Wilson et al., 1997b, Angrill et al., 2001, Hill et al., 2000, Martinez-Garcia et al.,
2005). Inclusion of patients chronically infected with a variety of pathogens represents a
far greater section of the bronchiectasis patient population, and provides an evidence
based treatment for more patients.
A significant reduction in bacterial density was seen after 3 months of nebulised
gentamicin, an effect sustained throughout the 12 months' of treatment. In the
gentamicin group pathogen eradiction was achieved in 92.8% of patients colonised by
pathogens other than Pseudomonas aeruginosa and in 30.8% of patients colonised with
Pseudomonas aeruginosa. In those not achieving complete eradication of pathogens,
there was still a significant reduction in bacterial density seen from a median
8.061ogiocfu/ml at baseline to 6.171ogiocfu/ml at the end of treatment. These results are
similar to a previous study of 4 weeks of inhaled tobramycin solution in patients
colonised with Pseudomonas aeruginosa that achieved eradication in 35% and observed
an overall reduction of 4.541ogiocfu/g in sputum bacterial density (Barker et al., 2000).
A previous study of airway bacterial colonisation in clinically stable patients with
chronic bronchitis and bronchiectasis found that with lower bacterial loads there was
significantly lower neutrophilic inflammation as evidenced by lower levels of
myeloperoxidase activity, lower levels of interleukin-8, lower levels of leukotriene B4
and lower levels of elastase (Hill et al., 2000). In the gentamicin group in the study in
Chapter 3, as bacterial density in the sputum reduced, reductions in the concentration of
254
myeloperoxidase were seen with levels reducing from 51.6units/ml to 13.8units/ml at
the end of 12 months' treatment. A similar effect was also seen in free elastase activity
reducing from 3.6units/mg to Ounits/mg at the end of 12 months' treatment. These
findings provide support for the hypothesis of the vicious cycle of inflammation and
infection thought to occur within bronchiectatic airways; with a reduction in bacterial
density, neutrophilic inflammation in the airways also significantly reduces.
Despite good improvement in bacterial clearance, there was no significant change in
systemic inflammation between the groups at the end of 12 months' treatment.
Although previous work has shown that increased levels of WCC, CRP and ESR may
be present in patients with stable disease and correlate with some disease characteristics
they have not been shown to correlate with sputum bacteriology (Wilson et al., 1998)
and a separate study demonstrated the association between systemic and airways
inflammation to be poor (Angrill et al., 2001).
The effect of reducing bacterial density and neutrophilic airways inflammation was
evident in other clinical parameters studied. There was less sputum purulence with
gentamicin treatment (66.7% of patients had purulent sputum at the start of treatment
compare with 8.7% at the end), improved exercise capacity (the median distance
achieved at the start of treatment was 350m compared with 510m at the end) and fewer
exacerbations with a median number of 0 over the 12 month period compared with 1.5
in the saline group. With these significant reductions in sputum bacterial density and
inflammation and improved clinical features, significantly more patients in the
gentamicin group had a clinically relevant improvement in health related quality of life
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as assessed by both the LCQ and the SGRQ, arguably the most important goal of
management in chronic disease.
This study provides evidence for the efficacy of regular nebulised gentamicin therapy in
patients with chronic bacterial infection of the airways. Gentamicin was selected as it is
broad spectrum for the pathogens seen in non-cystic fibrosis bronchiectasis and has
previously been shown to achieve good sputum concentrations with a previous study
demonstrating that a single dose of 160mg of nebulised gentamicin, achieved good
sputum concentrations (97.2ug/g sputum) two hours following nebulisation. Nebulised
gentamicin was reasonably well tolerated with few adverse effects which contrasts with
studies of other nebulised antibiotics such as tobramycin which administered over a four
week period was associated with 70% of patients reporting at least one respiratory
symptom and an overall increased incidence of reported wheeze, cough, chest pain and
dyspnoea (Barker et al., 2000). A later study of 14 day cyclical nebulised tobramycin
administered for 12 weeks had adverse events related to treatment in 22% of study
patients (Scheinberg and Shore, 2005). Despite significant benefits with nebulised
gentamicin throughout the 12 months of treatment, it was disappointing that none of the
treatment effects were sustained in the 3 month treatment free follow up period, with
sputum characteristics returning to values similar to baseline. Only one randomised
controlled trial of nebulised antibiotics has previously included a follow up period
during which time eradication of Pseudomonas aeruginosa from the sputum was
sustained, but this was only over 2 weeks follow-up period and it is not known whether
this effect would be sustained over a longer follow-up period (Drobnic et ah, 2005).
Although the findings during the follow-up period of the nebulised gentamicin study are
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slightly disappointing, they provide clear guidance for clinicians that for treatment with
nebulised gentamicin to be effective, it needs to be continuous. There have been no
previous long term studies of nebulised gentamicin in bronchiectasis and further studies
to determine the optimum dose and regime are needed.
Ultimately, this study corroborates the hypothesis of the vicious cycle of infection and
inflammation in bronchiectasis. It provides evidence for the efficacy of regular
nebulised gentamicin with significant reductions in sputum bacterial infection, reduced
airways inflammation, improved sputum purulence, improved exercise capacity, fewer
exacerbations and a better health related quality of life in chronically infected patients
with bronchiectasis, irrespective of infecting pathogen.
7.4 Assessing response to treatment
The aim of interventional strategies for bronchiectasis is twofold: to disrupt or halt the
infective and inflammatory activity constantly occurring within the airways and to
alleviate the persistent, debilitating symptoms of the disease. The previous studies in
Chapters Three to Five have explored potential means of affecting the vicious cycle of
infection and inflammation by facilitating the impaired mucociliary clearance
mechanism, by limiting the impact of further insults to the airways with effective
treatment of infective exacerbations and by attempting to reduce chronic airways
infection. As with previous interventional studies in bronchiectasis, various markers
have been used to measure the success of these strategies. Markers used in these studies
have varied but have included clinical markers such as sputum volume, sputum
purulence, lung function, exacerbation frequency, reported cough and dyspnoea severity
scores as well as laboratory markers such as sputum bacteriology and sputum
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inflammatory indices (1957, Cherniack et al., 1959, Hill et al., 1988, Stockley et al.,
1984a, Currie et al., 1990, Elborn et al., 1992, Rayner et al., 1994, Tsang et al., 1999a,
Cymbala et al., 2005, Martinez-Garcia et al., 2006). Despite these studies and mutually
acknowledged treatment goals, there are few validated methods to allow clinicians to
assess response to treatment. The markers used have been selected based predominantly
on their utility in other chronic respiratory diseases such as cystic fibrosis and COPD
but the majority have not been validated for use in bronchiectasis and their application
and actual significance remains unknown. There is an urgent need to identify relevant,
reliable, non-invasive and easily accessible markers to assess response to treatment in
bronchiectasis.
The study in Chapter Six aimed to evaluate some of the measures that are used most
frequently to assess interventions in bronchiectasis, to try and establish their actual
relevance as outcome markers for a successful response to long-term treatment
strategies. Parameters used in the studies described in Chapters Three and Five were
evaluated using the SGRQ as a gold standard measure of treatment response for
comparison. Independent markers identified as potentially useful in the assessment of a
successful response to treatment included an improvement in the incremental shuttle
walk test of >50m and complete eradication of pathogens in the sputum. In addition, an
improvement in sputum colour and a reduction sputum bacterial density were identified
as potentially useful markers of treatment response.
Persistent bacterial infection of the airways is a diagnostic feature of bronchiectasis and
reflects the perpetual nature of the vicious cycle of inflammation and infection in the
airways. Patients who are chronically infected with potentially pathogenic
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microorganisms in their sputum have a poorer health related quality of life (Wilson et
al., 1997b) and may have a greater decline in lung function. Previous studies have
demonstrated that with less bacterial infection in the airways, there is less airways
inflammation limiting the locally destructive impact of the vicious cycle (Angrill et al.,
2001, Hill et al., 2000). Limiting bacterial infection is a major goal of management and
sputum bacteriology has therefore been utilised as a measure of treatment efficacy in
many of the therapeutic interventional studies to date. The univariate analysis conducted
in Chapter Four found a reduction in sputum bacterial density to be a marker of
treatment response and complete clearance of pathogens from the sputum was a
significant and independent predictor of a successful treatment response on multivariate
analysis. With reduced bacterial infection in the airways, patients' symptoms improve.
Chronic airways infection may limit the utility of qualitative microbial assessment in
bronchiectasis despite its power as an independent predictor of treatment response and
the role of quantitative bacteriology requires further validation.
The incremental shuttle walk test is a means of assessing exercise capacity. Exercise
capacity is influenced by several factors including both respiratory health and systemic
health. Lung function, bronchial secretions, respiratory muscle strength as well as
general health status (including nutrition and the impact of any comorbidity) may all
influence performance and increasing the distance completed in the test may reflect
either direct or indirect improvements in these aspects of health. It is interesting to
observe that despite the ISWT distance improving with chronic intervention, no parallel
improvement in spirometry (FEVi and FVC) occurred. This is intriguing and suggests
that exercise capacity may reflect systemic factors as well as respiratory factors. This
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hypothesis is further supported in a study of the 6 minute walking test as a measure of
exercise capacity in 27 patients with bronchiectasis (Lee et al., 2009). This study found
the FVC and health related quality of life as measured by both the Short Form-36 (SF-
36) and the SGRQ to correlate with performance in the 6 minute walking test. On
further analysis, the SGRQ activities and symptoms scores as well as the number of
bronchopulmonary generations affected by bronchiectasis emerged as independent
predictors of performance in the test, leading the authors to conclude that health related
quality of life had a stronger association with exercise capacity compared with
physiological measures of disease severity (Lee et ah, 2009). The relationship between
the ISWT with both systemic and respiratory factors, as well as the influence of
potential biases such as age and comorbidities requires further investigation. However,
the emergence of the test as an independent predictor of treatment success in both
models of the multivariate analysis in Chapter Six provides compelling support for an
external validation study of the ISWT in bronchiectasis.
Lung function has been used in many of the interventional studies in bronchiectasis to
date. However, it is evident both from the previous studies in Chapters Three, Four and
Five together with the findings in Chapter Six that although FEV i and FVC may have
statistical utility in response to acute interventional strategies the actual clinical impact
of the changes observed may be more limited: the median change in FEV i with acute
treatment was 0.09mls and with FVC 0.08mls. The lack of response of lung function in
the studies reported in this thesis as well as other studies is initially surprising,
particularly given the utility of FEVi and FVC in other chronic lung diseases such as
cystic fibrosis. It may be that the older median age of patients with bronchiectasis in
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these studies minimises the opportunity for airways reversibility. Different measures of
lung function such as the lung diffusion capacity, total lung capacity or residual volume
may offer more utility as markers of treatment response particularly as these measures
have been found to be independently associated with mortality (Loebinger et al.,
2009b). The lung diffusion capacity may be of further relevance with a longitudinal
study in 61 patients over a median of 7 years observed a progressive median decline of
2.4% of predicted value per year (King et al., 2010). Recently, in other chronic
inflammatory lung diseases such as cystic fibrosis and asthma, assessment of small
airway function as a measure of disease has been explored. The Lung Clearance Index
(LCI) is such a measure of lung physiology derived from multiple breath washout
(MBW) tests. MBW tests involve the washout of an inert tracer gas from the lungs
during relaxed tidal breathing- with each successive breath of the washout there is a fall
in the peak concentration of the exhaled tracer (Robinson et al., 2009). In chronic
inflammatory lung diseases factors that may contribute to airway narrowing such as
mucus retention, inflammation and airway wall remodelling contribute to ventilation
heterogeneity and washout takes longer. The LCI represents the number of times the
volume of gas in the lung at the start of the washout must be turned over to effectively
washout the inert tracer gas; with increasing disease severity, the LCI increases. The
LCI has been proven to be more sensitive than spirometry in adults with cystic fibrosis
(Horsley et al., 2008) and has proven utility in paediatric patients with asthma and
cystic fibrosis (Gustafsson, 2007). To date, the role of MBW tests and the LCI has not
been explored in non-cystic fibrosis bronchiectasis. Further studies are needed to
investigate the relevance of different aspects of lung function in bronchiectasis to help
assess its potential utility as a pertinent marker of treatment response.
261
It is disappointing that exacerbation frequency did not emerge as an independent
predictor of a successful treatment response in either the univariate or multivariate
analysis in the study in Chapter Six. Exacerbations are a significant source of morbidity
and reducing frequency is typically a major goal of management. The analysis in
Chapter Six may have been limited by the differing length of time in the two studies of
chronic intervention and indeed the study reported in Chapter Five found that treatment
with nebulised gentamicin lead to significantly fewer exacerbations and a longer time to
first exacerbation than those who received nebulised saline. More studies of longer
duration are necessary to accurately evaluate exacerbation frequency as a marker of
successful treatment response.
Systemic inflammatory markers did not emerge as discriminators of response to long
term treatment in the analysis in Chapter Six. However, in response to treatment of
acute exacerbations as described in Chapter Four, there were significant reductions
observed in mean total leukocyte count (3.7xl09cells/L), erythrocyte sedimentation rate
(17.7mm/hr) and in C-reactive protein (59.5mg/L). It is likely that the significant
improvement observed in these markers reflects the resolution of the systemic
inflammatory response in an infective exacerbation. In stable bronchiectasis, the role of
inflammatory markers is not yet established, with limited studies to date exploring the
association of a variety of markers with airways inflammation or the extent of clinical
disease (Lloberes et al., 1992, Wilson et ah, 1998). Larger and longitudinal studies in
stable bronchiectasis are needed to establish the role of systemic inflammatory markers,
but at present their utility in response to long term treatments is unproven.
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Sputum expectoration is a defining symptom of bronchiectasis and the volume
expectorated has been used to assess bronchiectasis and its response to treatment since
the earliest reported case studies of the disease. One of the first published studies of a
non-surgical treatment strategy in bronchiectasis was the twice daily intratracheal
injection of menthol and guaiacol with olive oil for an acute exacerbation (Grainger-
Stewart, 1893). This treatment was reported to be a clinical success based on the
observation that "the sputum gradually diminished in amount". 24 hour sputum volume
has since been used in several more formal studies both as a marker in assessing
potential long term therapeutic strategies including inhaled steroids and long term
antibiotics as well as assessing response to treatment in acute exacerbations (Cymbala et
al., 2005, Tsang et ah, 2005a, Currie et ah, 1990). The analysis in Chapter Six did not
however, include sputum volume as a potential marker of successful treatment response
due to its potential limitations in chronic disease. Collection of sputum is wholly reliant
on patient compliance which may be more difficult to depend on in long term studies of
stable bronchiectasis. The analysis also included a study of successful response to
regular chest physiotherapy. It is widely acknowledged that the aim of chest
physiotherapy is to enhance sputum expectoration and therefore volume which conflicts
with the overall management goal in bronchiectasis to improve symptoms by reducing
sputum volume- a successful response to chest physiotherapy may not therefore be
reflected at face-value in the assessment of sputum volume. However, the longer term
effect of regular airway clearance in stable disease is unknown and it may be that with
frequent practise the airways may become clearer and actual volume decrease. The role
of 24hour sputum volume as a marker of treatment response requires further study.
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There is a real and urgent need to establish pertinent, reliable and easily accessible
markers for treatment response in bronchiectasis particularly as exciting advances are
made in the development of new treatment strategies. At present, three key markers
have been identified from the studies reported in this thesis: an improvement in the
SGRQ of at least 4 units; an improvement of at least 50metres in the ISWT and
eradication of bacteria from the sputum. External validation studies are needed.
7.5 Future studies
1. The importance of the dysfunction of the mucociliary clearance mechanism in
bronchiectasis is clear. The study in Chapter One has provided evidence for the
efficacy of regular chest physiotherapy in enhancing the efficiency of mucus
clearance from the airways but raises questions that need to be explored and
answered in future studies: is there an optimum regime for patients?; is there any
further benefit in stratifying regimes according to predominant type of
bronchiectasis (cylindrical, varicose or cystic) or to the aetiology of
bronchiectasis?; do other airway clearance mechanisms offer additional benefit
when used with regular physiotherapy such as airways humidification and
whether there is a role for pulmonary rehabilitation in bronchiectasis?
2. Infective exacerbations perpetuate the vicious cycle of infection and
inflammation and are a major source of patient morbidity. Early studies
suggested that high doses of antibiotic are necessary but it is unknown as to
whether there is any benefit in duration of regime. Current consensus expert
opinion suggests prolonged treatment courses of 14 days but it is unknown as to
whether this confers any further benefit to a standard 7 day course of treatment
in terms of effect on sputum bacterial density, airways inflammation, systemic
inflammation or on health related quality of life as well as the increased
potential for adverse treatment effects to the prolonged course of antibiotics.
This optimum duration of treatment of infective exacerbations requires formal
study. The impact of multiple courses of antibiotics for recurrent exacerbations
on antimicrobial resistance patterns has not been established and may be of great
importance in the long term management of these chronically colonised patients,
impacting on choice of antibiotic for treatment of exacerbations and the potential
need for dual antibiotic therapy. This needs further exploration. Traditional
management of exacerbations has been with either oral or intravenous antibiotic
therapy. Furthermore, the role of adjunctive therapies in the management of
acute exacerbations including physiotherapy, airways humidification and
enhanced nutrition needs to be explored.
3. The importance of bacterial colonisation in bronchiectasis is a major therapeutic
target. The impact of chronic infection with Pseudomonas aeruginosa on lung
function, exacerbation frequency and severity as well as health related quality of
life is evident from the literature but it is not known whether targeted eradication
treatment for the first isolation of the pathogen is successful in terms of
complete curative clearance or duration of remission from infection and the
impact on airways inflammation, exacerbation frequency and health related
quality of life. Studies are needed to address this important issue and to explore
what the optimum regime for eradication could be in terms of drug delivery and
duration of eradication treatment or treatment attempts. Similarly the effect of
eradication regimes on other pathogens such as MRSA is unknown and should
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be studied. The role of long term antibiotics is hopeful but many questions
remain unanswered at a microbial level and longitudinal studies are needed to
assess the impact not only on resistance patterns but also on virulence factors
and adaptation of the bacteria such as biofilm formation.
4. It is clear that there is an urgent need for the validation of markers specific to
bronchiectasis that can be reliably and easily used to both assess response to
treatments and monitor disease progression. The goals of management of
bronchiectasis and the aspects of the vicious cycle offer the most obvious targets
and studies to date have highlighted the particular potential of both sputum
volume and exercise capacity. These measures need formal validation studies.
5. Bronchiectasis was once termed an orphan disease. It remains a significant
problem but little is known about the current incidence and the potential
influence of environmental factors on prevalence. Formal population studies are
needed to assess the actual incidence of bronchiectasis and its causes in order to
try and understand more of the aetiology of this debilitating chronic condition to
both gauge the impact of the disease on future healthcare provision and to
attempt to address causative factors that can be influenced.
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